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Abstract 
Over the past decade, it has become apparent that the human polybromo-1 protein 
(BAF180) has a critical role in cancer. BAF180 is known to be a driver mutation in clear 
cell renal cell carcinoma, where it has been found to be mutated in approximately 40% of 
cases. Mutations have also been found in several other cancers, including intrahepatic 
cholangiocarcinomas and epithelioid sarcomas. BAF180 is the chromatin targeting 
subunit of the PBAF (Polybromo-associated BRG1-associated factor) chromatin 
remodeling complex, a role facilitated by its nine domains: six bromodomains, which 
recognize and bind to acetylated lysines on histones; two BAH (bromo-adjacent 
homology) domains, found to be critical for PCNA ubiquitination following DNA 
damage; and one HMG (high mobility group) box, the DNA binding component. 
Furthermore, proper expression of BAF180 has also been linked to cardiac development 
and cell cycle regulation. 
Despite these associations, the molecular level interactions of full-length BAF180 
have yet to be studied; only the phenomenological effects of BAF180 
deficiency/mutation have been studied. It is crucial that we understand the binding 
dynamics and specificities of wild type and mutated BAF180, since it is the recognition 
component of PBAF. 
Expression of the recombinant full-length BAF180 protein has been difficult 
because of the complex nature of this protein, its unusual codon usage, and size. After E. 
coli expression failed, other expression systems were investigated and the yeast Pichia 
pastoris was chosen. Pichia was chosen for several reasons: its codon usage is similar to 
11 
that of BAF180 and it is a eukaryotic system possessing eukaryotic protein folding 
machinery and capable of performing post-translational modifications. Under control of 
the GAP promoter, full-length BAF180 has been successfully expressed in Pichia 
pastoris. This is the first time that full-length BAF180 has been cloned and expressed in a 
heterologous host. It was purified using anion exchange chromatography. 
The ability to express and purify full-length BAF180 is a huge first step towards 
increasing the understanding of the molecular mechanisms of this protein and its 
association with cancer development. 
12 
 
Chapter 1 : Background 
 1.1 Introduction 
Though discovered in the early 2000s, the complex interconnecting roles of 
human polybromo-1 or BAF180 are just starting to be understood. Though a lot of 
unknowns remains, it has been established that BAF180 plays roles in the development of 
the heart and the thymus (Sections 1.4.2.2 and 1.4.2.3), genomic stability and DNA repair 
(Section 1.4.3), and cell cycle regulation (Section 1.4.4) (Figure 1.1). Mutations in 
BAF180 are commonly observed in cancers (Section 1.5); most notably, it is mutated in 
41% of clear cell renal cell carcinoma cases.1 When BAF180 is mutated or its expression 
is affected, there are deleterious effects on normal cell function, such as increased cell 
proliferation and impaired DNA repair (Figure 1.2). 
 
Figure 1.1: Diagram illustrating the roles of BAF180 in normal cells. 
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Figure 1.2: Diagram illustrating the consequences of mutations or alteration of expression of BAF180. The 
consequences of cell cycle deregulation, genomic instability, and disrupted DNA repair has the potential to 
cause cancer. 
 
 1.2  Mutation Susceptibility 
When analyzing the DNA sequence of PBRM1 (the gene that encodes BAF180) 
some interesting trends are seen. There are a lot of repeats, particularly A- and T-tracts. 
Base repeats have been known to increase the chances of point mutations during 
replication.2-6 Poly-A tracks have been found to influence gene transcription both by 
stopping translation and creating frameshift mutations.7 The PBRM1 gene has 4905 base 
pairs (isoform two, GenBank ID: AAG48933.1); within the gene, there are numerous 
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two, three, and four repeats of all the bases (Table 1.1). BAF180 has nine alternate 
splicing isoforms. 
Table 1.1: The number of two or more base pair repeats found in the PBRM1 gene (GenBank ID: 
AAG48933.1). Numbers above the table refer to the number of consecutive of bases. The numbers in the 
box refer to how many times that base-tract is found in the mRNA sequence. 
 Number of Sequential Bases 
Base Two Three Four Five Six Seven 
A 394 135 54 21 7 1 
U 245 69 16 9 1 0 
C 232 48 11 4 1 0 
G 207 39 7 0 1 0 
  
 
1.3 Domain Organization 
The human polybromo-1 protein (BAF180) is encoded by the PBRM1 gene 
(Figure 1.3) and is considered to be the chromatin-recognition subunit of PBAF 
(polybromo-associated BRG1-associated factor). PBAF is involved in gene transcription. 
The PBRM1 gene is located at 3p21.1. BAF180 is comprised of nine domains: six 
bromodomains, two bromo-adjacent homology domains, and one HMG-box. It is 
considered to be homolog to yeast Rsc1, 2, and 4 (or a gene fusion product of them).8-9  
 
Figure 1.3: Domain organization of BAF180. BAF180 has 6 bromodomains (brd), the most of any known 
bromodomain-containing protein; 2 BAH (bromo-adjacent homology domains); and 1 HMG (high mobility 
group) box. The full-length protein has never been expressed in a heterologous host. The domain sizes and 
distances are approximately to scale [AAG48933.1]. BAF180 is encoded by the PBRM1 gene. 
 
Brd1 Brd2 Brd4Brd3 BAH1Brd6Brd5 BAH2 HMG
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1.3.1 Bromodomains 
Within chromatin, DNA is wound around a core of eight histone proteins (two 
each of H2A, H2B, H3, and H4). In this state, DNA is highly compacted and therefore 
less accessible to replication- and transcription-mediating proteins. For replication and 
transcription to occur, the DNA needs to become accessible. This is believed to occur 
when post-translational modifications (PTMs) on the histone tails cause the interactions 
between the negatively-charged DNA backbone and the positively-charged amino acid 
resides on the histones weaken. PTMs refer to the modification of the side chain of an 
amino acid by the addition of a molecular group, such as phosphate or ubiquitin. Of 
interest in this work is the acetylation of lysine residues. The N-terminal tails of histones 
are rich in lysine residues and the acetylation of the ε-amino group on the side chain is 
generally associated with transcriptional activation.10-13 It is hypothesized that the 
neutralization of the positive charge of the amino group on the lysine side chain weakens 
the DNA-histone interactions. Acetylation is carried out by histone acetyltransferases, a 
group of proteins which transfer an acetyl group from acetyl-CoA to the ε-amino group 
of lysine. 
Bromodomains were first identified in the 1990s as a domain found in the 
Drosophila brahma gene and are the only known recognition module that bind acetylated 
lysines. Within the human proteome, there are 46 proteins which contain at least one 
bromodomain.10,12-14 Of these, 15 function as transcriptional regulators and 8 function as 
chromatin remodelers (Figure 1.4).10,14 Bromodomain-containing proteins are divided 
into eight groups based on their structural similarity; the bromodomains of BAF180 are 
16 
 
classified into group 8.10,14  Figure 1.5 shows all known bromodomains grouped into 
families based on structural similarity; the functions of each are denoted by a colored dot. 
Functions within a family can vary, though consensus is seen in some families (as in 
families 2 and 8; see Figure 1.5). 
 
 
Figure 1.4: Functions of bromodomain-containing proteins. The majority are transcriptional regulators or 
chromatin remodeling factors. 
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Figure 1.5: Phylogenic tree of the bromodomain-containing proteins based on structural similarity. 
Bromodomain-containing proteins are divided into 8 families. The molecular functions of each 
bromodomain within a particular family varies, though some similarities can be observed (family 1 – 
transcriptional regulator, family 8 – chromatin remodeling). This figure is based on figure 1B from 
Filippakopoulos, 2012.14 Functional information from Filippakopoulos, 201214 and Muller, 2011.12 
18 
 
The ability of bromodomains to recognize and bind to acetylated lysines is critical 
for several cellular functions, including transcription, replication, and DNA repair.10,13,15 
The importance of this is demonstrated in the number of diseases caused by mutation or 
incorrect expression of different bromodomains. Among them are numerous cancers, 
mental disorders, immune disorders, and metabolic diseases.16 BRD4 (of the BET family 
of bromodomains) forms a fusion protein with the NUT protein, which causes NUT 
midline carcinoma (NMC), a rare aggressive cancer with no available treatments.10,16 
Other examples of bromodomains involved in cancers include ASH1L (hepatocellular 
carcinoma), BRD7 (breast cancer), ATAD2 (breast cancer, colon cancer, lung cancer, 
uterine cancer, stomach cancer, and lymphoma), and BPTF (neuroblastomas and lung 
cancers).16 A mental disorder, Rubinstein-Taybi syndrome, is often associated with 
mutations of CREBBP.16 BRD1, SMARCA2, and BAF180 are linked to schizophrenia 
and bipolar disorders.16 SP140 is linked to Crohn’s disease and BRD2 is linked to 
rheumatoid arthritis. BAZ1B has associations with type II diabetes and obesity.16 This is 
not a comprehensive list, but the relationship between bromodomain dysfunction and 
diseases is clear. 
Epigenetic based treatments for various diseases, such as cancer, are becoming 
more popular and the inhibition of bromodomains has emerged as a treatment option. 
Most of the small molecules developed so far target proteins in the BET family 
(bromodomain and extra-terminal domain family) and all of the bromodomain inhibitors 
currently in clinical trials target the BET family (BET bromodomains were classified as 
19 
 
“most druggable”).17 Table 1.2 shows the status of the bromodomain inhibitors currently 
in clinical trials, as well as the targeted conditions. 
The other seven families of bromodomains have generally been ignored, as early 
studies predicted that bromodomains outside of the BET family would be harder to 
target.17 Vidler et al. scored the bromodomains of BAF180 “intermediate” to “difficult” 
druggability, with brd1, 3, and 4 considered “difficult” targets and brd2 and 5, considered 
“intermediate” targets; brd6 did not have a score.17 
This analysis has recently been called into question when two groups created an 
inhibitor that selectively targets brd5 of BAF180.18-19 Vidler et al. based their analysis on 
the assumption that the water molecules in the binding pocket remained. Both 
Myrianthopoulos and Sutherell created compounds which were able to bind to 
bromodomain 5 selectively with good affinity, while displacing water molecules.18-19 
Sutherell et al. published their compound in April 2016 and showed that it had a KD = 
124 nM for BRD5.18 Myrianthopoulos et al. published in September 2016 and their 
compound had a KD = 3.3 µM for BRD5.19 Both compounds were able to displace 
BAF180 from chromatin.18-19 Structural analysis conducted by Vidler et al. demonstrated 
that the binding pocket of the fifth bromodomain of BAF180 is unusual when compared 
to other bromodomain structures; it appears to have a shorter ZA loop and some key 
residues located in the binding pocket are shifted, resulting in a smaller binding site.17 
This may be a reason why newly developed molecules selectively target brd5.  
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Table 1.2: Bromodomain inhibitors currently in clinical trials. All of the drugs listed target the BET family 
of bromodomains. Of note is Resverlogix Corp.’s RVX000222, which has progressed to phase three 
clinical trials for diabetes and cardiovascular diseases. Data gathered from clinicaltrials.gov on 16 January 
2017.20 
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1.3.1.1 Structure and Binding Mode  
The bromodomain structure consists of a left-handed helix bundle composed of 
four α-helices (αZ, αA, αB, αC) connected by three loops (ZA-, BC-, AB-loops) (Figure 
1.6A). Specificity is conferred by the ZA and BC loops10,13-14,16,21-22 which form a 
hydrophobic binding pocket. The acetylated lysine residue forms a hydrogen bond with a 
highly conserved asparagine residue located near the end of the αB helix (Figure 
1.6B).10,13-14,21-23 Water residues located within the hydrophobic binding pocket also form 
hydrogen bonds with the acetylated lysine (Kac).19,21  
Factors influencing acetyl-lysine specificity and affinity are (1) amino acid 
residues neighboring the binding pocket and (2) histone post-translational modification 
patterns. Amino acid residues surrounding the hydrophobic pocket have been 
demonstrated to influence acetyl-lysine recognition by interacting with residues that 
surround the acetylated lysine on the histone.10,19,21-22 Different post-translation 
modification (PTMs) patterns on the histones have been shown to influence binding 
affinity at a specific acetyl-lysine residue; surrounding PTMs may increase or decrease a 
bromodomain’s affinity for a specific acetylated lysine.10,14,22 Interestingly, some 
bromodomains have demonstrated an ability to bind to two acetylated lysines at a time 
within the same binding pocket.14,24 For example, the first bromodomain of the BET 
protein BRD4 has been shown to bind both acetylated lysines of H4K5/8ac at once; a 
crystal structure shows that both acetylated lysines are in the binding pocket (PDB ID: 
3UVW).14  
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Figure 1.6: Crystal structure of a bromodomain. (A) The crystal structure of bromodomain 3 of BAF180 
[PDB ID: 3K2J; structure not yet published: Filippakopoulos, P., Picaud, S., Keates, T., Chaikuad, A., Pike, 
A.C.W., Krojer, T., Sethi, R., von Delft, F., Arrowsmith, C.H., Edwards, A., Weigelt, J., Bountra, C., 
Knapp, S., Structural Genomics Consortium]. Labeled are the structural segments found in every 
bromodomain. The αZ-helix is located at the N-terminal end of the protein. (B) The crystal structure of 
bromodomain 2 (of BAF180) bound to an acetylated peptide [PDB ID: 2KTB].{Charlop-Powers, 2010 
#616} The binding pocket is located between the ZA- and BC-loops of the structure. The αZ-helix is 
located at the N-terminal end of the protein. Light blue: αZ-helix. Purple: ZA-loop. Green: αA-helix. Pale 
pink: AB-loop. Orange: αB-helix. Hot pink: BC-loop. Dark blue: αB-helix.{Berman, 2000 #1292;Xu, 2009 
#1085} Images manipulated using Protein Workshop.{Moreland, 2005 #1293} 
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Domains adjacent to the bromodomain (BRD) often include PHD zinc fingers, 
other bromodomains, and bromo-adjacent homology domains (BAH).10,14 These 
neighboring domains have been shown to act together to increase the binding affinity for 
a bromodomain-containing protein to an acetylated lysine site. For example, BRD2 
(bromodomain-containing protein 2), which has two tandem bromodomains, has a much 
higher affinity for H4K5/12ac (Kd=360 µM) than for the singly-acetylated H4K12ac 
(Kd=2.9 mM).10 TRIM33, which has a PHD (plant homology domain) zinc finger 
followed by a bromodomain, has been shown to bind H3K9me3 and H3K14ac 
simultaneously.10,13 
1.3.1.2 The Bromodomains of BAF180 
BAF180 has six bromodomains, the most of any known bromodomain-containing 
protein. Of particular interest is the question of why BAF180 has six bromodomains. At 
most, other bromodomain-containing proteins contain two. It is accepted that 
bromodomains bind to acetylated lysines, but the specific interactions of the BAF180 
bromodomains are unknown. It is possible that the bromodomains work in concert (as the 
tandem bromodomains of BRD4 do) and it is possible that they work independently 
(further discussion in Sections 1.3.1.1).10,14,23-24 
Filippakopoulos et al. performed a very thorough SPOT array of histone H3 
peptides with various combinations of post-translational modifications (acetylation, tri-
methylation, phosphorylation, etc.). The data indicates that modifications surrounding the 
acetylated lysine do have an impact on binding affinity. For example, brd4 (of BAF180) 
24 
 
had “strong” affinity for H3K4ac, but “very strong” affinity for H3K4/9ac. This suggests 
that brd4 of BAF180 may be able to bind two acetyl-lysines simultaneously, in a manner 
similar to the BET protein BRD4(1).14,24 Brd4 of BAF180 had “strong” affinity for 
H3K9ac, but “weak” affinity for a peptide containing additional acetylation sites on K4 
and K14, and two phosphorylation sites on S10 and T11 (H3K4/9/14acS10/T11p, where 
‘p’ means phosphorylation). It had no affinity for a peptide containing a tri-methylation 
mark on K4, acetylation at K9 and K14, and phosphorylation on S10 and T11 
(H3K4me3K9/14acS10/T11p, where ‘me3’ refers to tri-methylation). The data also 
demonstrates that brd4 of BAF180 is a fairly ubiquitous binding partner, as it showed 
‘very strong’ affinity for about 74% of peptides tested.14 Data presented in that 
publication also supports the hypothesis that the bromodomains work together, as some 
multiply modified peptides were recognized by more than one bromodomain.  
The bromodomains of BAF180 have been expressed individually and their 
affinities for specific acetyl-lysine sites on histones has been studied.12,14,27-30 However, 
there has been some divergence in results, in terms of recognition patterns and affinities 
(Table 1.3). This may be due to several factors: different lengths of the bromodomains, 
differing peptide lengths, and differing peptide locations may be influencing the results. 
In addition, the affinities are hard to compare because different methods were used to 
quantitate the affinities (nuclear magnetic resonance, isothermal titration calorimetry, 
fluorescence anisotropy, dot blot, peptide/SPOT array).12,14,23,27-30  
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Table 1.3: Comparison of the individual acetylated lysine sites on histones 1-4 recognized by the 
bromodomains of BAF180. The specificity data between publications varies, with little consensus between 
them. This may be a reflection of the different techniques used, thus emphasizing the need to a 
comprehension study of all the individual bromodomains’ binding sites.14,27-28 
 
A study was recently published wherein the researchers investigated the effect of 
point mutations of individual bromodomains. Porter and Dykhuizen reported that 
endogenous BAF180 isolated from HeLa lysate specifically recognizes H3K14/18/23/ 
27ac, as evidenced during a peptide pull-down assay.23 Porter and Dykhuizen suggest that 
the second bromodomain of BAF180 is the most critical for BAF180’s tumor suppressor 
properties. They created six constructs wherein a single point mutation was introduced 
into the binding pocket of a different bromodomain and introduced the constructs into 
Caki2 cells (clear cell renal cell carcinoma (ccRCC) cells lacking BAF180). They used 
immunoprecipitation with BAF180 and BRG1 antibodies to confirm that the mutants 
were integrated into the PBAF complex, though with weaker binding than is seen for 
wild type.23 Then they examined the effects of these mutations on cell growth and gene 
expression. 
When wild type BAF180 was introduced into Caki2 cells, the growth rate 
decreased significantly. In contrast, introduction of the mutant brd1, 2, 4, and 5 BAF180 
Histone H1-4 Histone H2A Histone H2B Histone H3 Histone H4
Reference Reference Reference Reference Reference
Bromodomain 14 14 27 14 27 14 27 28 14 27
PB1(1)
K33, K80, 
K84, K89 K15
K56, K64, 
K122 K36 K4 K44, K91
PB1(2) K36 K85 K14 K14 K9
PB1(3)
K62, K74, 
K80, K84 K15 K15 K23 K15
K18, K36, 
K56, K64 K115 K9 K12
PB1(4) K37, K122 K14, K115 K23
PB1(5) K85 K36, K112 K14
PB1(6) K84 K43 K24, K116 K56, K115
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constructs had no effect on cellular growth, meaning the cells continued to grow at a rate 
similar to control cells that lacked BAF180. Analysis of gene expression patterns for all 
the cells demonstrated that the mutant brd1, 2, 4, 5, and 6 BAF180 proteins were unable 
to bring about the up-regulation of apoptotic genes that is usually observed when wild 
type BAF180 is introduced. The mutation in brd3 had no effect on gene expression as 
compared to wild type BAF180.23  
The crystal structures of the first five bromodomains (BRDs) of BAF180 are 
similar to the structures of other bromodomains. Bromodomain 6 diverges from this 
pattern slightly as it has a fifth α-helix (Figure 1.7).14 This is the only published crystal 
structure of brd6 (PDB ID: 3IU6). However, Filippakopoulos et al. included about 35 
extra amino acids on the C-terminal end past where brd6 is predicted to stop.31 In the 
same article, brd6 was shown to bind strongly (via SPOT peptide array) to H2AK36ac 
and H2BK85ac.14 Another study by Charlop-Powers et al. used a dot blot array and saw 
that brd6 interacted with H2BK24ac and H2BK116ac.27 This difference might be 
attributable to a few things: first, the cloned brd6 domains were of different lengths in the 
two publications (Filippakopoulos et al. used amino acids 741-885 and Charlop-Powers 
et al. encompassed amino acids 743-821).  
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Figure 1.7: Comparison of the crystal structures of each of the six bromodomains from BAF180. Notably, 
brd6 contains an extra C-terminal helix (grey). The αZ-helix is located at the N-terminal end of the protein. 
Light blue: αZ-helix. Purple: ZA-loop. Green: αA-helix. Pale pink: AB-loop. Orange: αB-helix. Hot pink: 
BC-loop. Dark blue: αB-helix. [PDB IDs: brd1 – 3IU5; brd2 – 3HMF; brd3 – 3K2J; brd4 – 3TLP; brd5 – 
4Q0N; brd6 – 3IU6].{Filippakopoulos, 2012 #627;Berman, 2000 #1292} Images manipulated using 
Protein Workshop.{Moreland, 2005 #1293} 
B
R
D
1
B
R
D
2
B
R
D
4
B
R
D
5
B
R
D
6
B
R
D
3
28 
 
By comparison of the same reference sequence and analysis by multiple domain 
prediction software, brd6 is located around amino acids 743-850 (CDD:743-850; 
ProSite:785-830; Interpro:743-851; SMART:743-849; MOTIF Search:649-706; 
Pfam:751-835).31-36 Filippakopoulos added about 35 extra amino acids to the C-terminal 
end and Charlop-Powers did not actually clone the whole domain. As Filippakopoulos et 
al. had 35 extra amino acids past the boundary of predicted brd6, it is possible that their 
structure is flawed. Studying the sequence data of the crystal structure reveals that the 
fifth α-helix of brd6 begins at Thr863 (PDB ID: 3IU6); this is outside of the predicted 
domain boundaries (Figure 1.8).  
 
Figure 1.8: Sequence overlay of the brd6 structure. Brd6 is predicted to occur at amino acids 743-850 
(CDD prediction). Filippakopouplos et al. cloned AA741-885, resulting in 35 extra amino acids. The fifth 
α-helix (the anomaly separating it from other bromodomain structures) begins at Thr863, outside of the 
predicted domain boundary. Sequence display image from PDB ID: 3IU6.14,37 
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Additionally, the peptides used for testing interactions were of different lengths 
and different positions; this has been shown to influence the recognition of a specific 
acetyl-lysine site by the bromodomain.14,21-22 Third, they used different techniques for 
evaluating binding partners. Filippakopoulos et al. used SPOT arrays14 and Charlop-
Powers et al. used dot blot arrays.27 It would be interesting to test whether the different 
constructs have different acetylated lysine recognition patterns, when using the same 
qualitative and quantitative methods. 
1.3.2 Bromo-Adjacent Homology Domains 
Bromo-adjacent homology (BAH) domains are believed to mediate protein-
protein interactions.8,32,38 The BAH domain was first identified in BAF180 and was 
named as such because it was adjacent to the bromodomains.8 Since that initial discovery, 
BAH domains have been found in a wide variety of proteins, only some of which contain 
an adjacent bromodomain.8 Generally, BAH domains are classified into two groups: Sir3-
like BAH domains, which bind to nucleosomes, and RSC-like. The RSC-like BAH 
domains have not been extensively studied and their binding partners still need to be 
determined.9 
BAF180 contains two BAH domains, proximal to the six bromodomains. Based 
on sequence and structure comparisons, these BAH domains fall into the RSC-like class. 
Indeed, the BAF180 protein is believed to be the human homolog or fusion of the yeast 
Rsc1, Rsc2, and Rsc4 proteins.8-9  
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The BAH domains in BAF180 are still relatively unexplored and the exact 
function is still unknown; however, some inferences can be drawn from other BAH 
domain-containing proteins. The mammalian ORC1 (origin recognition complex subunit 
1) protein contains a BAH domain which has been shown to recognize and bind to a 
methylated lysine on histone H4.38-39 Analyses of the structures indicate that the first 
BAH domain of BAF180 may also recognize methylated lysines, as the methyl-lysine 
binding pocket is fairly conserved between ORC1 and BAH1 of BAF180.38 Pull-down 
assays of BAH1 of BAF180 demonstrated preferential binding to histone H3, but not to 
any of the other histones.9 Additionally, the BAH domain of yeast Rsc2 was able to 
independently associate with histone H3 in vivo, albeit at lower levels than full-length 
Rsc2.9 Experiments further demonstrated that BAH1 domain of BAF180 is capable of 
interacting with H3 as well.9 
BAH domains can also bind to chromatin: the two BAH domains of the enzyme 
DNA cytosine-5 are localized at replication foci during S-phase.8 Likewise, BAF180 is 
found to localize at kinetochores40 (the region of chromosomes that connect to the mitotic 
spindle).41 The BAH domains of BAF180 may play a role in maintaining genomic 
stability, since BAF180 is found at kinetochores and is known to be important for DNA 
repair and genomic stability. The roles of the BAH domains in BAF180 remain unknown.  
A crystal structure of the first bromo-adjacent homology domain of chicken 
polybromo was determined by X-ray diffraction in 2005 (Figure 1.9) The BAH domain is 
composed primarily of β-strands. The ten β-strands are connected by a few helices and 
form a barrel structure.42  
31 
 
Using the crystal structures as a guide, two conserved residues near the predicted 
H3 binding pocket were mutated in Rsc2 (W436A/W436L and K437E). All three of the 
mutations impacted histone H3 binding in a negative manner both in vivo and in vitro.9 
 
Figure 1.9: Crystal structure of the first bromo-adjacent homology (BAH) domain of chicken polybromo, 
as determined by X-ray diffraction.  The structure is composed of 10 β-strands that form a barrel structure, 
connected by helices [PDB ID: 1W4S].{Oliver, 2005 #1055;Berman, 2000 #1292} Image manipulated 
using Protein Workshop.{Moreland, 2005 #1293} 
 
The BAH domains are critical for proper ubiquitination of PCNA during post-
replication repair.43 Data suggests that the BAH domains are not capable of associating 
with the PBAF complex themselves, as a construct containing just the BAH domains was 
unable to bind with BAF200 or BRG1, both components of PBAF. Therefore, its role in 
PCNA ubiquitination is likely independent of the ATPase activity of PBAF.43 The same 
study also found that the BAH domains were localized throughout the cytoplasm and 
nucleus,43 although this may be a consequence of experimental conditions and the exact 
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amino acid sequences used in the tested construct. More experiments need to be done for 
clarification, as the de-localization of the BAH domains of BAF180 seemingly 
contradicts the data demonstrating that the BAH1 of BAF180 binds to histone H3.9 
1.3.3 High Mobility Group Box  
High mobility group (HMG) domains were first identified in 1973 by Goodwin et 
al., who noted the unusual electrophoretic mobility of these proteins in Triton-urea 
gels.44-46 There are three structurally distinct classes of HMG domains: HMG-
nucleosomal binding family (HMGN), HMG-AT-hook family (HMGA) and HMG-box 
family (HMGB). HMG-box domains mediate the interactions between certain proteins 
and DNA in either a sequence- or non-sequence-specific manner.44,47-48 Generally, 
proteins with sequence-specific motifs bind to promoter DNA and those with non-
sequence-specific bind to genomic DNA.48 HMG box-containing proteins bind to the 
minor groove of B-type DNA at the entry/exit points of nucleosomes, resulting in 
distortion of the DNA strand; they also recognize already distorted DNA, such as four-
way junctions, bulges, and kinks (Figure 1.11).44-45,47,49 The DNA bending and unwinding 
that occurs when an HMG-box binding is a result of intercalation of hydrophobic 
residues into the minor groove of DNA; these hydrophobic residues are flanked by basic 
residues which bind to the phosphodiester bond of DNA, thus stabilizing the 
DNA:protein complex. Sequence-specific HMG-box domains usually only intercalate 
with DNA at one site.47 This bending may aid in “opening” the DNA-histone complex to 
allow for transcription factors to bind.44-45,50-51 
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HMG-box domains also promote non-homologous end joining (NHEJ) by 
bending the ends of the DNA so that they have more energetically favorable 
interactions52 and influence transcription by distorting the nucleosomal complex.45 
Additionally, when the HMG-box binds to bent DNA, the conformation changes such 
that the acidic tail of the domain is available to interact with histones, thus weakening the 
binding of the histone to the nucleosome.47 This may be one mechanism by which 
BAF180 is involved in chromatin remodeling. PTMs may influence the specificity and 
binding capabilities of the HMG-box. In BAF180, two serines have been found to be 
phosphorylated (S1405 and S1453, isoform 1).53 PTMs on other HMG-box-containing 
proteins have been known to alter the biological interactions of protein:protein and 
protein:DNA type.45 
BAF180 has an HMG-box domain (50 amino acids in isoform 2: AAG48933.1) 
located on the C-terminus (Figure 1.3). The function of BAF180’s HMG-box is unknown 
though several inferences can be made. The particular domain of BAF180 (of the HMGB 
type) likely binds in a sequence-specific manner, since it most closely resembles HMGB-
containing transcription factors (has only one HMGB domain).44,47-48 Though the general 
structure of HMG-box domains is three α-helices in an L-shaped configuration (Figure 
1.10),44,47 the HMG-box of BAF180 differs in that it has a shorted third α-helix and an 
extended basic N-terminus.44,46 This difference likely plays a role in its sequence-
specificity, as the N-terminal strand and the third helix (also called the ‘minor wing’) are 
responsible for the sequence specificity of an HMG-box.47 The assembly of BAF180 into 
the PBAF complex has been demonstrated to be dependent on the HMG-box and/or the 
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C-terminus of BAF180.43 It is possible that the PTMs present in the HMG-box impact the 
ability of BAF180 to assemble into the PBAF complex.54 The HMG-box domain may 
affect the role of BAF180 in embryonic development, as other HMG-box containing 
proteins have been found to. 
 
Figure 1.10: The crystal structure of HMG domain A of the HMGB1 protein. Note the L-shaped 
configuration of the α-helices. The blue helix is at the N-terminus and the red at the C-terminus [PDB ID: 
1CKT].{Ohndorf, 1999 #1108;Berman, 2000 #1292} Image manipulated using Protein 
Workshop.{Moreland, 2005 #1293} 
 
 
Figure 1.11: The HMG-box domain of the HMGB1 protein of Rattus norvegicus bound to cisplatin-
modified DNA. (A) Ribbon view; (B) Surface view [PDB ID: 1CKT].{Ohndorf, 1999 #1108;Berman, 2000 
#1292;Xu, 2009 #1085} Images manipulated using Protein Workshop.{Moreland, 2005 #1293} 
A B
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BAF180 is known to be critical for proper heart development in human embryos 
(see Section 1.4.2.2 below) and normal development has been demonstrated to require 
the proper expression of various other HMG-box-containing proteins.44 HMG-box-
containing proteins have also been shown to be important for maintaining genomic 
stability in yeast; absence of several different proteins of this type were associated with 
increased genomic instability and hypersensitivity to DNA damage.44 These same effects 
are seen in BAF180 KO cells (discussed in Section 1.4.4). This leads to the supposition 
that some of BAF180’s roles in maintaining genomic stability and proper DNA damage 
repair may stem from its HMG-box. BAF180’s roles in embryonic development and 
NHEJ may be a consequence of the HMG-box domain. 
1.3.4 BAF180 Binding Hypotheses 
The binding mechanism by which BAF180 binds to nucleosomes is currently 
unknown and is made even more complicated because BAF180 has three-types of 
domains (6 bromodomains, 2 BAH domains, 1 HMG-box). With regard to the 
bromodomains, recognition of an acetyl-lysine site may be a singular event or may be 
cooperative. Bromodomains have been shown to be able to recognize and bind more than 
one acetyl-lysine at a time.14,24 The di-acetylated histone sequence has a stronger bond to 
the bromodomain than a single acetylated site. It is also possible that more than one 
bromodomain binds to the nucleosome at a time; they may recognize sites on the same 
histone, on multiple histones, or on adjacent nucleosomes. For example, the 
bromodomains might bind to more than one H3 protein (Figure 1.12A). This could be a 
result of sterics, which would prevent more than one bromodomain from binding to the 
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same histone. If only one bromodomain is bound at a time, the bromodomains may 
function as some sort of signaling mechanism; for example, bromodomain 1 binds to its 
specific acetylated lysine site and results in transcription of protein X. This hypothesis is 
supported by the large variety of PBAF subunits involved in maintaining cell state.56-62 
There are a few possibilities for the overall binding mechanism of BAF180. 
Hypothesis 1: The HMG box binds to the DNA surrounding the histone core and 
BAF180 changes conformation such that the bromodomains are bound to their preferred 
acetylated lysine sites (Figure 1.12B). Hypothesis 2: The bromodomain recognizes the 
acetylated lysine site first and then the HMG box binds to the DNA surrounding the 
histone core, creating a stabilizing effect (Figure 1.12C). Again, it is possible that more 
than one bromodomain binds at a time. Hypothesis 3: the HMG box binds to something 
besides the nucleosome-associated DNA. This is less likely than the others, as the HMG 
box domain is found primarily in chromatin remodeling and transcription-related 
proteins.44,47-48 
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Figure 1.12: Diagram of possible binding mechanisms between BAF180 and nucleosomes. (A) The 
bromodomains might bind to more than one histone and/or more than one nucleosome at any given time. 
The pattern of bound bromodomains might have an influence on which gene is transcribed. (B) The HMG 
box of BAF180 may bind to the DNA surrounding the nucleosome first, followed by the binding of the 
bromodomain(s). Again, perhaps more than one bromodomain is bound at a time. (C) The bromodomains 
first bind to acetylated lysines and then the HMG box binds to the DNA, creating a stabilizing effect 
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1.4 Known Biological Functions of BAF180 
As part of the PBAF complex, BAF180 is believed to be the chromatin-
recognition subunit, allowing targeted gene transcription. In addition, BAF180 has 
numerous individual roles in development and DNA repair and it is often mutated in 
cancers (Figure 1.13). 
Figure 1.13: Visual listing of the roles of BAF180 in development and its presence in cancers.
1.4.1 PBAF and Transcription 
The BAF (BRG-associated factor) and PBAF (polybromo-associated BRG1 
factor) complexes control gene expression in the human body by remodeling chromatin 
to alter the accessibility of DNA to transcription factors. They is accomplished by sliding, 
displacing, or replacing nucleosomes.56,58-59,62-65 The BAF and PBAF complexes are the 
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homologs of yeast SWI/SNF complexes and as such are generally referred to as 
SWI/SNF. Both complexes (BAF and PBAF) have a core catalytic subunit that possesses 
ATPase activity, the energy from which is used to remodel nucleosomes. In addition, 
they also contain various other subunits, some that are common to both complexes (such 
as BRG1) and some that are unique (such as BAF180) (Figure 1.14 and Table 1.4).56,58-
59,62-65  
 
Figure 1.14: The unique and shared subunits of the BAF and PBAF complexes.15 
 
It was recently reported that components of the SWI/SNF complexes are mutated 
in 20% of all cancers.58 The BAF and PBAF complexes have distinct roles in gene 
transcription; for example, PBAF is required for the ubiquitination of H2AK119 at sites 
of DNA damage.66 The exact roles of the individual subunits of the complexes is 
beginning to be understood. For example, BAF180 is believed to be the chromatin-
recognition component. However, the precise protein(s) involved in binding to the DNA 
wrapped around nucleosomes have not yet been identified. 
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Table 1.4: The subunits found in the BAF and PBAF complexes and their individual domains.15,39,67 
Subunit Present in  Domains 
BAF45B/C/D BAF Tandem PHD domains, zinc finger 
BRM BAF 
DNA-dependent ATPase, bromodomain, HAS, BRK, 
SnAC 
SS18/CREST BAF N-terminal conserved region 
BCL11A/B BAF Zinc finger 
BCL7A/B/C BAF N-terminal conserved region 
BRD9 BAF Bromodomain 
ARID1A/B BAF ARID/BRIGHT, DNA binding domain 
BAF57 Both HMG box 
SNF5 Both SNF5 domain 
BAF170 Both 
Chromatin related domain, SWIRM, SANT, leucine 
zipper 
BAF155 Both 
Chromatin related domain, SWIRM, SANT, leucine 
zipper 
BAF60A/B/C Both SWIB/MDM2 domain 
BAF53A/B Both Actin fold 
β-actin Both Actin fold, ATPase 
BRG1 Both 
DNA-dependent ATPase, bromodomain, HAS, BRK, 
SnAC 
BAF45A PBAF Tandem PHD domains, zinc finger 
BAF180 PBAF Bromodomain, BAH, HMG-box 
BRD7 PBAF Bromodomain 
ARID2 PBAF ARID/BRIGHT, DNA binding domain 
 
BAF180 interacts with at least BRG1 and BAF200 when assembled in the PBAF 
complex. The bromodomains and BAH domains were not able to associate with BRG1 
or BAF200 on their own, but the HMG domain was able to.43 This suggests that the 
HMG domain is the site through which BAF180 interacts with other components of the 
PBAF complex. This has interesting implications for the mutant BAF180 proteins in 
cancers. Most of the mutations result in the loss of all or part of the HMG domain, 
implying that these mutants are unable to associate and form the PBAF complex, which 
would impair transcription since the PBAF and BAF complexes are shown to interact 
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with nucleosomes differently. This hypothesis is in accordance with results from Gao et 
al. demonstrating that a mutant BAF180 protein (without the HMG-box) was unable to 
associate with other subunits of the PBAF complex.68 This raises an important question: 
If the mutant proteins of BAF180 are expressed and not immediately degraded by 
proteases or the ubiquitination degradation pathway, and they cannot associate with 
PBAF, what are the mutant BAF180 proteins doing in the cell? Does the mutant bind 
with something else, causing a deleterious effect or is the problem merely that it does not 
associate with PBAF? And since BAF180 is the chromatin-targeting subunit of PBAF, if 
BAF180 doesn’t associate with the other subunits of PBAF, maybe PBAF cannot bind to 
the DNA site of transcription, or at least it cannot pick the right site. The PBAF complex 
can still form in the absence of BAF180.69-70 When BAF200 was knocked down, 
BAF180 levels also decreased, suggesting that BAF200 recruits BAF180 to the PBAF 
complex or influences its stability. When BAF180 was knocked down, levels of BAF200 
did not change.71 We still do not understand how this data relates to the binding of 
BAF180 to nucleosomes. 
1.4.2 Development 
1.4.2.1 Retinoic Acid Pathway  
Retinoic acid (RA) mediated transcription is controlled by two nuclear proteins: a 
retinoic acid receptor (RAR) and a retinoid X receptor (RXR). By themselves, RAR and 
RXR are not active, but when they come together to form a heterodimeric complex, they 
are able to bind to specific DNA sequences called RA response elements (RAREs). These 
elements consist of two repeats of a conserved hexameric motif (PuG(G/T)TCA, where 
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“Pu” represents a purine base) separated by 1, 2, or 5 base pairs. For repeats separated by 
2 or 5 bases (referred to as DR2 or DR5), the RXR subunit interacts with the 5' motif, 
while RAR subunit interacts with the 3' repeat. In DR1 elements, the interactions are 
reversed (Figure 1.15).72 
 
Figure 1.15: The RAR/RXR complex binds to a hexameric repeat in the DNA. If the spacing between 
repeats is 2 or 5 base pairs, the RXR protein binds on the 5' end of the sequence and the RAR protein binds 
on the 3' end. If the spacing is only 1 base pair, the orientation is flipped: the RAR protein binds at the 5' 
end and the RXR protein binds on the 3' end. 
 
In the absence of retinoic acid, the RAR/RXR complex forms and retains binding 
to the RARE sequences, but performs a repressive role. The RAR/RXR complex recruits 
the co-repressors NCoR (nuclear co-repressor) and SMRT (silencing mediator for 
retinoid and thyroid hormone receptor) complexes, which contain histone deacetylase 
proteins, thus repressing transcription by compacting chromatin.72-73 The full pathway is 
detailed in Figure 1.16. 
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Figure 1.16: The retinoic acid-mediated transcription pathway. The presence of retinoic acid induces 
structural changes, allowing transcription factors (such as BAF180 in PBAF) to bind. 
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In the presence of retinoic acid, the RAR/RXR complex switches from a 
transcriptional repressor to a transcriptional activator. Retinoic acid is transported to the 
nucleus by CRABPII (cellular retinoic acid binding protein), where it can then bind to the 
RAR/RXR complex.74 When retinoic acid binds to the ligand-binding site, RAR and 
RXR undergo a conformational change which increases the affinity of the complex for 
the DNA RARE sequences.72 The conformational changes create a new hydrophobic cleft 
which causes the co-repressors to dissociate. The coactivators p160, p300/CBP, and 
CARM-1 now bind and proteins possessing histone acetyltransferase (HAT) activity are 
recruited. Once the histones have been acetylated, SWI/SNF complexes are recruited, 
sliding the nucleosomes and allowing for transcriptional machinery to bind to the gene 
promoter. The coactivators then dissociate and the SMCC complex (Srb and Mediator 
protein containing complex) is recruited. The SMCC complex then recruits the 
transcriptional machinery, such as RNA PolII.73,75  
Studies have demonstrated that the retinoic acid pathway is crucial for heart 
development, as absence of retinoic acid in quail and mouse embryos resulted in impaired 
heart development.76-77 The role of BAF180 in the retinoic acid pathway was elicited by 
Wang et al., who investigated the effects on heart development in BAF180 knockout 
mice. Mice which lacked BAF180 showed a decrease in the expression of CRABPII and 
RARβ2, two important genes involved in the retinoic acid pathway: BAF180 was 
demonstrated to be present at the promoter sites of these genes through ChIP (chromatin 
immunoprecipitation) assays.78 More details can be found in the heart development 
section (Section 1.4.2.2). 
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1.4.2.2 Heart 
Wang et al. first elicited the role of the BAF180 protein in heart development in 
2004 when it was found that BAF180 knockout mice (KO) died mid-gestation. Further 
investigation revealed heart defects to be the likely cause. The absence of BAF180 
resulted in severe hypoplasia (underdevelopment, thinning) of the cardiac ventricular free 
walls (outer walls of the heart) and ventricular septal defects (hole in the wall separating 
right and left ventricles).78 
Several experiments were conducted to determine if the observed heart defects 
were a direct or an indirect result of BAF180 KO. The possibility of inappropriate cell 
death during development of the cardiac tissues was ruled out after experiments indicated 
that apoptotic cells were not present in the developing heart of either normal or BAF180 
KO mice.78 Incorrect cell differentiation was eliminated as a possibility after cardiac 
biomarker analysis revealed normal expression in BAF180 KO hearts.78  
Microarray analysis revealed that the absence of BAF180 had an impact on the 
expression levels of numerous genes, many of which were structurally- or metabolically-
related. In particular, two growth arrest-specific genes were up-regulated, supporting the 
theory that the heart defects may be a result of growth arrest and that loss of BAF180 is 
directly responsible for the observed cardiac defects.78 
Building on the observation that placenta in BAF180 KO mice was abnormal, 
Wang et al. set out to determine if this could be the cause of the heart defects. Two types 
of experiments were performed to determine if the defective placenta had an impact on 
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the developing embryo’s heart. Studies wherein the placenta was derived from wild type 
(WT) cells and the embryo was derived from mutant BAF180 KO cells demonstrated that 
the heart defects still occurred even when placental development was normal. The inverse 
experiment, wherein the placenta was derived from mutant BAF180 KO cells and the 
embryo was derived from WT cells, showed that no heart defects were present, even 
though the placenta was abnormal. This suggested that the placenta defects did not play a 
role in cardiac defects.78  
Comparing the phenotypic similarities of BAF180, RXRα, and PPARγ null mice 
led to the investigation of BAF180’s role in the retinoic acid pathway (RXRα and PPARγ 
are involved in the retinoic acid signaling pathway). The PBAF complex is known to 
mediate the transcriptional activity of RXRα and PPARγ in vitro,79 so the researchers set 
out to determine if BAF180 specifically is required for the transcription of some RA-
related genes in vivo. Quantitative RT-PCR indicated that elimination of BAF180 
resulted in a 5-8 fold down-regulation of the retinoic acid transporting protein CRABPII, 
and a slight down-regulation in the expression of RARβ2, a retinoic acid binding protein. 
In normal cells, exposure to retinoic acid will increase the expression of RARβ2 (~100 
fold) and CRABPII (5-8 fold). However, after treatment with retinoic acid, BAF180 KO 
cells exhibited no response for CRABPII expression and decreased effect on RARβ2 
expression. ChIP analysis further linked BAF180 to the transcription of RARβ2 and 
CRABPII. BAF180 was found to be present at the RARβ2 and CRABPII promoters, 
where its occupancy level at the RARβ2 promoter increased in the presence of retinoic 
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acid. This data suggests that the observed heart defects in BAF180 KO mice may be 
partially linked to the role of BAF180 in the retinoic acid pathway.78 
A later study by the same lab revealed that these heart defects might be due to 
improper coronary vessel formation.80  Mice lacking BAF180 showed underdevelopment 
of coronary vessels in the epicardial and myocardial layers of the developing heart.80 It is 
possible that the hypoplasia observed in their previous study may be related to this, as 
underdevelopment of the coronary vessels results in reduced blood circulation, impeding 
the growth of cardiac cells. Another study, by Singh et al., showed that the expression of 
BAF180, along with two other SWI/SNF subunits, was higher in the heart as compared to 
the rest of the embryo during early development, again supporting the critical role of 
BAF180 in cardiac development.81  
Taken together, these studies strongly suggest that the cardiac defects observed in 
BAF180 KO mice are a direct result of the loss of BAF180, at least partially due to the 
role of BAF180 in coronary vessel development and the retinoic acid pathway. 
1.4.2.3 Thymus 
Proper immune system function is critical to everyday health. Improper immune 
function not only leaves the person more vulnerable to pathogens, but also makes them 
more susceptible to auto-immune diseases, wherein the body’s own T cells attack specific 
tissues (examples include rheumatoid arthritis and Crohn’s disease). The thymus is an 
organ in the lymphatic system which produces the T cells.82 T cells target and destroy 
infected cells.83-84  
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Wurster et al. selectively deleted BAF180 in late development T cells to discern 
the effect on thymus and T cell development. A cre recombinase cassette was used to 
specifically delete the BAF180 gene in T cells, leaving normal BAF180 levels throughout 
the rest of the embryo, including the placenta and heart. This is important as previous 
studies demonstrated that lack of BAF180 caused placental and heart defects, causing 
embryos to die mid-gestation.78 Due to the nature of the cre recombinase cassette, 
BAF180 is not deleted until later in development, allowing normal BAF180 levels in T 
cells during early embryonic development.85  
While overall T cell and thymic development were unaffected, a few changes 
were observed in peripheral CD4 T cells. A general down-regulation of the CD44 antigen 
(a surface glycoprotein involved in cell-cell interactions, adhesion, and migration)86 was 
seen, though it was not determined if this was a direct or indirect result of the loss of 
BAF180. Additionally, a small increase in the expression of a few cell cycle inhibitors 
was observed, corresponding with a slight decrease in the proliferative response to 
stimuli. A decrease in the expression of proteins involved in nucleosome assembly, 
transcription, and DNA binding was observed, along with an increase in expression of 
proteins involved in ribosome biogenesis and translation. Interestingly, the gene most 
affected by BAF180 deletion was IL-10, which was significantly up-regulated.85 IL-10 is 
an anti-inflammatory cytokine produced in many types of immune cells. It can regulate 
the innate and adaptive immune responses by inhibiting T cell activation and 
differentiation in lymph nodes and suppress pro-inflammatory responses in tissues.87 So 
overall, IL-10 hinders the immune response to pathogens. When IL-10 expression 
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increases as a result of BAF180 deletion, the immune response decreases. It was 
determined that BAF180 binds directly around the IL-10 locus, suggesting that BAF180 
directly affects the expression levels of IL-10. As can be imagined, in the absence of 
BAF180, the PBAF complex is replaced by BAF complex, which likely has an impact on 
binding patterns around the IL-10 locus. When PBAF was replaced with BAF, increased 
acetylation of histones was observed, suggestive of increased transcription; further tests 
were not performed to investigate this intriguing data.85 
1.4.3 DNA repair 
Malfunctions in DNA repair and genomic instability are hallmarks of cancer. 
BAF180 has a multitude of roles in double-strand break repair66 (via non-homologous 
end joining and homologous recombination) and post-replication repair.43 In addition, 
BAF180 was found to be important for maintaining genomic stability and preventing 
aneuploidy.88 
1.4.3.1 Genomic Instability 
In mice, genomic instability was shown to be caused by a lack of cohesion 
between the centromeres of chromosomes. This lack of cohesion can also lead to 
aneuploidy, where a cell contains an abnormal number of chromosomes. When BAF180 
was depleted in mouse embryonic stem cells, the distance between centromeres 
increased, suggesting less cohesion between them. This appears to be exclusive to 
centromeres, as the distances between telomeres and chromosomal arms showed no 
significant change. To determine the route by which BAF180 affects the centromeric 
cohesion in chromosomes, levels of other cohesion genes were tested in BAF180-
50 
 
deficient cells. It was found that the levels of the cohesion genes were normal, indicating 
that BAF180 did not affect the transcription of these genes.88  
Cancer-associated mutants of BAF180 were unable to restore cohesion to 
BAF180-depleted cells or reduce the cell’s sensitivity to DMSO-induced DNA damage. 
Three different point mutations were introduced in Rsc2, a homolog of BAF180: Rsc2-
H458P (which corresponds to H1205P in BAF180 isoform 9, located in second BAH 
domain); Rsc2-T67P (corresponding to T232P in BAF180, brd2); Rsc2-M280I 
(corresponding to M523I in BAF180, brd4). Yeast cells lacking Rsc2 are temperature 
sensitive and are sensitive to DMSO-induced DNA damage. Mutant Rsc2-H458P showed 
patterns of sensitivity similar to Rsc2 KO cells, but mutants Rsc2-T67P and Rsc2-M280I 
showed reduced sensitivity, indicating that these mutants were able to partially restore 
normal function. None of the mutants were able to restore cohesion between 
centromeres.88 
Insufficient cohesion between centromeres can have several repercussions, 
including mis-segregation of chromosomes, formation of micronuclei, and lagging 
chromosomes. Mis-segregation of chromosomes during mitosis results in acentric 
chromosomes, chromosomes which lack a centromere.89 Because they lack a centromere, 
they cannot attach to the spindle during mitosis and as such are lost during replication.90 
An acentric chromosome that has become enclosed by a nuclear membrane is called a 
micronuclei;90 micronuclei are commonly seen in cells with defective cohesion. Lagging 
chromosomes are another common characteristic of centromeric cohesion. Lagging 
chromosomes are chromosomes that are left near the spindle equator after anaphase (due 
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to improper segregation), while other chromosomes move toward the spindle poles. 
These can also become micronuclei.91-92 Both acentric chromosomes and lagging 
chromosomes can cause aneuploidy in a cell,93 wherein the individual cell has a different 
number of chromosomes than a wild type cell. Aneuploidy, micronuclei, and lagging 
chromosomes were each identified in BAF180 deficient cells.88  
Loss of cohesion negatively impacts recombination-based DNA repair. Therefore, 
loss of cohesion and chromosomal instability may be two ways in which BAF180 helps 
prevent tumorigenesis. When BAF180 is depleted from a cell, cohesion between 
centromeres greatly decreases, and as a result, chromosomal instability increases.88 This 
lack of cohesion and increase in chromosomal instability suggests that BAF180 may have 
a role in homologous recombination (HR), as other proteins, such as BRCA1, have dual 
roles in cohesion and HR.63 
1.4.3.2 DNA Double-Strand Break Repair 
BAF180 also plays a role in double-strand break (DSB) repair by silencing 
transcription near the break sites. When transcription is not silenced, DSB repair is 
delayed; since most irradiation-induced DSBs are repaired rapidly,66 this delay can lead 
to chromosomal translocations, as well as deletions.52 PBAF was found to silence 
transcription around DNA breaks. When BAF180 was depleted in reporter cells, 
transcription of the reporter gene (they used yellow fluorescent protein) was not silenced, 
suggesting that BAF180 is needed to silence transcription around DNA breaks. If 
transcription isn’t repressed, rapid DSB repair is impaired.66 Additionally, when 
BAF180-depleted cells were exposed to irradiation, the non-homologous end joining 
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(NHEJ) DNA repair pathway, a key mechanism by which DSBs are repaired,66 was 
compromised.94  
By treating siBAF180 cells with DRB (5,6-Dichlorobenzimidazole 1-β-D-
ribofuranoside), a transcription inhibitor, Kakarougkas et al. determined that the role of 
BAF180 in DSB repair is dependent on active transcription. In siBAF180 cells, DNA 
damage levels were high at 20 minutes post-IR, as indicated by a high number of 
γH2AX; when BAF180 was re-introduced, levels of γH2AX were similar to control 
cells.94 γH2AX is used as a biomarker to measure the quantity of DNA double-stranded 
breaks.95 Wherever double-stranded breaks form, H2AX is immediately phosphorylated, 
becoming γH2AX; therefore, the presence of γH2AX can be used to determine the extent 
of double-stranded breaks in a 1:1 ratio.95 The phosphorylation of γH2AX is the first step 
in recruiting DNA repair proteins.95 When siBAF180 cells (which were unable to stop 
transcription) were treated with DRB (which stops transcription), the DNA damage levels 
decreased to around that of the control cells, indicating that stopping transcription 
restored DNA damage repair function. This means that when transcription is stopped, 
BAF180 is not needed for double strand break repair.94  
A protein’s function can be influenced by the presence of PTMs. S963 (number 
corresponding to isoform 8 of BAF180) was found to be phosphorylated by ATM (ataxia 
telangiectasia mutated).96 ATM is a kinase that is critical for DSB repair.96 This 
phosphorylation site is located between the sixth brd and the first BAH domain. Two 
mutant constructs (a phosphomutant S963A and a phosphomimic S963E) were created by 
Kakarougkas et al. to determine if phosphorylation was critical to BAF180’s role in DSB 
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repair. When the phosphomutant was added to siBAF180 cells, no significant change was 
seen, indicating that the phosphomutant did not help DNA repair, meaning that 
phosphorylation is important to BAF180’s role in DNA DSB repair. When the 
phosphomimic was added, levels of damaged DNA were similar to control cells, 
indicating that proper DNA repair function was restored. This suggests that 
phosphorylation of BAF180 at S963 is a crucial step in DSB repair.94  
Some of the tumor suppressor properties of BAF180 may be related to its 
functions in DNA repair. Cancer-associated mutations were unable to restore normal 
DSB repair function in BAF180 KO cells,94 suggesting that cancer cells with mutations in 
BAF180 have a dysfunction in mediating DSB repair. Mutations which eliminated the 
phosphorylation site S963 were also unable to restore normal DSB repair functioning.94  
1.4.3.3 Ubiquitination of PCNA 
The BAH domains of BAF180 are required to ubiquitinate PCNA (proliferating 
cell nuclear antigen).43 PCNA regulates replication past sites of DNA damage and its 
ubiquitination is a necessary step in re-priming past damaged DNA forks during post-
replication repair (PRR).97  
When BAF180 was depleted, cells were unable to produce the proper levels of 
ubiquitinated PCNA, which leads to an inability to replicate past DNA lesions.98 After 
UV-irradiation, BAF180-depleted cells had far lower levels of chromatin-bound PCNA 
(both ubiquitinated and non-ubiquitinated) and decreased levels of Rad18, the E3 ligase 
that ubiquitinates PCNA, when compared to control cells (where BAF180 was present at 
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normal levels). It has been reported that BAF180 does play a role in regulating the cell 
cycle,99 therefore experiments were conducted to determine if the reduced levels of 
chromatin-bound PCNA were an indirect consequence of BAF180 impacting the cell 
cycle. Ubiquitination of PCNA and its binding to chromatin occurs during the S-phase; 
post-IR, the proportion of cells in S-phase actually increased, indicating that the lower 
levels of chromatin-bound PCNA and Rad18 are not an indirect consequence of cell 
cycle changes occurring upon depletion of BAF180.98 This suggests that BAF180 is 
directly responsible for the observed changes in chromatin-bound PCNA and Rad18, and 
therefore indirectly responsible for the decreased ubiquitination levels. The BAF180 
orthologue Rsc2 was found to be located near replication forks,98 strongly suggesting that 
BAF180 may be as well. 
Additionally, PCNA remained ubiquitinated longer in flag-BAF180 FL cells than 
in control cells during S-phase;43 there was very little ubiquitinated PCNA detected in G1 
and G2 phase cells. Interestingly, the levels of BAF180 were highest in S-phase cells,43 
suggesting that the S-phase specific function of BAF180 (i.e. ubiquitination of PCNA) 
requires higher levels of BAF180 than other phases, which has interesting implications 
since PBAF (and hence BAF180) is involved in transcription and has not been found to 
be limited to one phase of the cell cycle. It would be interesting to perform FACS 
(fluorescence-activated cell sorting) analysis on several components of the PBAF and 
BAF complexes to see how the protein levels change throughout the different phases of 
the cell cycle.  
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To determine which domain(s) of BAF180 are involved in PCNA ubiquitination, 
Niimi et al. created flag-tagged constructs of the different domains (bromodomains, the 
BAH domains, and the HMG domain). They found that levels of ubiquitinated PCNA 
between full-length flag-tagged BAF180 and flag-BAHs were similar; cells with the flag-
brds and flag-HMG constructs were unable to ubiquitinate PCNA, which suggests that 
the BAH domains are required for PCNA ubiquitination and that the other domains of 
BAF180 are not necessary. Additionally, BAF180 did not need to be in complex with 
PBAF in order for the BAH domains to facilitate ubiquitination.43  
1.4.3.4 DNA Repair Conclusion 
The tumor suppressor properties of BAF180 might stem from its roles in various 
DNA repair mechanisms, as discussed above. Cancer cells with a mutation in or 
decreased expression of BAF180 could be compromised with regards to DNA repair in 
four ways:  
(1) Genomic instability: An increased distance between centromeres leads to an 
increase in genomic instability, which may in turn prevent recombinatorial-based 
DNA repair mechanisms.88  
(2) Inability to ubiquitinate PCNA: Ubiquitination of PCNA is a key step in the 
post-replication repair pathway. The BAH domains of BAF180 are required for 
proper ubiquitination levels. Lack of the BAH domains likely leaves much of the 
DNA unrepaired.43,98  
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(3) Silencing of transcription at DNA double-strand breaks: At sites of active 
transcription near DNA DSBs, BAF180 is needed for the proper repair of these 
breaks. BAF180 silences transcription at sites of DSBs, allowing for the rapid repair 
of damaged DNA.94 
(4) HMG box and NHEJ: As mentioned in an above section (Section 1.3.3), an 
HMG-box binds to DNA and facilitates NHEJ by bending the ends of the DNA. 
Assuming this domain is the DNA-binding component of BAF180, deletion of this 
box likely hinders NHEJ (and transcription) because BAF180 can no longer bind to 
DNA. Many cancer mutants lack the HMG box.44,52 
1.4.4 p21 and the Cell Cycle 
BAF180 has been shown to influence the cell cycle progression in many types of 
cells. Evidence has demonstrated that the loss of BAF180 caused cells to replicate and 
grow faster than control cells (see Section 1.5.2 on ccRCC). Reintroduction of BAF180 
into these cells reduced cell proliferation and induced G1100  and G299 arrest, showing a 
direct link between BAF180 and cell cycle progression. The role of BAF180 in G1 cell 
cycle arrest is due, at least in part, to its regulation of p21 expression. In the absence of 
BAF180, the mRNA levels of p21 decreased, resulting in fewer cells in G1 arrest.100 p21, 
also known as cyclin-dependent kinase inhibitor 1, is used by cells to enter G1 and G2 
phase arrest.39 Flow cytometry and subsequent cell cycle analysis revealed that, upon re-
introduction of BAF180, more cells were entering G1 arrest than control cells which 
lacked BAF180.100 BAF180 has also been found to be critical for cellular senescence.101 
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Treatment with nutlin-3, which is used to induce p53-dependent transcription,101-
103 usually leads to a substantial increase in p21 levels; however, when BAF180 was 
knocked down, the levels of p53-induced p21 were significantly lower.101 Chromatin 
immunoprecipitation experiments demonstrated that BAF180 regulates the expression of 
p21 directly by binding to its promoter in vivo.100 
Cellular damaging agents, such as TGF-β and γ-irradiation, have been shown to 
up-regulate p21 expression, causing subsequent entry of the cell into G1 or G2 arrest, 
respectively (Figure 1.17). Their effect on up-regulation of p21 was diminished in 
BAF180-deficient cells. Interestingly, while the up-regulation of p21 was similarly 
diminished in both TGF-β and γ-irradiation treated cells, there was no effect on G2 arrest 
(Figure 1.17),100 indicating that BAF180’s role in G2 arrest may be through another 
pathway.99 The role in p21 expression is believed to be part of the mechanism by which 
BAF180 influences the cell cycle. When BAF180 is mutated, it cannot bind to the p21 
promoter and therefore G1 cell cycle arrest is prevented. Interestingly, a recent study by 
Chowdhury et al. showed that changes in BAF180 expression did not affect p21 levels in 
ccRCC cell lines A704 or 786-O.68 Xia et al.’s study was performed in breast cancer 
cells100 and Burrows et al., whose data supports that of Xia et al., performed their analysis 
in human fibroblasts and mammary cells.101 It is plausible that the effect of BAF180 on 
p21 is tissue specific. 
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Figure 1.17: Diagram of the role of BAF180 in p21 expression and cell cycle arrest. (A) When a cell is 
deficient in BAF180, through mutation or knockdown, there is deregulation of the cell cycle, resulting in a 
high rate of cell proliferation. Additionally, less p21 is produced, as BAF180 is required for its 
transcription. (B) and (C) Flow chart showing how different treatments, TGF-β and γ-irradiation, affect the 
cell cycle. In normal cells, upon treatment, there is an increase in p21 expression, resulting in G1 and G2 
phase arrest, respectively. In BAF180-deficient cells that are treated with TGF-β, there is less p21 and no 
G1 phase arrest. But if a cell is exposed to γ-irradiation, G2 arrest can still occur, though there is less 
p21.100 
 
Expression of p21 is regulated primarily by p53;104 however, p21 is also known to 
be regulated by the retinoic acid (RA) pathway in a manner independent of p53.101,105 
BAF180 binds to the promoters of CRABPII and RARβ2, both key components of the 
RA pathway; when there is less BAF180, there is less CRABPII and RARβ2.78 So 
BAF180 could affect p21 in an indirect manner by affecting the retinoic acid pathway. 
Additionally, BAF180 is known to bind to the p21 promoter, thereby affecting p21 
transcription directly.100 So BAF180 may influence p21 transcription in an indirect and 
direct manner (Figure 1.18).  
In bladder cancer cells, PBRM1 was found to be required for G2 phase cell cycle 
arrest by inhibiting the expression of cyclin-B1.99 This does not contradict the results that 
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Xia et al. published, as they did not examine cyclin-B1; they focused solely on p21 and 
p53. 
 
Figure 1.18: Plausible overall pathway for the regulation of p21 expression by BAF180 and p53.74,78,100-101 
For clarity, different colored arrows have been used to denote the different consequences. Blue arrows 
demonstrate the consequences of BAF180 mutations, while green arrows show the consequences of 
decreasing the amount of BAF180 in the cell. 
 
Additionally, BAF180 was found to be required for replication senescence,101 a 
state different from cell cycle arrest (temporary); in senescence, cell growth is 
permanently stopped.106 Once again, the role of BAF180 in senescence is related to its 
role in regulating the expression of some p53-controlled genes.101 
1.4.5 p53 Induced Degradation of BAF180 
BAF180 levels have been shown to be reduced upon activation of p53 by nutlin-
3.102 This activation of p53 led to a decrease in BAF180 protein levels. The reduction of 
BAF180 levels was demonstrated to be at the protein level, as RT-PCR revealed little 
change in the mRNA levels. Experiments showed that proteasomes were responsible for 
the degradation of BAF180, as the treatment of cells with proteasome inhibitors reduced 
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the level of degradation (i.e. more BAF180 remained). Further experimentation 
determined that an E1 ubiquitin ligase is responsible. Therefore, BAF180 degradation is 
controlled by a p53-dependent ubiquitin related pathway.102 Connecting this to section 
1.4.4 on p21, the reduction of BAF180 by a p53-dependent pathway leads to a decrease 
in p21 expression and a loss of G1 phase cell cycle arrest (Figure 1.18). 
1.4.6 Psychiatric Disorders 
Medications for schizophrenia and bipolar disorder have targeted the same gene 
for more than 60 years. These treatments are only effective for a small proportion of 
patients.107 In recent years, the lack of effective treatment options has led to numerous 
genome-wide association studies. Several of these studies identified PBRM1 as a 
significant risk locus for schizophrenia, bipolar disorder, major depressive disorder, and 
psychosis.107-117 A study by McMahon et al. discovered that PBRM1 is overexpressed in 
the prefrontal cortex of people with bipolar disorder.113 Unfortunately, the clinical impact 
of these discoveries remains undetermined. 
1.4.7 HIV and Tat protein 
During an HIV infection, the Tat protein promotes HIV virus replication and 
controls transcription occurring at the LTR promoter (long terminal repeat: a type of 
retroviral promoter).21,53,118-119 At the LTR, PBAF is recruited by the Tat protein, 
rearranging nucleosomes to promote transcription.120 BAF180 interacts with the Tat 
protein through acetylation sites at K50/K51, resulting in suppression of Tat protein 
expression.121-122  BAF180 association with Tat was increased in the presence of p300, as 
shown in co-immunoprecipitation of BAF180 and Tat.  
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1.5. Cancers 
Since Varela et al. published that PBRM1 is mutated in ~40% of clear cell renal 
cell carcinoma cases,1 the number of studies relating PBRM1 mutations to cancers has 
exponentially increased. PBRM1 is now linked to more than 30 types of cancers (Table 
1.5).123-125 Mutations of every type (frameshift, substitution (synonymous and missense), 
and truncation) have been identified, though truncation mutations (presence of a 
premature stop codon) are the most frequent (Figure 1.19).123-125 Mutations have been 
seen to affect all nine domains, though mutations are also found between domains. Figure 
1.20 displays the domain organization of wild-type BAF180 (A) and several mutants seen 
in cancers (B). It has been speculated that cancer-associated mutations of BAF180 may 
impair the ability of the PBAF complex to bind to nucleosomes, as BAF180 is believed to 
be the histone targeting component. Each of the six bromodomains of BAF180 are 
capable of binding to acetylated lysines present on histones, though it is unknown 
whether this occurs singularly or in tandem. Deletion of any of the bromodomains would 
affect the ability of BAF180 to bind histones, either by weakening the binding 
interactions or eliminating them completely (depending on the severity of the truncation). 
The inability of BAF180 to bind precludes the other subunits of the PBAF complex from 
being recruited; therefore, PBAF-mediated transcription cannot occur.  
Discussed in upcoming sections are some of the cancers for which specific studies 
on PBRM1 (BAF180) have been conducted. Most of the studies published have noted 
that PBRM1 was mutated, but they did not explore further. Therefore, an overall 
discussion of BAF180 in cancers is not possible.  
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Table 1.5: The frequency of PBRM1 alterations in different types of cancers. PBRM1, the gene for 
BAF180, has been found to be mutated in more than 30 types of cancers. Data was collected from 
cBioPortal.123-124 
Cancer Frequency of alterations in PBRM1 
Clear cell renal cell carcinoma 
(ccRCC) 39% 
Neuroendocrine Prostate Carcinoma 24% 
Cholangiocarcinoma 18-23% 
Cutaneous Squamous Cell Carcinoma 10% 
Breast Cancer 2-14% 
Bladder Cancer 2-10% 
Uterine Carcinomas 4-9% 
Stomach Adenocarcinoma 3-8% 
Diffuse Large B-Cell Lymphoma 3-8% 
Esophageal Carcinoma 2-8% 
Pancreatic Carcinomas 1-7% 
Prostate Adenocarcinoma 1-7% 
Lung Carcinoma 2-6% 
Melanomas 1-6% 
Mesothelioma 5% 
Papillary RCC 4% 
Colorectal Adenocarcinoma 3-4% 
Head and Neck Carcinoma 2-4% 
Thymic Carcinomas 2-4% 
Hepatocellular Carcinoma 1-4% 
Thyroid Carcinomas 3% 
non ccRCC 3% 
Gallbladder Carcinoma 3% 
Cervical Squamous Cell Carcinoma 3% 
Sarcoma 1-3% 
Adenoid Cystic Carcinoma 2% 
Ovarian Carcinoma 2% 
Neuroblastoma 2% 
Chromophobe Renal Cell Carcinoma 2% 
Gliomas 1-2% 
Adrenocortical Carcinoma 1% 
Chronic Lymphocytic Leukemia 1% 
Pediatric Ewing Sarcoma 1% 
Multiple Myeloma 1% 
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Figure 1.19: Chart of the frequency of different types of mutations of PBRM1 (BAF180) in cancers. Data 
was collected from COSMIC database.125 
 
 
 
Figure 1.20: (A) The domain organization of wild-type BAF180 and (B) various truncated mutant proteins 
observed in cancers.  
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1.5.1 Cell Proliferation 
The effect of BAF180 on cell proliferation appear to be cell line specific. In some 
cases, knockdown of BAF180 resulted in increased proliferation1,68-69,99-100,126 while in 
others, knockdown resulted in decreased proliferation68,127 or no effect1,68-69 (Table 1.6). 
Similarly, re-expression of BAF180 into BAF180-deficient cell lines showed either 
decreased proliferation68-69,99-100,126-127 or no had effect on proliferation68 (Table 1.7).  For 
example, Varela et al., Gao et al., and Xiao et al. demonstrated that knockdown of 
BAF180 results in increased proliferation in cell line 786-O,1,68,126 but Murakami et al. 
reported that BAF180 knockdown decreased proliferation in this cell line,127 suggesting 
that more studies need to be conducted in order for any true conclusions to be drawn.  
Interestingly, Gao et al. found that in some cell lines, for re-expression or 
knockdown of BAF180 to have an effect on cell proliferation, the cells needed to have 
BRG1, the ATPase subunit of the PBAF complex.68 Murakami et al. found that cells 
needed HIF1α in order for BAF180 to have a tumor-suppressor effect127 though Gao et al. 
did not find any correlation to levels of HIF factors.68  
Gao et al. demonstrated that a tumor-associated BAF180 mutation (missing the 
HMG-box and C-terminus) was not able to suppress proliferation in A704 cells (kidney 
adenocarcinoma cells), but was able to suppress growth in Caki2 cells (clear cell renal 
cell carcinoma cells). They also showed that a mutant lacking the first two bromodomains 
was able to reduce proliferation, though a mutant lacking all six bromodomains was not 
able to.68 Along that line, a recently published study by Porter and Dykhuizen 
demonstrated that single point mutations in BAF180 were able to abrogate its tumor-
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suppressive effects. Mutations in the first, second, fourth, and fifth bromodomain were 
unable to reduce proliferation in Caki2 cells, though wild type BAF180 could (Section 
1.3.1.2).23 
Table 1.6: Differing results on the effect of BAF180 knockdown on cell proliferation. The origin of the cell 
lines are as follows: bladder carcinoma: UM-UC-3; renal cell carcinoma: ACHN, 786-O, SN12C, TK10, 
UMRC2, KC-10, 769-P, RCC10, A498, A704; Clear cell renal cell carcinoma: Caki1 
 
Effects of BAF180 Knockout on Cell Lines
Knockdown BAF180, increased proliferation
Author Cell Line
Cell line +/- for 
BAF180 KD method
Huang99
Mice in vivo injection of UM-
UC-3 +
transfection, injection into 
mice
Varela1 ACHN + siRNA
Varela1 786-O + siRNA
Varela1 SN12C + siRNA
Varela1 TK10 + siRNA
Gao68 Mice in vivo implant of 786-O +
lentiviral, implant into 
mice
Xiao126 ACHN + miRNA targeting PBRM1
Xiao126 786-O + miRNA targeting PBRM1
Knockdown BAF180, decrease proliferation
Gao68 UMRC2 + shRNA
Murakami127 786-O + shRNA
Murakami127 KC-12 + shRNA
Murakami127 769-P + shRNA
Murakami127 RCC10 + shRNA
Murakami127 A498 + shRNA
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Table 1.7: Differing results of the effect of BAF180 re-expression on cellular proliferation. The origin of 
the cell lines are as follows: bladder carcinoma: UM-UC-3, 5637; renal cell carcinoma: ACHN, 786-O, 
A704, SKRC20, SLR24; Clear cell renal cell carcinoma: Caki2, RCC4; breast cancer: HCC1143; 
endometrial adenocarcinoma: EJ.  
 
Knockdown BAF180, no effect on proliferation
Author Cell Line
Cell line +/- for 
BAF180 KD method
Gao68 786-O (ex vivo) + shRNA
Gao68 SN12C +
Chowdhury69 Caki1 +
Chowdhury69 A498 + lentiviral
Varela1 A704 - siRNA
Effects of Reintroduction of BAF180 into Cell Lines
Re-express BAF180, decrease proliferation
Author Cell Line
Cell line +/- for 
BAF180 Method
Xia100 HCC1143 - Transfection
Gao68 A704 - Lentiviral
Gao68 Caki2 - Lentiviral
Chowdhury69 A704 - Lentiviral
Chowdhury69 Caki2 - Lentiviral
Huang99 UM-UC-3 + Up-regulation
Huang99 EJ + Up-regulation
Huang99 5637 + Up-regulation
Xiao126 ACHN + miRNA targeting PBRM1
Xiao126 786-O + miRNA targeting PBRM1
Re-express BAF180, no effect on proliferation
Gao68 SKRC20 - Lentiviral
Gao68 SLR24 - Lentiviral
Gao68 RCC4 - Lentiviral
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It should be noted that Varela,1 Gao,68 Xiao,126 Chowdhury,69 and Murakami127 
performed their studies in renal cells, while Xia100 and Burrows101 used mammary cells, 
Burrows101 used fibroblasts, and Huang used bladder cells.99 The discrepancies in 
BAF180’s tumor suppressor capabilities between different cell lines should be a focus of 
future studies; experiments in all these cell lines using a singular technique performed by 
the same lab would go a long way towards addressing this disagreement. The reasons 
behind the different proliferation responses of cell lines to BAF180 is still unknown, 
though Gao et al. presents several plausible explanations.68  
1.5.2 Clear Cell Renal Cell Carcinoma 
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell 
carcinoma (~92% of cases).128-129 Of these, ~40% of cases carry a mutation in the 
PBRM1 gene,1 though mutations of PBRM1 are rarely found in other types of renal 
carcinomas.130 This makes it the second most commonly mutated gene in ccRCC, after 
VHL (mutated in 75-80% of cases).131-132   
In cancer, there are “driver” and “passenger” mutations. A “driver” mutation is 
considered to promote tumorigenesis, whereas a “passenger” mutation does not 
contribute to cancer development.133-138 Additionally, a “driver” gene is one in which 
mutations occur at a rate higher than expected by chance alone.131 Loss of PBRM1 is 
considered to be a driver event in ccRCC.128,131,139 
Interestingly, in ~90% of ccRCC cases, the 3p arm of one copy of chromosome 3 
is deleted, which encompasses four tumor suppressor genes: VHL, PBRM1, SETD2, and 
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BAP1.128,131-132,139-143  This deletion results in loss of heterozygosity. Knudson’s 
hypothesis proposes that for tumor suppressor genes, “two hits” are required to bring 
about cancer. In this case, the “first hit” would be loss of heterozygosity (LOH). The 
“second hit” is the mutation of the remaining copy of the gene; this mutation may result 
in the production of a protein which has lost its function or is only partially functional, or 
result in loss of protein expression altogether.23,68-69,131,144  PBRM1, as a tumor suppressor 
gene, follows this “two hit” approach.139 
1.5.2.1 Mutations in BAF180 
Mutations in the PBRM1 gene are found in approximately 40% of ccRCC 
tumors.1 Of these, approximately 82% of them are truncating mutations,145 either by 
frameshifts or nonsense mutations. Interestingly, mutations in BAF180 are mutually 
exclusive with mutations of BAP1 (BRCA1-associated protein 1), a nuclear 
deubiquitinase protein.139-140,144,146-148 Most mutations are thought to be destabilizing, 
resulting in no protein expression. Some mutations might be expressed but are predicted 
to have detrimental functional effects.131,140,144-145,149  
In one study by Pena-Llopis, 53% of samples tested were negative for PBRM1. Of 
these, 90% had a mutation in the gene. In the 47% of samples that were positive for 
PBRM1, 90% had wild-type BAF180/PBRM1.144 It should be noted that the researchers 
used an antibody recognizing an epitope on the C-terminus, which is often absent in 
BAF180 mutant proteins.144 Actually, most publications use the same antibody from 
Bethyl Labs (Bethyl A301-591A), which recognizes an epitope at the C-terminus. It is 
possible that the antibody fails to recognize the mutant proteins, as the C-terminus is 
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often missing from the mutant BAF180 proteins. A study by da Costa et al. used an 
antibody that recognized an epitope on the N-terminus of BAF180 (Sigma-Aldrich 
HPA015629) and showed that in 112 immunostained ccRCC samples, 34 (30.4%) 
showed negative expression and 78 (69.6%) showed positive expression of BAF180.150 
More experiments need to be conducted using both N- and C-terminus recognizing 
antibodies on the same samples. Nonsense-mediated mRNA decay likely prevents most 
truncated proteins from being expressed, though it is possible that some escape this 
cellular checkpoint. 
Silencing of the PBRM1 promoter via hypermethylation has also been proposed 
as a possible mechanism for PBRM1 inactivation.145 Promoter hypermethylation of 
tumor-suppressor genes is commonly observed in cancer.151 However, Ibragimova and 
colleagues found that hypermethylation of BAF180 is actually a rare event in ccRCC, as 
is the hypermethylation of BAP1, SETD2, and some other chromatin modifying genes. 
The authors point out this is not unusual, as some tumor-suppressor proteins commonly 
have promoter hypermethylation, while other do not. They propose that the deletion of 
the 3p21 region (which affects four tumor-suppressor genes) is more favorable to 
oncogenesis than the inactivation of one gene by hypermethylation.151 Some 
consequences of the frequent mutations of BAF180 in ccRCC are discussed in other 
sections (Sections 1.4.1 and 1.5.2). 
1.5.2.2 Gene Expression Signature in BAF180¯ ccRCC Cells 
The gene expression profile of BAF180-deficient cells is substantially different 
from that of BAF180-proficient cells. Many of the genes differentially expressed upon 
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BAF180 re-expression are involved in cell adhesion, cell proliferation, chromosomal 
instability, and hypoxia response.69,139,149 
Most of the genes affected by loss of BAF180 were down-regulated (1910/2235 
genes in Kapur et al.139 and 485/613 genes in Wang et al.)149 Both groups looked at gene 
expression in clear cell renal cell carcinoma (ccRCC) cases, where VHL, PBRM1, BAP1, 
SETD2, PTEN, and KDM5C are known “driver” genes (see Section 1.5.2). The 
significant differences in the number of genes affected may be because Wang et al. 
selected samples that had only PBRM1 mutations (no VHL, BAP1, SETD2, PTEN, and 
KDM5C mutations),149 while Kapur et al. did not report any such selection criteria.139  
Additionally, Wang et al. investigated methylation of CpG sites in the genome and found 
that, of the 1405 differently methylated sites, 1229 were hyper-methylated, which would 
result in gene silencing. They do point out, though, that not all of the genes may be 
directly regulated by PBRM1. The Wang study also investigated effects in miRNA 
expression; again, most of the affected miRNAs were down-regulated.149 
Re-expression of BAF180 into Caki2 cells led to the up-regulation of genes 
involved in cell adhesion and actin cytoskeleton.69 This is in agreement with Wang et al. 
and Kapur et al., who reported that BAF180-deficient cells had down-regulation of the 
same genes, as compared to control samples.139,149 This is also in accordance with 
phenomenological data demonstrating that knockdown of BAF180 results in increased 
cell migration.1 Re-expression of BAF180 also resulted in the up-regulation of apoptotic 
processes, carbohydrate metabolic processes and response to hypoxia genes. Down-
regulation of genes involved in the cell cycle was observed in the same cells.69 
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BAF180-deficient cells have been noted as having a hypoxia signature1,69 
meaning the genes that are expressed when a cell is hypoxic are expressed when a cell is 
normoxic (i.e. normal oxygen levels) if BAF180 is absent. Gao et al. found that re-
expressing BAF180 resulted in decreased expression of HIF-target genes (hypoxia 
inducible factor),68 though it had no effect on HIF1α and HIF2α themselves. Chowdhury 
et al. found that re-expressing BAF180 increased the expression of HIF-target genes.69 
Also, Murakami et al. found that knockdown of BAF180 in hepatitis B cells and ccRCC 
cells resulted in down-regulation of HIF-target genes,127 correlating with data from 
Chowdhury et al.69 
1.5.2.3 Clinical Significance of BAF180 Mutations 
Multiple groups have attempted to correlate the presence of BAF180 mutations to 
clinical relevance. However, the studies provide conflicting data with regards to 
correlation between BAF180 mutations and tumor size, differentiation, and patient 
prognosis.128,131-132,139,145,147-148,150,152-153 It is generally accepted that patients with 
mutations in BAP1 have a worse prognosis than patients with a mutation in BAF180.131-
132,139,147,153 Additionally, it has been proposed that BAF180 be used as a biomarker, but 
more investigations need to be conducted before that can happen.68,139,142,145,148,154-155  
1.5.3 Epithelioid Sarcoma 
Epithelioid sarcoma is a rare sarcoma that occurs in the soft tissue of the 
extremities (referred to as “conventional type”), most often in young adults.156-158 It has a 
high metastatic rate. A second type of epithelioid sarcoma, referred to as “proximal-
type”, occurs in the pelvic area.156-158 Loss of PBRM1 expression was found 82.6% of 
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epithelioid sarcoma cases. It should be noted, though, that the sample size was relatively 
small (23 cases), so this percentage may be artificially high. There was no difference in 
PBRM1 expression between the two locations of epithelioid sarcoma (conventional and 
proximal) nor between the three types of tumors (spindle, epithelioid, rhaboid); loss was 
observed in all of them. The researchers did not notice a correlation between PBRM1 
expression and cellular morphology, nor did there appear to be a correlation between 
PBRM1 and prognosis. However, there was a correlation between PBRM1 mutations and 
mutations in INI1 (a core subunit of SWI/SNF), which frequently occurred together.156 
1.5.4 Bladder Carcinoma 
In bladder cancer, PBRM1 acts as a tumor suppressor by repressing gene 
expression of cyclin B1, a cell cycle checkpoint protein.99 Huang et al. found that mRNA 
and protein levels of PBRM1 were significantly lower in bladder cancer cells than in 
normal cells. Additionally, lower levels of PBRM1 were associated with poor patient 
survival rates in bladder cancer.99,150 Cancer cell proliferation, migration, and tumor sizes 
all increased when expression levels of PBRM1 were reduced. As proposed in other 
studies, PBRM1 may prove to be an effective biomarker of tumor grade. Overall, PBRM1 
is mutated in 2-10% of bladder cancers.123-125  
1.5.5. Breast Carcinoma 
Several studies have analyzed potential mutations and expression levels in breast 
cancer. Pereira et al. found that, in ER- (estrogen receptor negative) tissues, 25% of the 
samples had PBRM1 mutations and most of these resulted in loss of heterozygosity 
(LOH).159 More in-depth examination of PBRM1 mutations was performed by Xia et al. 
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Duplications in various exons (as revealed by PCR analysis) were common and 25 of the 
52 tumor samples had LOH for BAF180. Further analysis revealed that BAF180 plays a 
role in the regulation of p21 expression and induces G1 arrest upon reintroduction into 
BAF180-deficient breast cancer cell lines.100 Real time PCR and western blotting have 
demonstrated that breast cancer tumor samples and cell lines have reduced expression of 
the BAF180 protein, as compared to paired normal tissues.51,160 Additionally, low 
BAF180 expression had a strong correlation with higher tumor stage and worse survival 
prognosis.160 
1.5.6 Malignant Mesothelioma 
PBRM1 has been found to be deleted in several cases of malignant mesothelioma 
(MM). Loss of chromosome 3p21 is common in epithelial MM, resulting in the deletion 
of nine genes. This region includes PBRM1 (BAF180) as it is located at 3p21.1. 
Interestingly, this deletion also encompasses BAP1, which is sometimes deleted in 
ccRCC. Mutations in these chromatin modifiers are mutually exclusive in ccRCC, though 
that does not appear to be the case in MM.161 PBRM1 was found to be deleted in both 
types of MM (pleural and peritoneal), though the losses were more common in pleural 
MM.162-163 Two point mutations in PBRM1 were found161 and determined to be 
hemizygous mutations, because there was deletion of the other copy of the gene.164 
Monoallelic gene loss was observed in 12/33 cases (36%) and biallelic deletion in 3/33 
cases (9%).164 They also confirmed that depletion of BAF180 caused increased 
proliferation in a malignant mesothelioma cell line.164 cBioPortal reports deletion of 
PBRM1 gene in a frequency of 5% in patients with pleural MM.123-124 
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1.5.7 Cancers of the Biliary Tract 
Cancers of the biliary tract include intrahepatic (ducts within the liver) and 
extrahepatic (ducts outside the liver) cholangiocarcinomas and gallbladder carcinoma. 
Like in different types of renal carcinomas, the mutational frequency of PBRM1 differs 
between biliary tract locations. PBRM1 seems to be most frequently mutated in 
intrahepatic cholangiocarcinoma (ICC), ranging from 11-14% of samples.165-167 PBRM1, 
ARID1A, BAP1, and SMARCB1 seem to be tied for third most mutated gene in ICC.167 
PBRM1 has been suggested to be a driver mutation for ICC and patients had a worse 
prognosis when PBRM1 was mutated.165-166 In extrahepatic cholangiocarcinomas, the 
frequency was 3.5-5%.165,167 BAF180 is under-expressed in 53% of gallbladder 
carcinomas.168 
1.5.8 Lung Carcinoma 
In evaluating EGFR/KRAS/ALK-negative lung adenocarcinoma tissue samples, 
Ahn et al. found one nonsense mutation, E830* in PBRM1.169 EGFR, KRAS, and ALK 
are driver mutations in lung cancer. In 2005, Sekine et al. analyzed non-small-cell and 
small-cell lung cancer cell lines and did not unearth any mutations or abnormal 
expression patterns. However, it should be noted that they used cancer cell lines and used 
only RT-PCR and western blot to draw their conclusions.170 Izumchenko and colleagues 
investigated mutations found in adenocarcinoma in situ (AIS) and minimally invasive 
adenocarcinoma (MIA) and found PBRM1 to be mutated in one AIS patient’s samples.171 
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Chapter 2 : Motive and Challenges 
2.1 Motive 
Ever since Varela et al. reported that PBRM1 is mutated in 41% of clear cell renal 
cell carcinoma (ccRCC) cases,1 the human polybromo-1 protein (gene: PBRM1; protein: 
BAF180) has garnered the attention of medical researchers. PBRM1 is the second most 
mutated gene in ccRCC (the first being VHL), as well as a known driver mutation of that 
cancer.2-3 It has been found to be mutated (at lower frequencies) in more than 35 other 
cancers, such as cholangiocarcinomas,4 metastasizing pleomorphic adenomas,5 
esophageal squamous cell carcinoma,6 and breast cancer.7-8 As of November 2016, 
COSMIC (Catalogue of somatic mutations in cancer) has more than 1,100 unique 
PBRM1 mutations in its database, many of which are nonsense mutations.9 Nonsense 
mutations often result in the elimination one or more domains; in extreme cases, the 
mutated PBRM1 may only code for 2 or 3 domains.1 
The tumor suppressor properties of BAF180 likely stems from its many roles in 
DNA repair. BAF180 is critical for proper centromeric cohesion10 (important during 
recombinatorial repair) and silencing transcription at double-strand breaks.11 The BAH 
domains of BAF180 have been found to be critical for proper ubiquitination of PCNA 
during post-replication repair (PRR).12 The HMG box, though not well-studied in this 
protein, likely promotes non-homologous end-joining (NHEJ) by its interactions with 
DNA.13-15 Therefore, mutant BAF180 cancer cells could be compromised with regards to 
DNA repair in four ways: the chromosomes are further apart and have less cohesion, 
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which leads to genomic instability and prevents recombinatorial DNA repair; BAF180-
deficient cells cannot stop transcription at double-stranded breaks, thereby hindering 
DSB repair; mutant BAF180 without BAH domains cannot ubiquitinate PCNA, which 
obstructs most of the PRR pathway; and deletion of the HMG box likely hinders NHEJ 
and transcription because BAF180 can no longer bind to DNA.  
Phenomenological studies of BAF180 in mammalian cells have been conducted 
and provide valuable information on “cause and effect” of BAF180 in a cell. On the other 
end of the spectrum, several groups have expressed the bromodomains individually and 
studied their interactions with acetylated peptides.16-21 But these studies do not provide 
insight into the exact mechanisms/interactions of BAF180. 
A critical gap in knowledge still exists between the two: how do the domains of 
BAF180 work together to bind to the nucleosome and what changes result from the 
binding of different domains? It has been shown that domains within the same protein 
have the ability to work together to recognize multiple post-translational modification 
(PTM) sites, thus increasing the binding affinity of the protein to the nucleosome.17,22-25 
Therefore, it is logical to hypothesize that the domains of BAF180 might do the same 
thing. The ability to study distinct interactions is crucial to increasing our understanding 
of the role of BAF180 in cancer development and its progression. Only by studying the 
mechanisms of full-length BAF180 can we begin to develop better treatment options for 
cancer patients. 
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2.2 Challenges  
BAF180, the chromatin-remodeling subunit of the PBAF complex, is a 
complicated protein with 1634 amino acids (isoform 2) and 9 domains: 6 bromodomains, 
2 BAH (bromo-adjacent homology) domains, and 1 HMG (high mobility group) box 
(Figure 2.1).  
 
Figure 2.1: Diagram of the 9 domains of BAF180 with likely functions. Sizes of the domains and distances 
between are approximately accurate for isoform 2 (Genbank: AAG48933.1). The overall size is 1634 
amino acids. 
 
Recombinant expression of full-length BAF180 has proven to be extremely 
difficult and frustrating. There could be many reasons why this is so. First, it must be 
recognized that BAF180 is a very large protein with 9 domains. Large, multidomain 
proteins are inherently difficult to express in any heterologous system and have a higher 
likelihood of folding improperly. Proteins are usually expressed by cloning and 
expressing the individual domains separately. Secondly, it has numerous rare codons, 
even compared to the overall usage of Homo sapiens. Third, its DNA can form multiple 
complex secondary structures, making it difficult for PCR modification to occur. Fourth, 
Brd1 Brd2 Brd4Brd3 BAH1Brd6Brd5 BAH2 HMG
Bind different acetylated lysine residues on histones
Signals for Ub of PCNA in PRR
• Promotes NHEJ by bending the 
ends of the DNA so that they 
have more energetically 
favorable interactions
• Influences transcription by 
distorting the nucleosomal
complex
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its DNA sequence has many base runs (A-tracts, etc.), thus increasing the probability that 
polymerase might skip bases during PCR. 
2.3 Conclusion 
This is the first time full-length BAF180 has been successfully expressed and 
purified in a heterologous host. The creation of recombinant BAF180 will enable 
researchers to conduct detailed mechanistic studies of the precise binding interactions of 
the entire protein. The ability to study distinct interactions is crucial to increasing the 
understanding of the role of BAF180 in cancer development and its progression. In 
studying the exact mechanisms by which BAF180 performs its many roles, scientists can 
begin to develop better treatment options for cancer patients. 
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Chapter 3 : Recombinant Expression of BAF180 in E. coli 
Expression of heterologous proteins is a time-consuming and difficult task, as the 
specific characteristics of the individual protein must be considered alongside the 
characteristics of the expression system. Escherichia coli (E. coli) is the most commonly 
used heterologous protein host, because it is cheap and easy.26-30 Additionally, the fast 
cell growth of E. coli makes it an efficient factory for the production of large amounts of 
recombinant protein; large quantities can often be produced in one day and the 
recombinant protein can comprise up to 50% of the total cellular protein content.26 
However, this fast production can be a disadvantage as well, especially when expressing 
eukaryotic proteins. It can often result in misfolded, insoluble, and/or inactive proteins, 
which are often sequestered in inclusion bodies.26,28 Proteins found in inclusion bodies 
can be resolubilized and/or refolded after cell lysis, but this is a difficult process and is 
not always successful. Furthermore, as is increasingly understood, the production of an 
active protein does not depend solely on proper folding; often, a specific post-
translational modification (PTM) is required in order for a protein to be active. E. coli is 
unable to perform post-translational modifications. 
The successful expression of heterologous proteins in E. coli is often dependent 
on the protein size and the presence of rare codons. Large proteins are more difficult to 
express than smaller proteins, and often larger proteins form inclusion bodies.26 Another 
problem is rare codons and codon bias. Codon bias is the preference for a particular 
codon of an amino acid. These codon biases affect protein translation. For example, 
translation of glutamine is highly biased in humans: 26.5% of codons for glutamine are 
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CAA, whereas 73.5% are CAG. The codon usage is often different between hosts, as 
demonstrated when comparing the codon usage for arginine between humans and E. coli 
B strains. In humans, the AGA codon is used 21.5% of the time, but in E. coli it is only 
used 5% of the time. The CGC codon is used 18% of the time in humans, but used 40% 
of the time in E. coli. These so-called “rare codons” (such as those for arginine) can lead 
to translational stalling, premature termination, frameshifts, and mis-incorporation of 
amino acids.26-28  
One of the most commonly used promoters for E. coli expression is the T7 
promoter.26  T7 actually refers to the use of T7 RNA polymerase, which has transcription 
rates five times higher than the native RNA polymerase (of E. coli).26,28  Cell strains 
denoted with “DE3” have the T7 gene present in its genome. The T7 gene itself is 
controlled by the lacUV5 promoter. When IPTG (isopropyl β-D-1-thiogalatopyranoside) 
is added, the lacUV5 promoter is induced, resulting in expression of the T7 polymerase, 
which in turn causes expression of the heterologous protein.26,28 
 The pET30a vector and Rosetta(DE3) cells were used for expression of BAF180 
in E. coli. The pET30a vector from Novagen was chosen for expression of BAF180 
because the pET30 vectors were readily available. The pET30 system of vectors possess 
kanamycin resistance and a T7 promoter; thus, expression of the recombinant gene is 
inducible by the addition of IPTG. For expression, the Rosetta(DE3) E. coli cell strain 
was chosen. It is a derivative of BL21(DE3), which is deficient in lon and ompT 
proteases and has the T7 gene on a chromosome. Rosetta possesses a plasmid with 
chloramphenicol resistance, which codes for 7 rare tRNAs: AUA, AGG, AGA, CGG, 
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CUA, CCC, and GGA.26,28 There are a few other cell strains that have the ability to make 
some rare tRNAs, but Rosetta is capable of producing more rare tRNAs than other 
strains. The BAF180 gene sequence contains a lot of rare codons, so it was reasoned that 
expression in the Rosetta(DE3) strain would give the highest probability of success. 
3.1 Materials 
The BAF180 gene sequence (pBabepuroBAF180; isoform 2; Genbank: 
AF177387.1) was a gift from Ramon Parson’s lab (Addgene #41078).7 EcoRI-HF (cat. 
R3101), TriDye 1 kb ladder (cat. N3272), Instant Sticky-end Master Mix (cat. M0370) 
and Calf Intestinal Phosphatase (cat. M0290) were purchased from New England 
BioLabs (Ipswich, MA). Zyppy™ Plasmid Miniprep Kit was purchased from Zymo 
Research Corp. (Irvine, CA). Wizard® SV Gel and PCR Clean-Up Kit (cat. A9281) was 
purchased from Promega Corp. (Madison, WI). Micropulser electroporator and 0.2 cm 
electroporation cuvettes (cat. 1652086) were from Bio-Rad, Inc. (Hercules, CA). Tris 
hydrochloride and kanamycin sulfate were purchased from Amresco (VWR: Radnor, 
PA). Rosetta(DE3) cells (cat. 70954), pET30 vectors (cat. 69909-3) and NaCl were 
purchased from EMD Millipore (Billerica, MA). DH5α cells (cat. 18259012), lysozyme 
(cat. BP535), BME (betamercaptoethanol, cat. BP176), LB broth Miller (cat. BP1426), 
and ampicillin (cat. BP1760) were purchased from ThermoFisher Scientific (Waltham, 
MA). Chloramphenicol (cat. 227920250), IPTG (Isopropyl β-D-1-thiogalactopyranoside, 
cat. 302790250), and PMSF (phenylmethylsulfonyl fluoride, cat. 215740050) were 
purchased from Acros Organics (NJ). Urea, DTT (dithiothreitol, cat. 43815), and TCEP 
(Tris(2-carboxyethyl)phosphine hydrochloride, cat. 646547) were from Sigma-Aldrich 
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(St. Louis, MO). DTE (dithioerythritol, cat. 2185D) was from Research Organics 
(Cleveland, OH). The Digital Sonifier 450 and accessories were from Branson 
Ultrasonics (Dansbury, CT). 
3.2 BAF180 Expression in E. coli 
3.2.1 Cloning 
BAF180 was cloned into the E. coli strain Rosetta(DE3) using the pET30a vector. 
The BAF180 gene sequence (pBabepuroBAF180; isoform 2; GenBank: AF177387.1) 
was a gift from Ramon Parson’s lab (Addgene #41078).7 As received, the BAF180 gene 
had been inserted into the pBabepuro vector using EcoRI on both the 5' and 3' ends. The 
5' EcoRI site was immediately upstream of the start codon and only 50 base pairs 
separated the 3' EcoRI site and the stop codon. For time efficiency, the 3' restriction 
enzyme site was not changed. Both pBabepuroBAF180 and pET30a were digested with 
EcoRI and purified using the Promega Wizard® SV Gel and PCR Clean-Up Kit. pET30a 
was dephosphorylated using Calf Intestinal Phosphatase to prevent re-ligation and gel 
purified again. The BAF180 gene (4961 bp) was ligated into pET30a (5422 bp) using a 
5:1 (insert:vector) ratio with Instant Sticky-end Master Mix. The resultant plasmid 
(BAF180-pET30a) was 10,381 base pairs (Figure 3.1). 2 µL of the ligation reaction was 
immediately transformed into chemically competent DH5α cells using the protocol 
outlined in the pET30 manual.7 Cells were then grown on LBK plates (50 µg/mL 
kanamycin) overnight at 37 °C. 12 colonies were produced. Each colony was grown in 15 
mL LBK overnight at 37 °C and 250 rpm. 5 mL of this was used to prepare freezer stock 
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and 10 mL was miniprepped. The minipreps were used to confirm the plasmid size 
(Figure 3.2A). 
 
Figure 3.1: Plasmid map of BAF180-pET30a. The BAF180 gene sequence is highlighted in teal in the 
vector. 
 
When a gene is inserted into a vector using the same restriction enzyme site on 
both the 5' and 3' ends, it is possible for the gene to be inserted in the 3' to 5' direction, 
instead of the correct 5' to 3'. BAF180 was inserted into pET30a using EcoRI on both the 
5' and 3' ends of the gene (Figure 3.1), so the 12 transformation products were screened 
for insert direction using PCR and restriction enzyme digests. For PCR, a forward primer 
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for the T7 promoter (on the vector) and a reverse primer for bromodomain 2 were used to 
confirm that BAF180 was inserted in the correct direction. The correct product size (1064 
bp) was seen on the gel (Figure 3.2B). Additional PCR reactions were performed to 
confirm that full-length BAF180 was inserted into the pET30a vector. To perform 
diagnostic digests, a restriction enzyme was chosen that cut twice within the BAF180-
pET30a plasmid. The product sizes would change depending on the insert direction 
(Figure 3.3). Unfortunately, results were inconsistent, possibly due to mixed-
transformation colonies (where some of the cells had the insert and some did not). 
 
Figure 3.2: Screening of the BAF180-pET30a transformants. (A) Four of the transformants were 
miniprepped and run on a 1% TBE agarose gel. The expected plasmid size was 10,383 bp. The bands 
slightly above the 10 kb band on the ladder were believed to be BAF180-pET30a. It was thought that the 
other bands seen were supercoiled plasmids. (B) PCR screen to confirm the correct insert size. The T7 → 
D2 product was 1064 bp. 
10 kb
3
2
1.5
1
0.5
T7 → D2
10 kb 86 54
3
2
1.5
1
Transformation products: 
BAF180-pET30a (10,383 bp)
A. B.
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Figure 3.3: Theory behind using restriction enzyme diagnostic digests. If BAF180 had been inserted in the 
5' to 3' direction (“correct” direction), digestion of BAF180-pET30a with EcoRV would have resulted in a 
product approximately 6900 base pairs (bp) and 3500 bp. Insertion of BAF180 in the 3' to 5' direction 
(“incorrect”) would have resulted in products approximately 8900 bp and 1500 bp. 
 
After it was confirmed that BAF180 had been inserted in the 5' to 3' direction, one 
of the miniprepped BAF180-pET30a plasmids was transformed into electrocompetent E. 
coli Rosetta(DE3) cells using the Bio-Rad Micropulser electroporator on the “ec2” 
setting. A 0.2 cm electroporation cuvette was used. The electroporation procedure 
outlined in the Micropulser manual was followed.31 The cells were then grown overnight 
on LBCK plates (35 μg/mL chloramphenicol and 50 μg/mL kanamycin).  
3.2.2 Expression 
To test for BAF180 expression, the following variables were manipulated: growth 
temperature (30 °C and 37 °C); lysis conditions (native and denaturing); incubation 
temperature during lysis (4 °C to 25 °C); incubation time during lysis (30 minutes to 
overnight); IPTG concentration (0.25 mM, 0.50 mM, 1.0 mM, 1.5 mM); induction time 
(1-24 hours); elimination of possible protein oxidation during lysis by addition of 
Correct Direction: Incorrect Direction:
6888 bp
3493 bp
8892 bp
1489 bp
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reducing agents (5% BME, 100 mM DTT, 100 mM DTE, 20 mM TCEP); and inhibition 
of proteases using PMSF (Table 3.1). No protein band around 190 kDa was ever seen on 
SDS-PAGE gels. 
Table 3.1: Variables manipulated while attempting to express BAF180 in E. coli cells. 
 
3.3 Other Considerations 
When efforts to express BAF180 in E. coli failed, several different options were 
explored. Often, large proteins are found in inclusion bodies, where they are insoluble 
and inactive. The presence of certain protein tags has been found to increase the 
solubility, thus preventing a recombinant protein from being included in an inclusion 
body. Fusion tags are polypeptide sequences (such as a 6x His-tag) or proteins (such as 
GST) which are expressed in-frame with the recombinant protein, thus resulting in a 
fusion protein which contains both the recombinant protein of interest and the tag. The 
use of fusion tags has long been known to increase the solubility of some recombinant 
proteins expressed in E. coli.26,32-33 
Variables Tested: Actions Taken:
Growth Temperature 30 °C and 37 °C 
Lysis Conditions Native and Denaturing
Lysis Incubation Temperature (4 °C to 25 °C) and Time (30 minutes to overnight)
IPTG Concentration 0.25 mM, 0.50 mM, 1.0 mM, 1.5 mM
Induction Time 1-24 hours
Reducing Agents 5% BME, 100 mM DTT, 100 mM DTE, 20 mM TCEP
Proteases PMSF
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Some of the most commonly used tags are 6x His, GST (glutathione S-
transferase), and MBP (maltose binding protein).26 Vectors are available which allow for 
in-frame expression of one of these tags with the recombinant protein gene. Fusion tags 
also have another benefit in that purification of the fusion protein is simplified because 
affinity methods can be employed (such as IMAC for a 6x His-tag). However, there are 
drawbacks to using tags during recombinant protein expression. The most notable is that 
the fusion tag can disrupt the biological functions of the recombinant protein. For 
mechanistic studies, enzymatic cleavage of the fusion tag from the recombinant protein is 
often needed.26  Additionally, protein solubility is not equivalent with protein quality; 
sometimes the soluble proteins are biologically inactive, which essentially negates the use 
of a solubility tag.34-35  
Possible co-expression of chaperone proteins was also explored. Chaperone 
proteins aid in properly folding newly synthesized proteins into their native state. 
Overexpression of recombinant proteins in E. coli often leads to the production of 
inclusion bodies, where the desired protein is improperly folded and isolated. Co-
expression of prokaryotic chaperone proteins, particularly DnaK and GroEL, has been 
used to increase the yield of some recombinant proteins.26-27,33-35 DnaK and GroEL are 
already present in E. coli cells; however, when a recombinant protein is overexpressed, 
there are insufficient quantities of these chaperones and the recombinant protein is 
misfolded. The chaperones can be co-expressed in the same cell as the recombinant 
protein by placement on a separate vector (such as those available from Takara Bio Inc.) 
or by placement on the same vector as the recombinant gene (Duet system by Novagen). 
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However, the over-expression of these chaperone proteins can have detrimental effects on 
protein production and on the cell overall, such as cell growth inhibition and enhanced 
proteolysis of the protein.34-38  
3.4 Conclusion 
While fusion tags and co-expression of chaperone proteins were considered, these 
were not tried for a few reasons. One, there was doubt whether the fusion tag would be 
enough to overcome the size of BAF180. They work well with smaller proteins, but the 
relatively small size of the fusion tags (28 kDa for GST and 43 kDa for MBT)26 in 
relation to BAF180 (190 kDa) made it doubtful that the tag would be enough to 
encourage the proper folding of BAF180. Additionally, there was doubt whether the 
prokaryotic chaperones would be able to properly fold all of the BAF180 protein; there 
was a significant possibility that the chaperones would be insufficient, resulting in partial 
folding of BAF180. 
There are many possible reasons why BAF180 failed to express in E. coli cells. A 
few of the most likely are the protein size (190 kDa), presence of multiple domains (9 
domains), and the presence of rare codons. Both size and the presence of several domains 
can influence the expression of recombinant proteins.26 Large proteins and multi-domain 
proteins often fail to express or are found in inclusion bodies. Additionally, E. coli and 
other prokaryotic expression systems are limited in their ability to create post-
translational modifications (PTMs) on recombinant proteins. Though PTMs on BAF180 
are relatively unexplored, there are a few known sites of phosphorylation, which may 
influence the activity (see Section 1.3.3). Possibly the biggest obstacle to BAF180 
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expression in E. coli (and other bacterial systems) is the codon usage. Though 
Rosetta(DE3) cells were used for its several rare tRNAs, BAF180 has so many rare 
codons that this may not have been sufficient; 19 codons have a usage difference greater 
than 10% (Table 3.2). Though other bacterial systems are available, such as B. subtilis 
and L. lactis, the same concerns exist, particularly about codon usage and size (Table 
3.3). 
 
Table 3.2: Table showing the codons with a high difference in usage between E. coli and BAF180. % 
difference refers to how much more often a codon is used in BAF180 versus the host. Number refers to 
how many times that codon is used in BAF180. 
 
Amino Acid Codon % Difference Number
Ala GCA 13.0 31
Ala GCT 24.2 32
Arg AGA 25.0 26
Arg AGG 17.5 19
Arg CGA 11.8 18
Asn AAT 23.8 49
Cys TGT 21.4 14
Glu GAG 10.3 57
Gly GGA 15.0 23
Ile ATA 15.0 17
Leu CTT 12.9 36
Lys AAG 13.3 56
Phe TTT 13.1 37
Pro CCA 28.3 48
Pro CCT 15.0 37
Ser TCT 11.3 27
STOP TAA 35.7 1
Thr ACA 32.3 25
Thr ACT 10.9 15
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Table 3.3: Codon usage comparisons of BAF180 to bacterial expression systems. The number of codons 
with a certain percentage difference are noted. % difference refers how much more often a codon is used in 
BAF180 versus the host. 
  
Bacteria
% Difference E. coli B E. coli K12 C. crescentus S. lividans L. lactis B. subtilis B. megaterium
Codons 10-14.99%: 9 10 5 4 9 5 9
Codons 15-19.99%: 5 2 6 6 4 2 3
Codons 20-29.99%: 3 5 6 8 2 1 0
Codons 30-39.99%: 2 2 5 1 1 1 2
Codons 40-40.99%: 0 0 3 4 1 0 0
Codons ≥ 50% 0 0 4 6 0 0 0
Total codons ≥10% 
difference: 19 19 29 29 17 9 14
STOP codons % 
diff: 36.36 35.71 80 90.97 39.99 39.08 32.87
P. fluorescens P. haloplanktis P. putida M. smegmatis H. elongata C. salexigens
L. lactis subsp
cremoris MG1363
Codons 10-14.99%: 5 8 10 2 3 3 6
Codons 15-19.99%: 4 5 2 5 5 6 4
Codons 20-29.99%: 3 0 2 8 10 10 4
Codons 30-39.99%: 2 0 1 4 5 3 1
Codons 40-40.99%: 0 2 3 6 2 3 0
Codons ≥ 50% 1 0 1 3 2 2 1
Total codons ≥10% 
difference: 15 15 19 28 27 27 16
STOP codons % 
difference: 66.46 40 77.87 93.64 65.22 84.05 31
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Chapter 4 : The Use of Pichia pastoris as an Expression 
System 
The yeast Pichia pastoris (Pichia) has become increasingly popular as a 
recombinant host over the last decade. Pichia is a methylotrophic budding yeast that is 
often found in its vegetative state (i.e. not mating).39 A methylotrophic yeast is capable of 
utilizing methanol as its sole carbon source. Similar to E. coli, Pichia has a fast doubling 
time (approximately 90 minutes in rich medium like YPD)40 and is relatively inexpensive 
to grow. But unlike E. coli, Pichia is capable of performing post-translational 
modifications and it has eukaryotic protein machinery, which makes it more likely that 
the recombinant protein will be folded correctly.41 Expression in Pichia has become 
preferred over other yeast heterologous systems, such as S. cerevisiae, partly because 
Pichia has a strong preference for respiratory growth over fermentative growth. This 
allows Pichia cultures to be grown to extremely high cell densities, as toxic ethanol (the 
product of fermentation) is not present.40-44  
However, for all its advantages, Pichia has one major drawback. The 
glycosylation pattern produced in Pichia is different from that produced in human. 
Glycosylation of proteins often occurs during secretion. Though proteins produced in 
Pichia are often less hyperglycosylated than recombinant proteins produced in S. 
cerevisiae,45 Pichia produces glycosylation patterns that are different enough from 
human glycosylation patterns that an immune response can be triggered in a patient. This 
is especially important in recombinant pharmaceutical production. To overcome this 
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problem, new strains have recently been engineered that mimic the human glycosylation 
pattern (such as YSH44 and the GlycoSwitch system).42-43,45 
4.1 Choosing a Promoter 
Several promoters are commercially available for recombinant protein expression 
in P. pastoris. The two most common promoters are the GAP promoter (constitutive) and 
AOX1 promoters (inducible by methanol). Both of these are strong promoters capable of 
similarly high levels of recombinant protein expression.40-48 
The AOX1 promoter is inducible by addition of methanol. An inducible promoter 
is exactly what it sounds like: it promotes gene expression when induced. This can be an 
advantage for the production of some proteins, particularly toxic ones, as the protein is 
not expressed during the growth phase. A culture is first grown to a particular density 
before the AOX1 promoter is induced by addition of methanol. Using an AOX1 promoter, 
the recombinant protein can reach up to 30% of the cell biomass.42 However, there are 
disadvantages to using the AOX1 promoter. Because it uses methanol as an inducer, it is 
unsuitable for large scale expression, because methanol is highly flammable.40-52 
Additionally, the fast production of recombinant protein may result in unfolded or 
inactive proteins, as an inducible promoter makes a lot of protein all at once. 
On the other hand, the GAP promoter is a constitutive promoter. A constitutive 
promoter allows for the constant production of the recombinant protein. This type of 
promoter does not require an inducer, as it is always “on”. Some researchers have 
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reported higher recombinant protein production with the AOX1 promoter than the GAP 
promoter, while others have reported the opposite.42-46,50,52-55 
Considering the size of the BAF180 protein (190 kDa), it was hypothesized that 
continuous expression of the protein (under control of the GAP promoter) might be more 
favorable than inducible expression, in terms of cellular stress and protein folding.44,46,56 
Synthesis of a lot of protein all at once might be toxic to the cell or impede growth or 
there might not be sufficient levels of chaperone proteins available for folding the 
protein.40-48,50,53-55,57 The GAP promoter is found in pGAPZ vectors. 
4.2 Choosing an Expression Strain 
There are several Pichia strains commercially available. Wild-type (WT) strains 
include Y-11430 and X33. Other strains have mutations in a biosynthesis pathway (such 
as his4 mutants), AOX1/2 mutants, protease-deficient strains, and glycosylation 
mutants.43,45 Strains with a mutation in a biosynthesis pathway, such as his4, are only 
able to grow if the vector (containing the replacement HIS4 gene) has been integrated.45 
Other strains have mutations in one or both of the AOX genes, because cells with AOX 
mutations can sometimes produce larger quantities of recombinant protein.43,45  
Most of the protease activity in yeast is contained in the membrane bound 
vacuoles.56,58  Upon cell lysis, the organelles release their contents. Cell lysis can happen 
during cell growth, as the cell density increases. The proteases are released into the media 
wherein secreted proteins are targeted. Therefore, protease-deficient strains have been 
developed. Most often, these strains have been engineered to be deficient in PEP4. PEP4 
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is a gene that activates carboxypeptidase Y and protease B1 in vacuoles, therefore 
mutants without PEP4 do not have either of these proteases.40-41,43-46,48,58 The use of 
protease-deficient strains has improved extracellular expression in about 10% of cases,41 
but there is no reported success of using a protease-deficient strain to increase yield of an 
intracellularly produced protein.40-41 Protease-deficient strains have several problems, 
such as much slower growth, faster death on agar plates, lower transformation 
efficiencies, lower levels of expression, and difficulty utilizing the methanol-inducible 
AOX1 promoter.40-41,43,45 Use of a protease-deficient strain is generally not recommended 
unless absolutely necessary.45 The WT strain X33 was chosen for expression because it 
was readily available. 
4.3 Integration of A Recombinant Gene into the Pichia pastoris 
Genome 
Expression of a recombinant gene into Pichia involves the integration of the gene 
into the Pichia genome through homologous recombination. The plasmid containing the 
recombinant gene is linearized in a location which shares homology to a location in the 
Pichia genome. Usually this is accomplished by cutting a plasmid within the promoter 
and then transforming this linearized construct (“expression cassette”) into Pichia cells. 
The free DNA ends then promote recombination of the plasmid into the genome, usually 
with a single-crossover event.45-46 Incorporation of the recombinant gene is far more 
stable41-44,46 than the E. coli method of simply inserting a plasmid with its own replication 
system into the cell. Actually, there are no autonomous plasmids available for Pichia, 
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because Pichia seems to spontaneously integrate the plasmid into its genome 
anyway.41,44,59 
Due to homologous recombination, multiple copies of the expression cassette can 
sometimes be integrated into the genome. These “jack-pot” clones are very rare, 
occurring spontaneously approximately 1% of the time.60-61 This percentage can be 
increased by constructing a vector that has multiple copies of the gene in the vector 
itself.45 Identification of high-copy number clones is time-consuming and laborious, as it 
usually requires screening of hundreds of clones. One of the commonly used techniques 
to isolate multi-copy strains is step-wise increase in antibiotic concentration, where 
colonies are plated on subsequently higher and higher concentrations of the antibiotic.40-
41,45 Interestingly, while logic would dictate that more copies of the gene would equal 
more protein, this is not always the case. Sometimes, integration of more than one copy 
actually leads to a decrease in the recombinant protein production.43,45,60 
4.4 Choosing to Use Pichia as the heterologous system for 
BAF180 Production 
Pichia was chosen as the expression system for BAF180, because the Pichia 
codon usage is similar to the usage for BAF180. BAF180 contains a lot of rare codons, 
even when compared to the usage in humans (15 codons have a usage difference greater 
than 10%; see Table 4.1). As such, once E. coli failed to express BAF180, other 
expression systems were investigated. Complete codon analysis was performed on 12 
different systems to identify which system had codon usage closest to BAF180: 4 
bacterial, 6 yeast, and 2 insect. The results are shown in Table 4.2.  
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Table 4.1: Codon usage comparisons of BAF180 to humans (native host). The number of codons with a 
percentage difference greater than 10 are shown. Note that % difference refers to how much more often a 
codon is used in BAF180 versus the host. Number refers to the number of times that codon is used in the 
BAF180 gene sequence. 
 
 
 
 
 
 
 
 
 
 
 
 
Amino Acid Codon % Difference Number
Ala GCA 10.88 31
Asn AAT 23.98 49
Asp GAT 16.65 65
Cys TGT 18.02 14
Glu GAA 17.89 86
His CAT 18.67 23
Ile ATT 11.94 37
Leu CTT 11.49 36
Lys AAA 16.60 84
Phe TTT 23.40 37
Pro CCA 14.45 48
STOP TAA 70.30 1
Thr ACA 21.17 25
Tyr TAT 11.67 42
Val GTT 14.76 28
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Table 4.2: Codon usage comparisons of BAF180 to 14 different expression systems. A positive percentage 
means the codon usage is biased towards BAF180 (i.e. that particular codon is used more often in 
BAF180). A negative percentage means the codon usage is biased towards the host organism (i.e. that 
particular codon is used more often in the host organism). 
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BAF180 codon usage was similar to that of Pichia; only 11 codons had a usage 
difference greater than 10%, meaning that only 11 codons were used more than >10% 
more frequently in BAF180 than in Pichia (Table 4.3).  
Table 4.3: Codon usage comparisons of BAF180 to Pichia pastoris. The number of codons with a 
percentage difference greater than 10 are shown. Note that % difference refers to how much more often a 
codon is used in BAF180 versus the host. Number refers to how many of that particular codon are found in 
the BAF180 gene sequence. 
 
Pichia pastoris was chosen because it is a eukaryotic expression system, therefore 
it is capable of performing post-translational modifications and it has eukaryotic protein 
machinery. This makes it more likely that the recombinant protein will be folded 
correctly.41 Pichia also has codon usage similar to BAF180, making it more likely that 
the protein will be transcribed from the DNA. 
  
Amino Acid Codon % Difference Number
Ala GCA 10.3 31
Arg CGC 10.8 15
Asn AAT 22.6 49
Gln CAG 28.2 41
Gly GGC 22.3 30
Lys AAA 13.0 84
Phe TTT 15.9 37
Ser AGC 11.7 25
STOP TAA 49.3 1
Thr ACA 21.2 25
Val GTG 11.4 26
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Chapter 5 : Cloning and Expression of BAF180 in Pichia 
pastoris 
After attempts to express BAF180 in E. coli were unsuccessful (see Chapter 3), 
the yeast Pichia pastoris was chosen. There were two primary reasons why P. pastoris 
was chosen (more details in Chapter 4):  
(1) Eukaryotic system: P. pastoris is a eukaryotic organism, capable of 
performing post-translational modifications in a manner similar to humans. It 
also possesses eukaryotic transcriptional machinery. 
(2) Codon Usage: BAF180 has unusual codon usage. The codon usage of P. 
pastoris is similar to BAF180 and has only 11 codons have a usage difference 
greater than 10% (as opposed to 19 for E. coli).  
The pGAPZA vector was chosen for expression because it contains the constitutive GAP 
promoter. A constitutive promoter permits constant low level expression of a 
recombinant gene; in other words, the promoter is always “on.” It was hypothesized that 
constant low-level production of BAF180 would be more favorable in terms of cellular 
stress and protein production. Continuous low level synthesis of BAF180 might be less 
toxic to the cell than the synthesis of a large amount of protein at one time (as happens 
with inducible promoters). Additionally, continuous low level expression may increase 
the probability of BAF180 folding correctly. BAF180 is such a large protein that the 
protein folding machinery (such as chaperone proteins) may be more likely to fold 
BAF180 correctly if the machinery is doing so constantly and not being bombarded all at 
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once as happens with an inducible promoter. In this chapter, several topics are discussed 
including the cloning of BAF180 into P. pastoris. Cell growth conditions and lysis 
procedures were also investigated to determine which conditions resulted in the highest 
expression and recovery levels of BAF180. The expression of BAF180 was confirmed 
with western blot. 
5.1. Materials 
 Pichia pastoris wild-type strain X33 and pGAPZA vector were purchased from 
Invitrogen (Carslbad, CA). Zeocin (cat. ant-zn-1p) was purchased from Invivogen (San 
Diego, CA). The BAF180 gene sequence (pBabepuroBAF180; isoform 2; GenBank: 
AF177387.1) was a gift from Ramon Parson’s lab (Addgene #41078).7 Primers were 
purchased from Integrated DNA Technologies (IDTDNA: Coralville, IA). Q5 
polymerase (M0491), T4 ligase (M0202), all restriction enzymes, TriDye 1 kb ladder 
(N3272), and Color Prestained Broad Range Protein Marker (P7712) were purchased 
from New England BioLabs (Ipswich, MA). PCR mutagenesis was performed on the G-
Storm GS482 Thermocycler (Gene Technologies, UK). Tryptone, peptone, yeast extract, 
and dextrose were purchased from Amresco (VWR: Radnor, PA). Urea, sodium 
phosphate monobasic (NaH2PO4), Lyticase from Arthrobacter luteus, 
phenol:chloroform:isoamyl alcohol (25:24:1), chloroform:isoamyl alcohol (24:1), sodium 
acetate, and 100% ethanol were purchased from Sigma Aldrich (St. Louis, MO). 
Zirconia/silica disruption beads (0.5 mm) were purchased from Research Products 
International Corp. (Mt. Prospect, IL). DNA purification kits (Zyppy™ Plasmid Miniprep 
Kit, Zymo Gel Extraction Kit, and Zymo DNA Clean & Concentrator™) were purchased 
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from Zymo Research Corp. (Irvine, CA). The Wizard® SV Gel and PCR Clean-Up Kit 
(cat. A9281) was purchased from Promega Corp. (Madison, WI). Samples were 
concentrated with the Savant Refrigerator Condensation Trap and Savant Speed Vacuum 
Concentrator (ThermoFisher: Waltham, MA). E. coli subcloning strain DH5α, Ampicillin 
(cat. BP1760), 0.45 µm nitrocellulose membrane (cat. 77010), 0.45 µm PVDF membrane 
(cat. 88585), blotting paper (cat. 8860), NuPAGE Tris-Acetate gels 3-8% (cat. EA0375), 
NuPAGE LDS Sample Buffer 4x (cat. NP0007), NuPAGE Tris-acetate running buffer 
(LA0041), NuPAGE transfer buffer (cat. NP0006), NuPAGE antioxidant (cat. NP0005), 
NuPAGE reducing agent (cat. NP0004) and Pierce Fast Western Blot Kit, ECL substrate 
(cat. 35050) were purchased from ThermoFisher (Waltham, MA). Anti-PBRM1 antibody 
(cat. 12563-1-AP, rabbit polyclonal) was purchased from Proteintech (Rosemont, IL). 
Western blot transfer was performed using a Hoefer TE22 transfer tank (Holliston, MA). 
Ponceau staining solution (cat. AC2125) was purchased from Azure Biosystems (Dublin, 
CA). Dialysis membranes were purchased from Spectrum Labs (Rancho Dominguez, 
California): Spectra/Por 1 (6-8 kD MWCO membrane; part 132660) and Spectra/Por 6 
(50 kD MWCO membrane; part 132544). SDS, glycine, Tris hydrochloride, Tris base, 
glycerol, guanidine hydrochloride, and Protease Inhibitor Cocktail (cat. 97063-970) were 
purchased from Amresco (VWR: Radnor, PA). EDTA was purchased from Mallinckrodt 
Baker Inc. (Phillipsburg, NJ). NaCl was purchased from EMD Millipore (Billerica, MA). 
MicroPulser electroporator and 0.2 cm electroporation cuvettes (cat. 1652086) were from 
Bio-Rad, Inc. (Hercules, CA). PMSF (phenylmethylsulfonyl fluoride, cat. 215740050) 
was purchased from Acros Organics.  
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5.2 Construction and Transformation of Expression Plasmid 
Before BAF180 could be cloned into Pichia pastoris, a few modifications needed 
to be made to the gene sequence. (1) A Kozak consensus sequence was added to facilitate 
gene expression; (2) Insertion of a spacer between 5' restriction enzyme site and the 
Kozak consensus sequence; (3) The 3' restriction enzyme site was changed to allow for 
directional cloning; (4) The endogenous stop codon was deleted; (5) An enterokinase site 
was inserted. 
A Kozak consensus sequence was added immediately upstream of the start codon, 
for use as a transcription initiation start site (Figure 5.1). The BAF180 sequence 
contained a start codon, but a yeast-specific Kozak consensus sequence needed to be 
added because the chosen vector did not contain one. To make the Kozak sequence, three 
adenosine residues were added upstream of the BAF180 start codon (AAAATGG). 
Literature indicated that higher initiation rates are observed when adenosine residues are 
located at the -3 to -1 positions and when a guanine is located at the +4 position relative 
to the start codon (the guanine was already present).61-62 A spacer of 6 base pairs was 
added between the 5' restriction enzyme site and the Kozak consensus sequence (Figure 
5.1). Ligation efficiency is decreased when a restriction enzyme site and a start codon are 
immediately adjacent to each other. 
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Figure 5.1: Insertion of the Kozak consensus sequence and a spacer into the BAF180 sequence, to facilitate 
expression in the yeast Pichia pastoris. A spacer was added between the restriction enzyme site (EcoRI) 
and the Kozak consensus sequence. 
 
Additionally, the 3' restriction enzyme site was changed to allow for directional 
cloning. The group who constructed the parent vector (pBabepuroBAF180) used EcoRI 
on the 5' and 3' ends of the gene. When the same restriction enzyme site is used on both 
ends of the gene, there is a possibility that the gene will be inserted in the 3' to 5' 
direction instead of the correct 5' to 3' direction. To facilitate directional cloning, the 3' 
site was changed to KpnI (GGTACC) (Figure 5.2). Analysis of the BAF180 sequence 
revealed limited options for the choice of restriction enzyme; of all commercially 
available enzymes, only 67 restriction enzymes did not cut within the BAF180 sequence. 
When comparing those to the available sites in pGAPZA, only five enzymes remained: 
EcoRI, PmlI, KpnI, SacII, and NotI. PmlI was eliminated as it creates blunt ends. EcoRI 
was eliminated as it is already being used on the 5' end. KpnI is downstream of EcoRI 
and creates hanging ends. KpnI was chosen partially because the Thompson lab has had 
success with this enzyme in the past.  
DNA Sequence After Mutation: 
Original DNA Sequence (from Addgene): 
TAGGAATTCATGGGTT
EcoRI Start 
codon
TAGGAATTCGAACTCAAAATGGGTT
Spacer
Kozak Sequence
EcoRI
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As mentioned, the pGAPZA vector was chosen for expression of BAF180. The 
pGAPZA vector has a 6x His-tag downstream of the gene. The stop codon already 
present in the BAF180 gene sequence was deleted so that a His-tag could be included on 
the recombinant protein, because His-tags can be used for affinity purification of a 
recombinant protein. Additionally, an enterokinase site (GAC GAC GAC GAC AAG) 
was included to cleave off the His-tag after purification, as tags can sometimes interfere 
with mechanistic studies (Figure 5.2). 
 
Figure 5.2: Modifications on the 3' end of the BAF180 DNA sequence. Deletion of stop codon was done to 
allow expression of 6x His-tag on the C-terminus of BAF180. The His-tag would be cleaved off after 
purification using enterokinase. The 3' restriction enzyme was changed to KpnI to allow for directional 
cloning of BAF180 into the pGAPZA vector. 
 
The PCR modifications (insertion of Kozak consensus sequence, insertion of 
spacer, alteration of 3' restriction enzyme site, and insertion of an enterokinase site) were 
accomplished using the following primers: (Color key: blue – GC clamp; red – EcoRI 
site; italics – Kozak sequence; black – spacer; purple – BAF180 gene; green – KpnI site; 
pink – enterokinase site; dark orange – pGAPZA vector): 
 
DNA Sequence After Mutation:
PBRM1 DNA Sequence:
5’ – GAAAATGTTTAATCACATCATTACGTTTCTTTTATATAGAAGCATAAAGAGTTGTGGATCAGGAATTC – 3’
Stop Codon EcoRI
5’ – GAAAATGTTGACGACGACGACAAGGGTACCTCACATCATTACGTTTCTTTTATATAGAAGCATAAAGAGTTGTGGATCAGGAATTC – 3’
KpnI
Enterokinase
No Stop Codon Original EcoRI
Site
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Forward: 
GCGCTGGTACGTAGGAATTCGAACTCAAAATGGGTTCCAAGAGAAGAAG 
Reverse: 
GCGCTAATGATGTGAGGTACCCTTGTCGTCGTCGTCAACATTTTCTAGGTT 
GTA 
PCR conditions were as recommended by NEB for the Q5 Polymerase: 98 °C for 30 
seconds, 30 cycles of 98 °C for 10 seconds, 76.3 °C for 30 seconds, 72 °C for 2 minutes 
followed by a final elongation time of 2 minutes at 72 °C. The PCR product was purified 
and concentrated before digesting. The modified BAF180 (i.e. PCR product) and the 
pGAPZA vector were digested with EcoRI and KpnI; 2000 ng of modified BAF180 and 
2000 ng of pGAPZA vector were digested with 10 units (2 µL) of each enzyme. The 
digests were purified and pGAPZA and BAF180 were ligated together in a 5:1 ratio 
(insert:vector) using T4 ligase. The pGAPZA-BAF180 construct (Figure 5.3) was 
transformed into E. coli DH5α cells (for propagation) via electroporation. 
Electrocompetent E. coli DH5α cells were prepared according to the Bio-Rad 
MicroPulser manual; the electroporation procedure was from the manual as well.31 It 
should be noted that pGAPZA contains the sh ble gene, conferring zeocin resistance. 
Therefore, zeocin was used for antibiotic selection. Because of this, low-salt LB at pH 7.5 
had to be used for all procedures in E. coli, as zeocin is only active at low-salt 
concentrations and at that pH.61 Transformants were grown on low-salt LB plates with 25 
µg/mL zeocin overnight at 37 °C. The positive transformants were selected and cultured 
in low-salt LB with 25 µg/mL zeocin at 37 °C and 250 rpm. BAF180-pGAPZA plasmid 
was isolated from these cells using a miniprep kit. 
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Figure 5.3: Plasmid map of the pGAPZA-BAF180 construct. BAF180 is highlighted in teal. The EM7 
promoter allows for replication of the plasmid in E. coli. The GAP promoter and AOX1 terminator are for 
use in yeast. The restriction enzyme sites EcoRI and KpnI are noted, as is the enterokinase site and 6x His-
tag. Image created with SnapGene software. 
 
Figure 5.4: Linearized pGAPZA-BAF180 and control pGAPZA plasmids. (A) The linearized pGAPZA-
BAF180 plasmid. pGAPZA-BAF180 was linearized with AvrII, which cuts within the GAP promoter. This 
linearization creates an expression cassette which is incorporated into the P. pastoris genome via 
homologous recombination. (B) The linearized pGAPZA vector. pGAPZA was linearized with AvrII and 
used as a positive control for transformation. Abbreviations: CYC1 TT: CYC1 transcription terminator 
region; GAP: constitutive GAP promoter; ZeoR: Sh ble gene, conferring zeocin resistance; PT: TEF1 
promoter, controls expression of the Sh ble gene in P. pastoris; PE: EM7 promoter, controls expression of 
the Sh ble gene in E. coli; AOX1 Term: AOX1 transcription terminator region. 
  
Before transformation into P. pastoris X33 cells, 4000 ng of pGAPZA-BAF180 
was linearized with 20 units (1 µL = 5 units) of AvrII for 16 hours at 37 °C. AvrII cuts 
within the GAP promoter, thereby allowing for homologous recombination at that same 
His 
Tag
AOX1 
Term
TGA
ZeoRPT PE CYC1TTMCSPGAP
B. pGAPZA
His 
TagBAF180
AOX1 
Term Zeo
RPT
CYC
1TTPGAP PE
Enterokinase 
SiteKozak Sequence TGA
A. pGAPZA-BAF180
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site in the P. pastoris genome (Figure 5.4A).45,56,61 Homologous recombination results in 
incorporation of the linearized plasmid into the P. pastoris genome.45,61 As a positive 
control, pGAPZA was linearized using the same restriction enzyme (Figure 5.4B) and 
transformed into P. pastoris cells as well. Electrocompetent X33 cells (80 μL) and 10 μg 
of linearized pGAPZA-BAF180 (or control pGAPZA) were combined in a 
microcentrifuge tube and subsequently transferred to a cold 0.2 cm electroporation 
cuvette. The cells were incubated on ice for 5 minutes.61 A Bio-Rad MicroPulser (under 
the setting “Pic”) was used to transform the cells.63 Immediately after pulsing the 
cell/plasmid mixture, 1 mL of ice-cold 1 M sorbitol was added to the cuvette; sorbitol is 
used to stabilize the electroporated cells, because they can be sensitive to osmotic 
pressure.61 It was very important that the sorbitol be added immediately, as 
transformation efficiency decreases exponentially with time delay.63 The mixture of 
cells/plasmid/sorbitol was transferred to a 15 mL tube and incubated at 30 °C for 2 hours 
without shaking. Various amounts of the transformation mixture (5 µL, 10 µL, 15 µL, 25 
µL, 50 µL, 75 µL, 100 µL, 125 µL, 150 µL, 175 µL and 200 µL) were spread on YPDS 
(YPD with sorbitol) plates with 100 µg/mL zeocin and grown for 3 days at 30 °C.61  
Colonies possessing the zeocin resistance gene grow better at lower densities, which is 
why various amounts of the transformation mixture was used.61 The transformation of 
pGAPZA-BAF180 resulted in 6 very small colonies (~1 mm) and the transformation of 
pGAPZA resulted in 2 colonies. Consultation with another lab experienced in P. pastoris 
expression suggested that the recommended zeocin concentration (100 µg/mL) is too 
high and noted that it is not used in that lab. This lab uses 25 µg/mL, 50 µg/mL, and 75 
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µg/mL. Therefore, the low transformation efficiency may be a result of the high zeocin 
concentration. 
 The transformation products were purified to ensure that there were no mixed 
colony transformants, as mixed colony transformants have a tendency to lose the foreign 
DNA.61 The six colonies were streaked on YPD plates with 25 µg/mL zeocin, and grown 
for approximately 42 hours. Each of these colonies were removed and re-streaked on 
plates with 100 µg/mL zeocin and grown for 3 days at 30 °C. Isolating single colonies 
was difficult as the cell density was very high. After consultation with the other lab, a 
new method for plating for single colonies was used, wherein a single colony was picked 
up and added to 200 µL YPD. A toothpick was dipped in the media and used to streak 
new plates (YPD with 100 µg/mL zeocin). These resulting single colonies were used to 
create freezer stock. 
5.3 Preliminary Test for Protein Expression 
An initial test for BAF180 expression was performed using cultures grown at 4 
time-points. Zeocin selection was only used for plates; liquid YPD cultures did not have 
any zeocin added. A pGAPZA-BAF180 transformant (BAF180 X33) was grown for 3 
days at 30 °C on a YPD plate with 100 µg/mL zeocin. A single colony was used to 
inoculate 10 mL of YPD and was grown overnight at 30 °C and 225 rpm. Four separate 
cultures were created from this initial stock, each culture having 2 mL of overnight 
culture added to 50 mL fresh YPD. Consequently, all the cultures stem from the same 
colony, thereby eliminating the possibility of expression differences between colonies. 
Each of the 4 cultures were grown at 20.5 °C and 225 rpm, and 1 culture was removed 
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every 24 hours. The temperature of 20.5 °C was chosen because it was hypothesized that 
this lower temperature would increase the probability of BAF180 production. These cells 
were harvested by centrifuging at 12,000 g for 15 minutes at 4 °C and lysed using the 
method presented by Johnson et al.64 Harvested cells were re-suspended in lysis buffer 
(50 mM Tris-Cl, pH 7.4, 1 mM PMSF) at 2 mL/gram cell (PMSF is highly unstable in 
aqueous solutions and therefore needed to be added immediately prior to use). The cell 
suspension was then added to 1.5 mL microcentrifuge tubes along with 0.5 mm 
zirconia/silica disruption beads. The quantities used for each are shown in Table 5.1. 
Volumes of zirconia/silica beads were measured by displacement. Each tube was 
vortexed on maximum speed for 30 seconds, followed by a 30 second rest on ice; this 
cycle was repeated a total of 6 times. The samples were then centrifuged at 12,000 g for 
15 minutes at 4 °C and the lysate collected. 8 M urea was added to the cell debris to 
recover any insoluble protein.  
Table 5.1: Ratios of cell suspension and zirconia/silica disruption beads used in the initial screening for 
BAF180 production. 
 
 
 
Time Point Cell Suspension Zirconia/Silica Beads
0 hour ~500 µL ~250 µL
24 hour ~500 µL ~250 µL
48 hour ~650 µL ~150 µL
72 hour ~680 µL ~320 µL
96 hour ~680 µL ~320 µL
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All samples were visualized on SDS-PAGE to determine if BAF180 production 
occurred (Figure 5.5A & B). Additionally, the media was tested to confirm that BAF180 
was not being secreted from the cell (Figure 5.5C). Results suggested that there was no 
BAF180 present in the soluble fraction (lysate), but a band around 190 kDa (the size of 
BAF180) was seen for the 96 hour insoluble fraction. Surprisingly, bands ~190 kDa were 
seen in the 72 hour media and 96 hour media samples. P. pastoris secretes very low 
levels of native proteins43,45,65-67 and the pGAPZA vector does not have a secretion signal, 
therefore no protein should be seen in the media. It was suspected that these bands are 
present because some of the cells were being lysed during cell growth.43 
 
Figure 5.5: SDS-PAGE results from the initial screening for BAF180 production in Pichia pastoris X33 
cells; BAF180 is approximately 190 kDa. (A) The soluble fraction (i.e. lysate); no band was seen at 190 
kDa. (B) The insoluble fraction; a band about 190 kDa was seen for the 96 hour sample. (C) The media 
samples; bands at ~190 kDa were seen for the 72 hour and 96 hour media samples. The band for BAF180 is 
found in the red box. 
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When using yeast as a heterologous host, it is possible for multiple copies of the 
recombinant gene (i.e. BAF180) to be integrated into the genome. Though these are rare 
occurrences, the presence of multiple copies can increase recombinant protein 
yield.45,56,60 Both BAF180 low-producing (likely 1 copy) and high-producing (likely 
more than 1 copy) clones were identified via SDS-PAGE of BAF180 X33 lysate (Figure 
5.6). On YPD plates, WT X33 cells consistently formed larger colonies than high-
producing BAF180 clones (Figure 5.7A) grown under the same conditions (30 °C, 72 
hours) and WT X33 cells appeared slightly more white in color than high-producing 
BAF180 X33 cells (Figure 5.7B). Colonies of high-producing clones were noticeably 
“stickier” on solid media as well. In liquid media, there were no significant changes in 
the cellular masses of WT X33 cultures and BAF180 X33 cultures. However, high-
producing BAF180 cell cultures were significantly more viscous than cultures of low-
producing BAF180 cells or WT X33 cells. Additionally, low-producing BAF180 cells 
and WT X33 both compacted much better during centrifugation than high-producing 
cells did, so a higher centrifuge speed was required. High-producing BAF180 cells were 
also harder to re-suspend during the lysis procedure, which resulted in increasing the 
buffer:cell ratio (3mL/gram from 2 mL/gram). 
High-producing cells were only discovered after visualizing the lysate on SDS-
PAGE. Therefore, the high-producing cells needed to be obtained from the soluble lysate. 
200 μL of soluble lysate was added to 3 mL of YPD and grown at 30 °C for 20-24 hours. 
Luckily, this culture grew and plates were made. Various volumes of the high-producing 
culture were added to YPD plates, as decreasing the cell density on plates can improve 
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growth.61  The plates were grown at 30 °C for 3 days and then used to re-streak for single 
colonies. A single colony was used to inoculate a 5 mL YPD culture, which was grown 
overnight at 30 °C with 225 rpm. Freezer stock was obtained from this culture. 
        
Figure 5.6: SDS-PAGE comparison of low-producing (LP) and high-producing (HP) clones of BAF180 
X33 cells. The high-producing clones were identified by visual comparison between the soluble lysates of 
multiple clones. All cells were lysed using the same method. BAF180 (190 kDa) is within the red box. 
 
 
Figure 5.7: Direct visual comparison of colonies of WT X33 cells (left) and colonies of high-producer 
BAF180 X33 cells (right). (A) Differences in colony size between the two cell types. (B) Differences in 
color of the colonies. 
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5.4 Optimization of Growth Conditions 
In order to obtain maximum expression levels of BAF180, growth conditions 
were optimized. This involved the manipulation of growing temperature, time, and 
growing media.64,68-70 
5.4.1 Investigating the Role of Temperature and Time on BAF180 
Production 
The temperature used during heterologous cell growth has been demonstrated to 
change the yield and activity for several proteins.64,68-70 Three temperatures were tested: 
30 °C, 25 °C, and 20.5 °C to study the influence of temperature on BAF180 production. 
While yeast is normally grown at 30 °C, lowering the temperature can result in a higher 
quantity of “active” protein; this is especially important for proteins destined for 
mechanistic studies. As mentioned previously, the constitutive GAP promoter was chosen 
because it allows for continuous protein production during cell growth. Lowering the 
temperature slows cell growth which would subsequently result in a slower rate of 
BAF180 production. It was hypothesized that a slower rate of protein production would 
give the cell more time to properly fold the recombinant protein, because the quantity of 
protein present would be less and the protein would not overwhelm the cell’s protein 
folding machinery. Therefore, a lower temperature might result in more functional 
BAF180 being produced.  
The growing time is related to the cell density as it takes a certain amount of time 
for a culture to reach exponential growth, where it is growing the fastest. Because 
lowering the temperature slows down cell growth, the time that the cultures require to 
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reach exponential growth changes; therefore, temperature and time were tested in 
tandem. Since the GAP promoter was chosen (constitutive, not inducible), the exact point 
of exponential cell growth was not needed. The time to reach exponential cell growth is 
important with inducible promoters (such as T7 and AOX1), as it is best to add the 
inducer (IPTG or methanol) at the beginning of this phase. To determine if the stage of 
cell growth, and thus cell density, affected the expression of BAF180 different growing 
times were tested: 24 hours, 48 hrs, 72 hrs, 96 hrs, and 120 hrs. It was hypothesized that a 
higher cell density would result in more BAF180. However, at higher cell densities the 
cells can burst and release proteases, which would degrade BAF180.  
To test the effects of temperature and time on the production of BAF180, 
BAF180-containing X33 cells were streaked on YPD plates containing 100 µg/mL zeocin 
and grown at 30 °C for 3 days. A 10 mL YPD culture was inoculated with 1 colony and 
grown overnight at 30 °C and 225 rpm. YPD cultures (50 mL each) were inoculated with 
2 mL of the overnight culture and grown at 30 °C for 24, 48, 72, 96, or 120 hours. Every 
24 hours, a different culture was removed and spun down at 12,000 g for 15 minutes at 4 
°C. The cells for each time point were lysed and the lysate visualized on SDS-PAGE 
(Figure 5.8). This procedure was repeated for tests at 20.5 °C and 25 °C; the overnight 
culture conditions remained the same. At least 6 replicates of each time and temperature 
combination were compared to determine changes in protein content. The results shown 
in Figure 5.8 are representative of the results obtained. Results repeatedly indicated that 
growing the cells at 25 °C was ideal (Figure 5.9); 24 and 48 hour time spans did not 
exhibit any significant difference, so 24 hours was chosen for brevity.  
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Figure 5.8: SDS-PAGE gels displaying the soluble (s) and insoluble (i) lysate fractions for BAF180 X33 
cells. Cells were grown at different temperatures and times and the BAF180 content was compared. Results 
repeatedly demonstrated that 25 °C was optimal. (A) 20.5 °C; (B) 25 °C; (C) 30 °C. The band for BAF180 
is found in the red box. 
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Figure 5.9: SDS-PAGE of lysates from BAF180 X33 cells grown at 25 °C. All lysates shown are the 
soluble fractions. Results repeatedly demonstrated that optimal growing time was 24 or 48 hours. There 
was no significant difference in BAF180 content between the 2 time spans; therefore, 24 hours was chosen 
for brevity. The band for BAF180 is found in the red box. 
 
5.4.2 Influence of Media Composition 
Experiments were also conducted to determine if pH or media composition would 
have a significant impact on cellular growth and BAF180 production.64,68-70 Each 50 mL 
culture was started from 2 mL of the same 20 mL overnight culture (25 °C, 225 rpm, ~16 
hrs). The 50 mL cultures were grown at 25 °C for 24 hours. YPD was used as the base 
media for all the tests; pH was varied (4 or 6.7) and various additives (glycerol, sorbitol, 
NH4OH, dextrose) were included (Figure 5.10). Interestingly, the pH of the culture had 
the most significant impact on cell density; normal YPD had approximately 4x higher 
cell growth than YPD at pH 4. However, YPD+G results demonstrated the opposite 
effect; pH 4 grew better than pH 6. Results indicate that growing the cells in YPD results 
in the highest expression levels of BAF180 (Figure 5.11). 
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Figure 5.10: Comparison of growth mediums. All cells were grown at 25 °C for 24 hours and lysed in a 5 
mL tube with a 1:1 ratio of lysate:beads. (A) Graphical representation of the cell densities observed for the 
different cultures; (B) Visual comparison of cultures. Growth mediums were: A: YPD (normal pH of 6.7); 
B: YPD, pH 4; C: YPD, 5% NH4OH at 5 hours; D: YPD, 5 mL 20 % dextrose at 5 hours; E: YPD+G, pH 4 
(YPD + 1 % glycerol); F: YPD+G (normal pH); G: YPDS (YPD + 18.2 % sorbitol); H: YPD in baffled 
flask; I and J: YPD. 
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Figure 5.11: Optimization of media composition and pH. All gels were run using the same ladder as seen 
on the far left side. Some media compositions resulted in more or less BAF180 being produced, though the 
general protein composition of the cells did not change significantly. All cells were grown at 25 °C for 24 
hours and lysed in a 5 mL tube with a 1:1 ratio of lysate:beads. Growth mediums were: A: YPD (normal 
pH of 6.7); B: YPD, pH 4; C: YPD, 5% NH4OH at 5 hours; D: YPD, 5 mL 20 % dextrose at 5 hours; E: 
YPD+G, pH 4 (YPD + 1 % glycerol); F: YPD+G (normal pH); G: YPDS (YPD + 18.2 % sorbitol); H: YPD 
in baffled flask; I and J: YPD. The band for BAF180 is found in the red box. 
 
5.4.3 Influence of Culture Volume on BAF180 Production 
After preliminary tests were performed to determine optimal growth conditions, 
culture scale-up conditions were tested. Because yeast growth can be highly dependent 
on available oxygen,71-77 it was unknown whether the increase in volume would impede 
growth and/or BAF180 production. Though the GAP promoter does not rely on oxygen 
as much as the AOX1 promoter, tests were still performed. In tandem with culture scale-
up experiments, different time spans were tested to determine if the larger culture 
volumes required a longer growing period. All initial tests were done with 50 mL cultures 
that had been inoculated with 2 mL of overnight culture. For scale-up experiments, the 
amount of overnight culture added to a new culture varied depending on the final culture 
volume. For culture volumes of 100 mL, 3.5 mL of overnight culture was used. Larger 
culture volumes (200 mL and 500 mL) were inoculated by taking aliquots from a 50 mL 
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24 hour culture; 5 mL was used to inoculate a 200 mL culture and 10 mL was used for 
500 mL. Conditions tested are shown in Table 5.2. Each culture was harvested and lysed 
in the same manner and the soluble fractions were visualized on SDS-PAGE. As shown 
in Figure 5.12, the amount of BAF180 produced did not vary significantly with culture 
volume or time. It appeared that the quantity of oxygen did not affect BAF180 
production, as increasing the volume did not significantly affect BAF180 content. 
Therefore, all subsequent culture volumes were increased to 500 mL so a larger volume 
of lysate could be obtained. 
Once high-producing cells were discovered, a brief scale-up test was performed 
again. In this case, a 15 mL overnight culture was used. Culture volumes of 50 mL, 100 
mL, and 500 mL were investigated; as before, the amount of overnight culture used to 
inoculate the fresh cultures varied depending on the volume. 50 mL cultures were 
inoculated with 2 mL of overnight, while 3.5 mL was used for the 100 mL culture and 5 
mL of overnight was used for 500 mL culture. Again, scale-up did not significantly affect 
BAF180 production (Figure 5.13). Results indicate that ideal growing conditions for 
BAF180-producing cells are: 25 °C, 225 rpm, 24 hours, 500 mL YPD inoculated with 5 
mL of overnight culture. 
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Table 5.2: The combinations of culture volume and growth time used during scale-up testing. Also 
displayed are the various volumes of overnight culture added to the larger culture. 
 
 
              
Figure 5.12: Culture scale-up testing. To determine how expression of BAF180 changes when the culture 
volume changes, multiple experiments were run and the lysates compared. Above are representative 
samples of the different combinations; all combinations were grown with low-producing cells at 25 °C and 
225 rpm shaking. All fractions shown are the soluble fractions and all cells were lysed in the same manner. 
As can be seen, culture volume did not significantly affect BAF180 production, suggesting that scaling-up 
the growth of BAF180-producing cells was possible. The band for BAF180 (~190 kDa) is in the red box. 
 
Culture volume Volume of overnight 
culture added
Growth time 
(hours)
50 mL 2 mL 24
100 mL 3.5 mL 24
100 mL 3.5 mL 48
200 mL 5 mL 24
500 mL 10 mL 24 
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Figure 5.13: Scale-up testing of high-producer cells. Once the high-producing strains were discovered and 
isolated, scale-up conditions were tested again. There was no significant difference in BAF180 content 
between the different culture volumes. Cells were grown at 25 °C with 225 rpm shaking. The fractions 
shown are the soluble fractions and all cells were lysed in the same manner. As can be seen, culture volume 
did not significantly affect BAF180 production, suggesting that scaling-up the growth of BAF180-
producing cells was possible. The band for BAF180 is found in the red box. 
 
5.5 Optimization of Lysis Conditions 
To ensure the highest recovery of BAF180, lysis conditions were manipulated and 
optimized. Lysis of P. pastoris cells involves harvesting the cells from the culture and re-
suspending them in a lysis buffer. The cell suspension is combined with 0.5 mm beads 
wherein they are subjected to repeated mechanical agitation. Buffer composition, lysis 
mixture volume, agitation time, and the ratio of cell suspension to beads were 
investigated in an effort to maximize the recovery of BAF180. 
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The initial lysis conditions were based on the procedures outlined in the 
Invitrogen manual61 and in publications from Dr. P. Murthy’s lab.64,68 These protocols 
involved harvesting the P. pastoris cells via centrifugation (12,000 g for 15 minutes at 4 
°C), followed by wash and subsequent re-suspension in a lysis buffer at a ratio of 2 mL 
buffer per gram cell. A volume of cell suspension was combined in a tube along with 
zirconia/silica beads (0.5 mm) and the mixture of cells and beads were vortexed multiple 
times for a duration of 30 seconds, followed by 30 second rest on ice.61,64,68 The lysate 
was recovered after further centrifugation (soluble fraction). Insoluble proteins were 
extracted by addition of 8 M urea to the cell debris (insoluble fraction). 
Three lysis buffers were examined to determine if the buffer composition affected 
the lysis efficiency and BAF180 protein stability (Figure 5.14). The buffers were as 
follows: Buffer 1 – 50 mM Tris-Cl, pH 7.4 with 1 mM PMSF;64,68 Buffer 2 – 50 mM 
NaH2PO4, pH 7.4; 1 mM PMSF; 1 mM EDTA; 5 % glycerol;61 Buffer 3 omitted EDTA 
from buffer 2. Since BAF180 is a very large protein (190 kDa), attempting to refold it 
into its native state after denaturation during would be very difficult, therefore the goal 
was to determine which buffer composition resulted in the largest amount of BAF180 in 
the soluble fraction of the lysate. When using buffer 1, BAF180 was primarily found in 
the insoluble fraction. For buffer 2, BAF180 repeatedly appeared in the soluble fraction. 
Therefore, buffer 2 was chosen for all future experiments. It was hypothesized that the 
EDTA and glycerol found in buffer 2 had a stabilizing effect on the protein: glycerol 
slows down the kinetic energy of the solution and EDTA inhibits metalloproteases. 
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Figure 5.14: Comparison of the soluble (sol) and insoluble (ins) fractions for lysis with buffer 1 and with 
buffer 2. Though the bands are faint, the gel shows that most of the BAF180 (190 kDa) protein is found in 
the insoluble fraction (8 M urea) when using buffer 1, but found in the soluble fraction when using buffer 2. 
Since the BAF180 protein is so large, attempting to refold it into its native state after denaturation during 
lysis would be very difficult. Therefore, the buffer that had more BAF180 in the soluble fraction was 
chosen for all future work. Each fraction shown was lysed under the same conditions (1.5 mL tube, 1:1 
ratio), except for the buffer composition. The lysis fractions shown here were from low-producing cells. 
The band for BAF180 is found in the red box. 
 
Various volumes of lysis mixture (total volume of cell suspension and beads) 
were tested to determine if the total volume impacted recovery of BAF180. It was 
considered that perhaps the amount of dead space in the tube might affect how the cells 
and beads interacted (such as number of collisions). In a 1.5 mL tube, total volumes of 
0.75 mL, 1 mL, and 1.25 mL were tested. In a 5 mL tube, total volumes of 4 mL and 4.5 
mL were tested. There was no significant difference in the amount of BAF180 recovered 
when comparing lysis volumes (Figure 5.15). Lysis in 5 mL tubes was most time 
efficient, though recovery of the lysate was more difficult than for 1.5 mL tubes; 
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however, this trade-off was considered to be worth it because it reduced the overall time 
required for cell lysis. A volume of 4 mL lysis mixture in a 5 mL tube was chosen for 
future experiments. 
 
Figure 5.15: Effects of total volume and cell:bead ratio. Three cultures (A, B, C) were grown at 25 °C for 
24 hours, all started from the same seed culture. All cultures were lysed in buffer 2 (50 mM NaH2PO4, 1 
mM PMSF, 1 mM EDTA, 5 % glycerol, pH 7.4); cells were re-suspended at 2 mL/g cell pellet. Different 
volumes and different ratios of lysate:beads were tested. The differences in lysate content indicate that total 
volume and ratio of cells:beads did not a have a significant impact.  All fractions shown are soluble 
fractions. BAF180 (~190 kDa) is the intense band between 260 and 140 kDa marker (in red box). 
 
The ratio of cell suspension:beads was tested to determine if the ratio affected 
BAF180 recovery. It was hypothesized that there might be an optimal ratio to ensure the 
most favorable interactions between the cells and beads (such as number of collisions). 
Ratios of 1:1, 2:1, 3:1, and 4:1 were tested (Table 5.3), but no significant difference in 
BAF180 content was observed for each of the ratios used (Figure 5.15 and Figure 5.16). 
A ratio of 3:1 was chosen for future work because it was easiest to remove the lysate after 
centrifugation, meaning that it was easier to separate the supernatant from the beads at 
this ratio. 
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Table 5.3: Volumes used when testing different volumes of cells and beads, in both a 1.5 mL tube and a 5 
mL tube. All ratios are cells:beads. 
 
 
 
Figure 5.16: Lysis of high-producing cells. Three cultures were grown at 25 °C for 24 hours, all started 
from the same seed culture. All cultures were lysed in buffer 2 (50 mM NaH2PO4, 1 mM PMSF, 1 mM 
EDTA, 5 % glycerol, pH 7.4); cells were re-suspended at 2 mL/g cell pellet. Different volumes and 
different ratios of lysate:beads were tested. The differences in lysate content indicated that volume and ratio 
did not a have a significant impact on BAF180 recovery. These gel images also demonstrate the variation 
in BAF180 content between cultures, possibly due to inactivation of PMSF over time. The band for 
BAF180 is found in the red box. 
 
The established methods for lysing yeast cells are enzymatic treatment and 
mechanical agitation. Mechanical agitation was chosen for use because it is more cost-
efficient than enzymatic lysis. Zirconia/silica beads are added to the cell suspension and 
the mixture is subjected to vortexing for 30 seconds, followed by a 30 second rest on ice. 
The number of cycles was varied to determine how it affected BAF180 recovery. Repeats 
Ratio 1.5 mL Tube 5 mL Tube
1:1 500 µL:500 µL 2 mL: 2 mL
2:1 500 µL:250 µL 3 mL:1.5 mL
3:1 3 mL:1 mL
4:1 800 µL:200 µL
1 mL:250 µL
1. A sol 1.5 mL
2. B sol 1.5 mL
3. C sol 1.5 mL
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3. C sol 5 mL 1:1
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of 6, 8, 10, 12, and 16 were tested (Figure 5.17). It was determined that 12 cycles 
consistently yielded the most BAF180 in the soluble fraction. 
      
Figure 5.17: Experimental results comparing buffers 1 and 2, the total volume, and the number of cycles. 
All samples shown are soluble fractions and were lysed using a 1:1 ratio. Note that the total volume did not 
make a difference in lysate content. However, buffer type and number of cycles did. It can be seen that 
BAF180 (190 kDa) is more prevalent in the buffer 2 soluble lysate samples than in buffer 1. This is likely 
due to the presence of glycerol and EDTA in buffer 2. Additionally, the number of cycles did not 
significantly affect lysate content, though there was a small, but reproducible increase in BAF180 content 
for 12 cycles. The band for BAF180 is found in the red box. 
  
Once the high-producing clones were discovered, volume and ratio experiments 
were performed again to verify that the results would not be different (Figure 5.16). 
High-producing cells were harvested by centrifuging at 17,000 g for 30 minutes at 4 °C. 
Both centrifugation speed and time were increased due to the increased culture viscosity 
of high-producing cells. After decanting the media, the cells were re-suspended in 
breaking buffer at a ratio of 3 mL/gram cell (this was increased from the previous 2 
mL/gram cell because a larger volume was necessary to re-suspend the BAF180 high-
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producing cells as intercellular adhesion was high, resulting in cells that were noticeably 
“stickier”). 
Additionally, the effect of the protease inhibitor composition was examined in 
relation to BAF180 recovery. It was thought that perhaps a more stable protease inhibitor 
would yield more consistent results. Use of PMSF gave inconsistent results, likely due to 
its instability and short half-life in aqueous solutions (30-60 minutes). The amount of 
time between starting and finishing lysis did vary and this likely impacted BAF180 
recovery. Comparisons were done between PMSF and a protease inhibitor cocktail 
purchased from VWR. PMSF inhibits only serine proteases, while the protease inhibitor 
cocktail from VWR inhibits serine proteases (AEBSF, Aprotinin, and Leupeptin), 
cysteine proteases (E-64, Leupeptin), and aminopeptidases (Bestatin). Also, the lysis 
buffer contains EDTA, a metalloprotease inhibitor; EDTA was present for both tests. 
Larger yields of BAF180 (i.e. more intense bands on SDS-PAGE) were consistently 
observed when using the protease inhibitor cocktail (Figure 5.18). All subsequent cell 
lysis was performed using the cocktail from VWR instead of PMSF. 
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Figure 5.18: Choice of protease inhibitor type. Both PMSF and a protease inhibitor cocktail were used 
during lysis and the results were compared. A slightly more intense BAF180 band was consistently seen 
when using the protease inhibitor cocktail (PIC). The band for BAF180 is found in the red box. 
 
After testing numerous combinations of the above variables, the optimal lysis 
procedure was established as follows: Cells were harvested by centrifuging at 17,000 g 
for 30 minutes at 4 °C. After decanting the media, the cells were washed by re-
suspending them in 100 mL of buffer 2 containing 1 mM PMSF. The cells were spun 
down again, decanted, and re-suspended at a ratio of 3 mL/gram cell in buffer 2 with 
protease inhibitor cocktail (at the recommended concentration). The cell suspension was 
combined with 0.5 mm silica/zirconia beads at a ratio of 3:1 (3 mL cells/1 mL beads, 
total volume 4 mL). The cell/bead mixture was vortexed on maximum speed for 12 
cycles (30 seconds on vortex/30 sec on ice). The lysate was centrifuged at 17,000 g for 30 
minutes at 4 °C and the supernatant was removed (soluble fraction). 
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5.6 Confirmation of BAF180 
To determine if the 190 kD band seen was an endogenous protein, wild-type X33 
(transformed with pGAPZA for zeocin resistance) soluble and insoluble fractions were 
compared to the soluble fraction of BAF180 X33 cells (transformed with pGAPZA-
BAF180) (Figure 5.19). Only the soluble lysate of BAF180 cells is shown, because this 
experiment was just to demonstrate that a band at the approximate molecular weight of 
BAF180 (~190 kDa) is not normally present in X33 cells. The 2 cultures, WT X33 and 
BAF180 X33, were treated in the same manner: growth was conducted for 96 hours at 
20.5 °C and lysed using the same method. Comparison of lysates and insoluble fractions 
of WT X33 did not show a band around 190 kDa. When compared side by side, a band, 
approximately 190 kDa was seen only in BAF180 X33 cells (Figure 5.19). This 
experiment was also repeated several times after ideal growth conditions were established 
(25 °C for 24 hours). 
                                 
Figure 5.19: A comparison of the lysates WT X33 cells to the lysate of BAF180 X33 cells. SDS-PAGE 
gels (7.5%) showed a band around 190 kDa (expected molecular weight of BAF180) only in the BAF180 
X33 fraction. Neither the soluble (sol) nor insoluble (ins) fractions of WT X33 cells displayed a band of the 
correct BAF180 size, so it was concluded that BAF180 is not normally expressed in wild type cells. The 
band for BAF180 is found in the red box. 
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Confirmation of BAF180 was also done using an anti-PBRM1 antibody via 
western and dot blots. A dot blot is the same concept as a western blot, except the protein 
sample is spotted directly onto the membrane. For the dot blot, 2 µL of protein sample 
was spotted onto a 0.45 µm nitrocellulose membrane and allowed to dry; the membrane 
was hydrated in wash buffer for 5 minutes. A Pierce Fast Western ECL kit was used; kit 
instructions were followed with one exception: a 5 minute wash step was added between 
primary and secondary antibody incubations, to remove azide present in the primary 
antibody storage solution. Anti-PBRM1 antibody was used at a ratio of 1:1000 (10 µL of 
stock antibody was added to 10 mL of Fast Western Antibody Diluent). After incubation 
in ECL (enhanced chemiluminescence) substrate, the membrane was imaged with Bio-
Rad XRS+ imager (CDD camera). Crude lysates of BAF180 X33 cells and of WT X33 
cells (both soluble and insoluble fractions) were spotted onto the membrane and tested 
against the antibody. The results (displayed in Figure 5.20) indicate that BAF180 is not 
present in WT X33 cells, as no spot was seen. This test served two purposes: one, to 
confirm that the protein being produced was BAF180 and two, that this protein is not 
endogenous to WT X33 cells. 
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Figure 5.20: Confirmation of BAF180 production via dot blot. Crude lysates of BAF180 X33 and WT X33 
cells were spotted onto a nitrocellulose membrane and allowed to dry. The membrane was then exposed to 
anti-PBRM1 antibody and imaged using a CDD camera. As can be seen, signals were detected for the crude 
lysate of BAF180 X33 cells (boxes 1 and 2), but not for WT X33 cells (boxes 3 and 4).  Both soluble and 
insoluble lysate fractions of each cell were used. Box 1: insoluble fraction BAF180 X33; box 2: soluble 
fraction BAF180 X33; box 3: insoluble fraction WT X33 cells; box 4: soluble fraction WT X33 cells.  
 
Western blot experiments were performed using Tris-glycine and Tris-acetate 
SDS-PAGE gels. All attempts with the Tris-glycine system were unsuccessful. However, 
western blots were successfully carried out using pre-cast NuPAGE Tris-Acetate gels (3-
8%). Tris-acetate gels were chosen because they are thought to be the best option when 
transferring large molecular weight proteins.78 1x NuPAGE Tris-acetate running buffer 
was prepared with NuPAGE antioxidant. NuPAGE antioxidant is a proprietary formula 
purchased from ThermoFisher which is added to the upper chamber of the gel assembly 
to ensure that the samples remain reduced; in the neutral pH of Tris-acetate gels, reducing 
agents do not travel with the sample and therefore the samples have the potential to be re-
oxidized during electrophoresis.79 10 µg of sample (quantified via bicinchoninic acid 
assay) was prepared and loaded into each well. The gel was run for 1 hour at 150 V. After 
running, the gel was removed and incubated for 10 minutes in 100 mL of 2x NuPAGE 
transfer buffer with 0.02% SDS and NuPAGE antioxidant. 1x NuPAGE transfer buffer 
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was prepared with 0.01% SDS, 10% methanol, and NuPAGE antioxidant. 0.45 µm PVDF 
membrane was activated in 100% methanol for 30 seconds, rinsed with water, and 
incubated in 1x transfer buffer. Once the gel and PVDF membrane were prepared, the gel 
sandwich was prepared and wet transfer was performed at 70 V for 1 hour.80 The PVDF 
membrane was air dried and stored overnight at -20 °C.79 The western blot procedure was 
carried out the same as for dot blots. Exposure for 55 seconds with a CCD camera 
showed multiple bands being recognized (Figure 5.21). The most intense band appears at 
approximately 190 kDa, the expected molecular weight of BAF180. The other bands 
were a lower weight than this. There are a few possible reasons why multiple protein 
bands were recognized: degradation of the protein by proteases is possible, as is 
premature termination during DNA translation. The anti-PBRM1 antibody used 
recognizes an epitope on the C-terminus of BAF180. For a band to be recognized by the 
antibody, the C-terminus of BAF180 must be present, eliminating premature termination 
as an option and suggesting that degradation occurs. Further investigations using other 
anti-PBRM1 antibodies that recognize epitopes on the N-terminus and in the middle of 
the protein are needed before the hypothesis can be confirmed. Regardless, the 
concentration of the protease inhibitor cocktail will be increased for future experiments. 
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Figure 5.21: Western blot performed on BAF180 lysate samples. The most intense band (top) is thought to 
be full-length BAF180 (190 kDa). The reasons that bands of lower molecular weight are present are 
currently unknown. The antibody used recognized an epitope on the C-terminus of BAF180. 
 
The recognition epitope of the antibody used was located at the C-terminus. 
Therefore, for a signal to be seen, this epitope must be present. Proteintech (the 
manufacturer of the antibody) used an immunogen 306 amino acids in length, 
encompassing the HMG box to the end of the protein. After researching the relationship 
between immunogens and epitopes, analysis was performed using SVMTriP online 
software81 to determine the most probable epitope sequences (Figure 5.22). 
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Figure 5.22: The complete immunogen sequence used by Proteintech to create the anti-PBRM1 antibody. 
(A) The most likely antibody recognition epitopes are colored and the HMG box sequence is underlined. 
(B) The most probable recognition epitope is located 128 amino acids downstream of the HMG box. 
Numbering is relative to the HMG box, where the first amino acid of the HMG box is denoted as 1. There 
is no 0 position (-2, -1, 1, 2, etc.). 
 
Additionally, PCR mapping of the domains was done to confirm the integration of 
the full PBRM1 gene (i.e. BAF180) into the P. pastoris genome (Figure 5.23). Genomic 
DNA (gDNA), isolated from the yeast cells as described in the appendix, was used as a 
template. Each fragment was generated individually. The fragments cover most of the 
gene sequence. The fragments were staggered so that each fragment overlaps with at least 
one other to confirm the gene was integrated in the proper order. All PCR reactions had 
500 ng of gDNA.  
Proteintech Immunogen Sequence: 
MGEEDSEVIEPPSLPQLQTPLASELDLMPYTPPQSTPKSAKGSAKKEGSKRKINMSGYILFSSE
MRAVIKAQHPDYSFGELSRLVGTEWRNLETAKKAEYEGMMGGYPPGLPPLQGPVDGLVSMG
SMQPLHPGGPPPHHLPPGVPGLPGIPPPGVMNQGVAPMVGTPAPGGSPYGQQVGVLGPPGQQ
APPPYPGPHPAGPPVIQQPTTPMFVAPPPKTQRLLHSEAYLKYIEGLSAESNSISKWDQTLAAR
RRDVHLSKEQESRLPSHWLKSKGAHTTMADALWRLRDLMLRDTLNIRQAYNLENV
Possible Epitopes: (SVMTriP)
KYIEGLSAESNSISKWDQTL Score: 1.00 Position: 178-197
FGELSRLVGTEWRNLETAKK Score: 0.709 Position: 27-46
RKINMSGYILFSSEMRAVIK Score: 0.619 Position: -1-19
QPTTPMFVAPPPKTQRLLHS Score: 0.538 Position: 154-173
Brd1 Brd2 Brd4Brd3 BAH1Brd6Brd5 BAH2 HMG AOX1GAP
BAH2 HMG AOX1
AA -51
AA1 AA50
AA255
AA288-293AA -255
His 
Tag
New stop
Original stop
Antibody Immunogen
178
Most likely epitope
197
A.
B.
Underlined is HMG box sequence
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Figure 5.23: Genomic DNA was isolated from BAF180 X33 cells and domain-specific primers were used 
to confirm integration of the PBRM1 sequence in P. pastoris. (A) Map of the PBRM1 gene with fragments 
numbered and expected sizes (inclusive of primers). (B) PCR products for domain mapping. 
 
5.7 Conclusion 
For the first time, full-length BAF180 was successfully produced in a 
heterologous host. BAF180 was an enormously difficult protein to clone, likely owing to 
the size, presence of multiple domains, presence of many rare codons, frequent base 
tracks in the DNA, and instability. Regardless, after much effort, BAF180 was 
successfully produced in the yeast Pichia pastoris. To recover the most BAF180, growth 
and lysis conditions were optimized. Ideal growth conditions were determined to be 24 
hours at 25 °C in 500 mL YPD. The optimal lysis procedure was established as follows: 
the cells were harvested by centrifuging at 17,000 g for 30 minutes at 4 °C. The media 
was decanted and the cells were washed by re-suspending them in 100 mL of buffer 2 
containing 1 mM PMSF. The cells were spun down again, decanted, and re-suspended at 
a ratio of 3 mL/gram cell in lysis buffer 2 with protease inhibitor cocktail. The cell 
suspension was combined with 0.5 mm silica/zirconia beads at a ratio of 3:1 (3 mL 
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Fragment 5Fragment 1 Fragment 4Fragment 3 
3 kb
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cells/1 mL beads, total volume 4 mL). The cell/bead mixture was vortexed on maximum 
speed for 12 cycles (30 seconds on vortex/30 sec on ice). The lysate was centrifuged at 
17,000 g for 30 minutes at 4 °C and the supernatant was recovered (soluble fraction). 
Following growth and lysis optimization, the presence of BAF180 was confirmed 
in multiple ways. Lysates of BAF180 X33 cells and WT X33 cells were compared to 
confirm that the 190 kD band seen on SDS-PAGE gels of BAF180 X33 lysate was not 
endogenous to X33 cells. The possibility of an endogenous X33 protein not appearing on 
the gel was considered and dot blot experiments were performed. After probing with an 
anti-PBRM1 antibody, comparison of BAF180 X33 and WT X33 lysates (control) proved 
that BAF180 was not present in WT X33 cells. Western blot experiments were 
successfully carried using the Tris-acetate gel system. Probing the membrane with the 
anti-PBRM1 antibody showed multiple protein bands being recognized. This is likely due 
to degradation of the protein; more protease inhibitor cocktail will be added in an attempt 
to minimize this. Integration of the PBRM1 gene into the Pichia pastoris genome was 
confirmed using PCR with genomic DNA and domain-specific primers. Results 
supported the hypothesis that the PBRM1 gene was successfully integrated into the host 
genome. 
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Chapter 6 : Purification of BAF180 in Pichia pastoris 
Purification of recombinant BAF180 was the next step after cloning and 
optimization of the expression and lysis conditions. As stated in a previous chapter, 
BAF180 has not been produced in a heterologous host and therefore has never been 
purified from a heterologous host. Researchers utilizing mammalian cells generally 
“purify” BAF180 by pull-down assay; this yields only small amounts of BAF180 and as 
such is unsuitable for larger studies. The properties of BAF180 were studied before 
attempting purification. Multiple purification methods were tried including IMAC (His-
tag affinity), strong and weak anion exchange (AEX), CHT hydroxyapatite (multi-mode), 
hydrophobic interaction chromatography (HIC), size-exclusion (SEC), ultrafiltration, and 
dialysis. Only strong AEX was able to purify BAF180 from the crude lysate.  
6.1 Materials 
SDS, glycine, Tris hydrochloride, Tris base, and glycerol purchased from 
Amresco (VWR: Radnor, PA). NaCl was purchased from EMD Millipore (Billerica, 
MA). EDTA was purchased from Mallinckrodt Baker Inc. (Phillipsburg, NJ). Dialysis 
membranes were purchased from Spectrum Labs (Rancho Dominguez, California): 
Spectra/Por® 1 (6-8 kD MWCO membrane; part 132660), and Spectra/Por 6® (50 kD 
MWCO membrane; part 132544). Macro-Prep High Q® Support (cat. 1580040), and 
Econo® glass columns were purchased from Bio-Rad, Inc. (Hercules, CA). Sodium 
phosphate monobasic (NaH2PO4) and Whatman Puradisc 25 syringe filters – 1.0 µm PES 
membrane (cat. WHA67812510) were purchased from Sigma Aldrich (St. Louis, MO). 
Blotting paper (cat. 8860), 0.45 µm PVDF membrane (cat. 88585), NuPAGE Tris-
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Acetate gels 3-8% (cat. EA0375), NuPAGE LDS Sample Buffer 4x (cat. NP0007), 
NuPAGE Tris-acetate running buffer (cat. LA0041), NuPAGE transfer buffer (cat. 
NP0006), NuPAGE antioxidant (cat. NP0005), NuPAGE reducing agent (cat. NP0004) 
and Pierce Fast Western Blot Kit, ECL substrate (cat. 35050) were purchased from 
ThermoFisher (Waltham, MA). Anti-PBRM1 antibody (cat. 12563-1-AP, rabbit 
polyclonal) was received as part of the antibody exchange program at Proteintech 
(Rosemont, IL). Western blot transfer was performed using a Hoefer TE22 transfer tank 
(Holliston, MA). 
6.2 Purification of BAF180 by Anion Exchange Chromatography 
Purification of a recombinant protein by ion exchange chromatography uses the pI 
of the protein (i.e. its charge at a certain pH) to separate it from other cellular proteins. 
Above the pI, the protein is negatively-charged and can be separated by anion exchange 
resins; below the pI, the protein is positively-charged and can be separated by cation 
exchange resins.82-83 The pI of recombinant BAF180 is calculated to be 6.29. Anion 
exchange chromatography (AEX) was chosen because of the known stability of BAF180 
at pH 7.4, in lysis buffer 2 (see Section 5.5); since this is above the pI, BAF180 would 
carry a net negative charge. A strong anion exchanger was chosen, because the 
effectiveness of the resin is not affected by the pH of the buffer system, as weak anion 
exchangers are.82,84-85 MacroPrep® High Q was chosen as the strong AEX resin because 
it is noted as being good for separating large biomolecules and acidic and neutral 
proteins.82,86-89 MacroPrep® High Q is a methacrylate polymer with a quaternary 
ammonium group attached.88,90  
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A well designed buffer system is critical for anion exchange to be successful. 
When designing a buffer system for AEX, some general rules must be considered: 
• The pH of the buffer system should be 0.5-1.5 pH units above the pI of the 
protein.83,85,91 Therefore, the pH of the buffer system needed to be between 6.8 
and 7.8. 
• The pKa of the buffer system should be within 0.5 pH units of the buffer’s pH.91 
• The protein should be stable in the buffer system. Several different buffer systems 
are possible, depending on the pH needed83,85,87-88,91 but Tris was chosen because 
previous experiments demonstrated that BAF180 was stable in it. Tris buffers 
have an approximate buffering range pH 7.5-8.83,85,87-88 
• An effective buffer system should be greater than 10 mM concentration.83,91-92 
Calculating pKa values of various concentrations of Tris at room temperature led to the 
decision to use 17 mM Tris at pH 7.6.92 A pH of 7.6 is 1.3 pH units above the pI of 
BAF180 (6.29). Elution off an anion exchange column is accomplished by increasing the 
salt (NaCl) concentration. Buffers with 0 M, 0.1 M, 0.5 M, and 1.0 M NaCl were 
recommended as starting points to determine the salt concentration at which BAF180 
elutes.  
Samples were prepared for purification by dialyzing crude lysate overnight in 17 
mM Tris, pH 7.6. Samples were collected the next day and stored at -20 °C until needed. 
Samples were defrosted at room temperature and centrifuged at 17,000 g for 20 minutes 
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at 4 °C to reduce viscosity and remove unwanted particulates. The supernatant was 
collected and run through a 1.0 µm PES syringe filter before loading onto a column. 
Preliminary results indicated that BAF180 was eluting from the resin at 0.5 M NaCl, with 
only a few contaminant proteins (Figure 6.1). More precise buffers (0.1 M, 0.2 M, 0.3 M, 
0.4 M, 0.5 M NaCl) were used to narrow down this range. BAF180 co-eluted with two 
contaminant proteins (~80 kDa and ~70 kDa) at 0.4 M NaCl (Figure 6.2). A buffer with 
0.35 M NaCl was used in an attempt to separate these bands, but this did not show any 
significant difference (Figure 6.3). More buffers were made at concentrations between 
0.35 M and 0.4 M NaCl (0.36 M, 0.37 M, 0.38 M, 0.39 M). The results indicated that 
BAF180 was eluting at 0.36 M, 0.37 M, 0.38 M, 0.39 M, and 0.40 M; the contaminants 
remained and did not separate from BAF180 (Figure 6.4). Though BAF180 eluted at 0.36 
M NaCl and up, 0.4 M NaCl was chosen as the elution concentration in order to 
maximize recovery and reduce the dilution factor.   
 
176 
 
   
 
Figure 6.1: First attempt at anion exchange purification. Buffers of 0 M, 0.1 M, 0.5 M, and 1.0 M NaCl 
were used to elute BAF180 from MacroPrep® High Q resin. This preliminary test indicated that BAF180 
was eluting at 0.5 M NaCl. The band for BAF180 is found in the red box. 
Flow-Through (0 M NaCl) Wash A (0 M NaCl)
Wash A (0 M NaCl) Wash B (0.1 M NaCl) Wash B (0.1 M NaCl) Wash C (0.5 M NaCl)
Wash D (1.0 M NaCl)Wash C (0.5 M NaCl) Wash D (1.0 M NaCl)
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Figure 6.2: Anion exchange purification in 0.1 M NaCl increments. More precise buffers were used to 
determine the exact NaCl concentration required to elute BAF180 from the anion exchange resin; elution 
occurred at 0.4 M NaCl. The band for BAF180 is found in the red box. 
 
Figure 6.3: Anion exchange purification with Tris buffers with 0.3 M, 0.35 M, and 0.4 M NaCl. Buffers 
with 0.3 M, 0.35 M, and 0.4 M NaCl were used to zone in on the exact NaCl concentration required to elute 
BAF180 from the contaminant proteins that remained after washing the column with 0.3 M NaCl. Results 
indicated that BAF180 eluted after 0.35 M NaCl along with a few other contaminant proteins. The band for 
BAF180 is found in the red box. 
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Figure 6.4: Anion exchange elution with 0.01 M increments of NaCl. Though BAF180 co-eluted at 0.36 M 
NaCl and up, this also decreased the final concentration. To maximize recovery, elution at 0.4 M NaCl was 
chosen. The BAF180 band is found in the red box. 
 
Full-length BAF180 always eluted at 0.4 M NaCl, however the sizes of the 
contaminant bands sometimes changed. It was thought that these contaminant bands were 
other proteins. However, a recent western blot reveals (see Section 5.6) that full-length 
BAF180 is being produced but much of it is degraded (Figure 6.5). The antibody used 
recognizes an epitope on the C-terminus (see Section 5.6); therefore this epitope must be 
present in all the recognized bands. Premature termination during translation was 
eliminated as a cause because this would leave fragments containing the N-terminus but 
not the C-terminus, where the epitope is located. The use of different antibodies which 
recognize epitopes on the N-terminus or in the middle of the protein could be used to 
confirm that BAF180 is being degraded and that the other bands seen are fragments of it 
(see Appendix A). Proteolytic degradation could explain why BAF180 content varied 
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after lysis and why purification results were sometimes inconsistent. Increasing the 
protease inhibitor cocktail concentration above the recommended level might result in 
less proteolytic BAF180 degradation. 
 
Figure 6.5: Western blot performed on BAF180 lysate samples. The most intense band is thought to be full-
length BAF180 (190 kDa). The antibody used recognized an epitope on the C-terminus of BAF180. Lanes 
1 and 3 were crude samples. Lanes 2 and 4 were purified fractions. It is believed that the lower molecular 
weight bands are the result of BAF180 degradation by proteases. Exposure was 55 seconds with a CDD 
camera and ECL detection. 
 
It is believed that during lysis the BAF180 protein is being degraded by proteases, 
even though protease inhibitors are added to the lysis mixture. Proteolytic degradation in 
yeast mostly occurs in vacuoles which are membrane bound,56,58 therefore, the protein is 
only exposed to them during lysis. Increasing the protease inhibitor cocktail 
concentration or changing cocktail type altogether might reduce proteolytic degradation 
and result in a higher BAF180 yield. 
6.3 Conclusion 
For the first time, BAF180 was successfully purified from a heterologous host 
using strong anion exchange chromatography. Recent western blot results revealed that 
the bands seen on SDS-PAGE gels that were initially thought to be contaminants are 
actually BAF180 fragments (likely a result of degradation). The concentration and/or 
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composition of the protease inhibitor cocktail should be manipulated in order to eliminate 
as much protease activity as possible and increase the yield of BAF180. 
6.4 Supplementary Information 
The following experiments were run before it was discovered that the other bands 
seen in the AEX purified fraction were actually fragments of BAF180. The 
“contaminant” proteins, now known to be fragments of BAF180, eluted with full length 
BAF180 every time. It was thought that perhaps a protein complex was forming in the 
cell or that the “contaminant” proteins had a pI too close to that of BAF180 to be 
separated. 
Materials 
SDS, glycine, Tris hydrochloride, Tris base, glycerol, guanidine hydrochloride, 
and imidazole were purchased from Amresco (VWR: Radnor, PA). NaCl and Amicon® 
Ultra-15 100 kDa Centrifugal Filter Units (cat. UFC910024) were purchased from EMD 
Millipore (Billerica, MA). EDTA was purchased from Mallinckrodt Baker Inc. 
(Phillipsburg, NJ). Dialysis membranes were purchased from Spectrum Labs (Rancho 
Dominguez, California): Spectra/Por® 1 (6-8 kD MWCO membrane; part 132660), 
Spectra/Por 6® (50 kD MWCO membrane; part 132544) and Float-A-Lyzer G2 Dialysis 
Device CE (100 kDa MWCO; part G235035). Bio-Scale™ Mini Macro-Prep High Q® 
cartridge (cat. 7324122), Bio-Scale™ Mini CHT™ Type I cartridge (cat. 7324322), Bio-
Scale™ Mini Macro-Prep DEAE® Cartridge (cat. 7324142), Macro-Prep® t-Butyl HIC 
Support (1580090), Macro-Prep High Q® Support (cat. 1580040), and Econo® glass 
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columns were purchased from Bio-Rad, Inc. (Hercules, CA). HisPur™ Ni-NTA Resin 
(cat. 88222), 0.45 µm nitrocellulose membrane (cat. 77010), Western Blotting Filter 
Paper (cat. 88600), Pierce Fast Western ECL kit (cat. 35050), Pierce Fast Western Blot 
Kit, ECL substrate (cat. 35050) and anti-His-tag antibody (cat. PA1-983B) were 
purchased from ThermoFisher (Waltham, MA). Urea, sodium phosphate monobasic 
(NaH2PO4), Sephadex G-50 Fine (cat. 65080-106), Sephacryl 400-HR (cat. S400HR), 
Whatman Puradisc 25 syringe filters – 1.0 µm PES membrane (cat. WHA67812510), and 
Corning Spin-X UF 20 concentrators – 100 kDa MWCO (cat. CLS431491-12EA) were 
purchased from Sigma Aldrich (St. Louis, MO). 
Ni-NTA Affinity Chromatography 
Histidine tags (His-tags) are commonly used to purify recombinant proteins via 
IMAC (immobilized metal affinity chromatography). Recombinant BAF180 was cloned 
with a 6xHis-tag on the C-terminus (see Section 5.2). Ni-NTA affinity purification was 
tried several times, both batch and column under native and denaturing conditions. 
Initially, a 50 mM Tris buffer, pH 7.4 was tried; the cells were lysed in 50 mM Tris, so 
this removed a dialysis step. Both batch and column modes were tried and an imidazole 
gradient was used, from 50-250 mM. For batch mode, 10 mL of HisPur® resin slurry was 
added to a 50 mL tube and equilibrated with 50 mM Tris, pH 7.4. 15 mL of crude lysate 
(in the same buffer) was added to the tube and the mixture was incubated on an orbital 
shaker for 30 minutes. The resin was allowed to settle and the supernatant was collected. 
15 mL of wash buffer 1 (50 mM imidazole) and 15 mL wash 2 (100 mM imidazole) were 
added and collected using the same procedure. 15 mL of elution buffer (250 mM 
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imidazole) was added and incubated for 1.5 hours before being collected. Results 
demonstrated that BAF180 was not binding to the column and was leaving with the flow-
through.  
The next several attempts used buffers recommended by the manufacturer of the 
Ni-NTA resin.93 The samples were denatured to ensure that the conformation of the 
protein was not hindering the binding of the His-tag; many experiments have shown that 
the addition of denaturation agents does not affect the ability of a His-tag to bind with the 
Ni-NTA resin.94 In a column (6 cm bed height, 0.7 cm diameter),  approximately 2 mL of 
resin was equilibrated with 4 mL equilibration buffer (PBS, 6 M GuHCl, 10 mM 
imidazole, pH 7.4). Imidazole was included in the equilibration buffer to reduce non-
specific binding.94-99 Approximately 2 mL of crude lysate was mixed with 2 mL of 
equilibration buffer. The column was washed with 4 mL of wash buffer (PBS, 6 M 
GuHCl, 25 mM imidazole, pH 7.4) and eluted with 4 mL of elution buffer 1 (PBS, 6 M 
GuHCl, 250 mM imidazole, pH 7.4). No BAF180 band was observed in any fraction, so a 
second elution buffer with a higher imidazole concentration was used in the next trial 
(elution buffer 2: PBS, 6 M GuHCl, 500 mM imidazole, pH 7.4). Again, no BAF180 
band was observed in any fraction. It was concluded that perhaps BAF180 was degrading 
prior to purification, during purification, or that the BAF180 band was too faint to 
observe.  
After high-producing cells were discovered, Ni-NTA purification was tried again. 
New columns were prepared with 3 mL resin slurry (~1.5 mL resin) and equilibrated with 
6 mL equilibration buffer (PBS, 6 M GuHCl, 10 mM imidazole, pH 7.4). For this 
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attempt, five different columns were prepared, each loaded with a different crude sample. 
For each, 500 µL sample was mixed with 1 mL equilibration buffer and loaded onto the 
column. Bound proteins were eluted in 3 mL of elution buffer 1 (PBS, 6 M GuHCl, 250 
mM imidazole, pH 7.4). BAF180 was found in the flow-through fraction (Figure 6.6). No 
wash step was performed; this was a simple test to determine if BAF180 was binding to 
the Ni-NTA column at all. 
 
Figure 6.6: Denaturing Ni-NTA purification. BAF180 was found in the flow-through fraction (A), 
indicating that it did not bind to the column. No proteins were seen in the elution fractions (B). Both 
soluble and insoluble lysate fractions were used. FT stands for flow-through. The BAF180 band is denoted 
by the red stars. 
 
Final attempts used a third and fourth buffer system. The third buffer system was 
20 mM NaH2PO4, 300 mM NaCl, 6 M GuHCl, pH 7.4. 2 mL of resin slurry was added to 
a large column (2 x 23 cm) and equilibrated with equilibration buffer (20 mM NaH2PO4, 
300 mM NaCl, 6 M GuHCl, pH 7.4). Imidazole was excluded from this wash buffer to be 
sure that the low 10 mM imidazole concentration used in previous equilibration buffers 
was not preventing BAF180 from binding. Multiple soluble lysate fractions (of high-
producing cells) were combined (~32.5 mL) and mixed with 20 mL equilibration buffer 
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before being loaded onto the column. The flow-through was collected and a 5 mL aliquot 
was saved; the rest of the flow-through was added back into the column, so the sample 
would pass over the Ni-NTA resin bed twice. The column was washed twice with 
equilibration buffer. Samples were eluted with ~38 mL elution buffer (20 mM NaH2PO4, 
300 mM NaCl, 6 M GuHCl, 300 mM imidazole, pH 7.4) and 2 mL of 1 M imidazole. 1 
M imidazole was added to the column in an effort to elute anything that might be bound. 
All the samples were concentrated before being run on an SDS-PAGE gel. After 
concentration, samples were re-suspended and dialyzed in 50 mM Tris, pH 7.4 and run 
on an SDS-PAGE gel (Figure 6.7). 
              
Figure 6.7: Denaturing Ni-NTA purification. Soluble fractions were combined and added to a Ni-NTA 
column. The flow-through was collected and re-run over the resin bed, so that the sample would pass over 
the Ni-NTA resin twice. The column was washed twice with equilibration buffer and elution buffer was 
added (300 mM imidazole). A final elution with 2 mL of 1 M imidazole was loaded onto the column to 
elute everything that might be bound. 
 
The fourth buffer system was the same as the third buffer system, except the 6 M 
GuHCl was replaced with 8 M urea. A 1 mL Ni-NTA resin bed was equilibrated with 
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equilibration buffer (20 mM NaH2PO4, 300 mM NaCl, 8 M urea, pH 7.4). Insoluble 
lysate fractions (in 8 M urea) were pooled and combined with equilibration buffer and 
loaded onto the prepared column. The column was washed with 40 mL of equilibration 
buffer before 4 – 1 mL portions of 1 M imidazole was used to elute any bound proteins. 
BAF180 was found in all fractions (flow-through, wash, and 1 M imidazole elutions), 
which seemed to indicate that some of the His-tagged BAF180 was binding to the Ni-
NTA resin (Figure 6.8). Additional experiments were conducted, adding in a wash step 
with 30 mM imidazole and another elution series with 3 M imidazole. The results were 
unable to be replicated (Figure 6.9).  
                 
Figure 6.8: Denaturing Ni-NTA purification with 8 M urea. Insoluble lysate fractions were pooled and 
equilibrated with equilibration buffer. The column was washed with equilibration buffer before being 
treated to 1 M imidazole. BAF180 was found in most fractions, suggesting that some BAF180 was binding 
to the Ni-NTA resin. 
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Figure 6.9: Further Ni-NTA attempts with 8 M urea. For this particular experiment and a few others, 
aggregates formed during purification. Nevertheless, BAF180 appears to be in the flow-through fraction. 
As can be seen, very few proteins are found in the wash or elution steps. The experiment indicated that 
BAF180 was not binding to the Ni-NTA resin. 
 
Determination of the Presence of a His-tag 
After native and denatured protocols for Ni-NTA purification indicated that 
BAF180 was not binding to the Ni-NTA resin, it was thought that this might be because 
the protein is so big (190 kDa) and the His-tag is so small (1 kDa), that the protein might 
have trouble staying attached to the resin. Later, it was considered that perhaps the His-
tag was not actually present on the recombinant BAF180 protein. A dot blot was done to 
determine if the recombinant BAF180 protein was expressed with a His-tag. The negative 
control was WT X33 crude lysate (for which it had already been demonstrated that 
BAF180 was not present). The positive control was hPB1-1 (BAF180 protein, 
bromodomain 1 only) constructed by previous members of the Thompson lab and 
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successfully used in Ni-NTA affinity purification.20 The protein was expressed in E. coli 
Rosetta(DE3) cells in the pET30b construct.20 After growth and expression of the protein, 
the cells were lysed using a denaturing protocol, as only the His-tag was needed and this 
would ensure that the His-tag was exposed. The denaturing protocol was as follows: 
Harvested cells were re-suspended in E. coli denaturing lysis buffer (100 mM NaH2PO4, 
10 mM Tris-Cl, 300 mM NaCl, 8 M urea, pH 8.0) at 5 mL buffer per gram cell. The cell 
suspension was incubated on ice for 1 hour on an orbital shaker. Lysate was collected by 
centrifuging the cell suspension at 10,000 g for 25 minutes at 4 °C.20 The sample was 
dialyzed overnight in E. coli lysate dialysis buffer (50 mM Tris-Cl, 100 mM NaCl, pH 
7.6). This was done primarily to remove urea; urea removal was deemed necessary in 
order to run the crude lysate sample on an SDS-PAGE gel and also to ensure that the urea 
could not cause any problems during the blot protocol.  
In addition, to ensure that the His-tag was not buried within the protein structure, 
both samples of BAF180 (crude and anion exchange fraction, see Section 6.2) were 
denatured under harsh conditions. Approximately 100 µL of crude BAF180 was added to 
500 µL of E. coli denaturing lysis buffer and incubated for 30 minutes at room 
temperature. The sample was then incubated for 10 minutes at 95 °C (chosen because this 
temperature is used for SDS-PAGE sample preparation) and dialyzed overnight in anion 
exchange dialysis buffer (17 mM Tri, pH 7.6). This protocol was repeated for 100 µL of 
purified BAF180 sample from anion exchange.  
A dot blot was performed using an anti-His-tag antibody. Pierce Fast Western 
Blot Kit, ECL substrate was used. A grid was drawn in pencil and 2 µL of each sample 
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was spotted onto a nitrocellulose membrane (0.45 µm) and allowed to dry. The 
nitrocellulose membrane was then hydrated in 1x Fast Western Wash Buffer for 5 
minutes with gentle shaking. The primary antibody solution (10 mL Fast Western 
Antibody Diluent, 2 µL anti-His-tag antibody) was incubated with the membrane for 1 
hour. The membrane was washed for 5 minutes in wash buffer. The secondary antibody 
solution (10 mL Fast Western Antibody Diluent, 1 mL Fast Western Optimized HRP 
reagent) was added and incubated with the membrane for 10 minutes. The membrane was 
washed 4 times in wash buffer for 5 minutes each, followed by brief incubation in 
detection solution (5 mL Pierce ECL Detection Reagent 1, 5 mL Pierce ECL Detection 
Reagent 2). The membrane was visualized using a CDD camera. The results (shown in 
Figure 6.10) confirm that the positive control (hPB1-1) contains a His-tag and that the 
negative control (X33 WT crude) did not contain a His-tag. Most interestingly, none of 
the BAF180 samples showed a positive result, indicating, that in both native and 
denatured states, the recombinately expressed BAF180 did not contain a His-tag.  
During the original construction of the expression plasmid, the purchased 
BAF180 DNA was modified using PCR mutagenesis to remove the stop codon present in 
the original sequence. The reverse PCR primer was designed to remove the stop codon, 
add an enterokinase site, and add a KpnI site. It is most likely that the stop codon was not 
removed during PCR modification, therefore causing termination of protein translation 
before the His-tag sequence (Figure 6.11). However, the KpnI site was definitely added, 
because this restriction enzyme was successfully used to ligate BAF180 into pGAPZA. 
The difference in base pair length between deleting the stop codon and inserting the 
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enterokinase is very small from that with just the stop codon. This slight difference would 
not have been observed on a gel.  
 
Figure 6.10: The results of the His-tag detection dot blot. A grid was drawn on nitrocellulose membrane 
and the samples were spotted in different boxes. The box assignments are as follows: (1) hPB1-1, positive 
control; (2) X33 WT, negative control; (3) BAF180 crude (native); (4) Anion exchange purified BAF180 
(native); (5) Denatured BAF180 crude; (6) Denatured anion exchange purified BAF180. Only box 1 shows 
a positive result, indicating that hPB1-1 is the only sample that contained a His-tag. 
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Figure 6.11: Possible explanation for why there was no His-tag detected with an anti-His-tag antibody. All 
numbering is relative to the HMG box, with the first amino acid or base pair of the HMG box numbered as 
1. There is no 0 position (-2, -1, 1, 2, etc). The positions of the antibody immunogen and the most likely 
epitope are noted. It was thought that the original stop codon was not eliminated and therefore protein 
translation was terminated at this point, preventing a His-tag from being included on the expressed protein. 
(A) Amino acid positioning; (B) Base pair positioning. 
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Strong Anion Exchange Resin: Bis-Tris and Bis-Tris Propane 
Buffers 
Other buffers were tried during AEX when it was still believed that the co-eluting 
proteins in the purified fraction were contaminants. Decreasing the difference between 
BAF180’s pI and the buffer’s pH would result in a smaller negative charge on the 
protein, therefore it might elute at a lower NaCl concentration, possibly separate from all 
other cellular proteins. The buffer pH was still kept relatively close to pH 7.4, because 
BAF180 was shown to be stable at this pH; it was reasoned that a buffer pH further away 
from 7.4 would result in decreasing stability of BAF180. 
Decreasing the difference between BAF180’s pI and the buffer’s pH required the 
use of different buffer systems with lower pKa values. The pKa values of Tris buffers 
limited the pH values that could be used; 10 mM Tris has a pKa of 8.10 at 25 °C, and the 
pKa increases as the concentration increases. Therefore, the lower limit for the pH of a 
Tris buffer was 7.6, which was used. The structures of the different buffer salts was also 
considered; it was reasoned that molecules with a structure closer to that of Tris would be 
better, since it was already known that the recombinant BAF180 was stable in Tris. 
Organic molecules were avoided because of the unknown effect on protein stability and 
the likelihood of denaturation. 
 After analysis of different buffer systems at different concentrations and 
temperatures, it was decided to use Bis-Tris next. Bis-Tris has an effective buffering 
range of 5.8-7.2.85 A buffer system of 50 mM Bis-Tris, pH 7.3 was tried first; this buffer 
needed to be used at 4 °C in order for the pH and pKa values to be in agreement (i.e. keep 
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the pKa within 0.5 pH units of buffer pH). A step-wise elution from 0 – 1.0 M NaCl was 
used. Results show that most of the cellular proteins and BAF180 were eluting at 0.5 M 
NaCl (Figure 6.12). Therefore, this buffer system is essentially useless, because it did not 
separate BAF180 from any other proteins. 
               
Figure 6.12: Anion exchange with 50 mM Bis-Tris, pH 7.3. As can be seen in the gel, most of the cellular 
proteins and BAF180 eluted at 0.5 M NaCl. This buffer system did not separate BAF180 from the other 
proteins. The purification experiment was conducted at 4 °C. 
 
When the SDS-PAGE results showed that pH 7.3 did not separate BAF180 from 
other cellular proteins, the pH was changed to 7.0. With a 50 mM Bis-Tris buffer at pH 
7.0, anion exchange was conducted again at room temperature (~20 °C). BAF180 did 
elute in a different fraction than many other cellular proteins, though quite a few cellular 
proteins eluted in the same fraction as BAF180 (Figure 6.13). BAF180 eluted primarily at 
0.4 M and 1.0 M NaCl, though a small amount was seen in 0.3 M NaCl and the flow-
through. The BAF180 elution fraction was not as pure as that achieved with 17 mM Tris 
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buffer, pH 7.6. Additionally, BAF180 appears to be eluting at a higher concentration of 
NaCl. Increasing the NaCl concentration increases the risk of protein denaturation. 
pH values below 7.0 were not attempted, for concern that the pH would start to 
denature the BAF180 protein. pH 7.0 is 0.4 pH units away from known stability at pH 7.4 
(lysis buffer 2). In fact, proteins can be seen aggregating in the wells at pH 7.0 (Figure 
6.13). 
 
Figure 6.13: Anion exchange with 50 mM Bis-Tris, pH 7.0. BAF180 did separate from many of the cellular 
proteins, though quite a few eluted with BAF180. BAF180 eluted at 0.4 M NaCl and 1.0 M NaCl, with a 
small amount in the 0.3 M NaCl fraction. The BAF180 elution is not as clean as the elution achieved with 
17 mM Tris buffer, pH 7.6 and requires a higher concentration of NaCl to elute. BAF180 is denoted by the 
red star. 
 
A Bis-Tris propane (BTP) buffer system was tried next. The pKa of 50 mM BTP 
is 7.12 at 20 °C. The effective buffering range for BTP is 6.4-7.3;100 pH 7.4 was chosen. 
BAF180 eluted at 0.3 M NaCl, along with several other cellular proteins. Comparing 
these results (Figure 6.14) to those from AEX with 17 mM Tris, pH 7.6 (Figure 6.3), 
BAF180 eluted at a lower NaCl concentration (0.3 M vs. 0.4 M, respectively). However, 
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it eluted with many more contaminant proteins in BTP buffer than in Tris buffer. Since 
BAF180 appears to be stable at pH 7.6 (Tris buffer) and elutes with fewer contaminants, 
anion exchange was conducted with Tris buffer for all future experiments. The tradeoff 
(eluting at a lower NaCl concentration but with more contaminants) was not considered 
to be advantageous. It was interesting that the two proteins that co-eluted with BAF180 
using the Tris buffer also co-eluted here. It was puzzling at the time why those proteins 
always eluted together. It is now understood, however, that the other bands are fragments 
of BAF180. 
 
Figure 6.14: Anion exchange with 50 mM Bis-Tris propane buffer, pH 7.4. Though faint, BAF180 can be 
seen eluting at 0.3 M NaCl, along with several other cellular proteins. Even though BAF180 eluted at a 
lower concentration of NaCl (0.3 M vs. 0.4 M in 17 mM Tris, pH 7.6), so did other cellular proteins. 
BAF180 is denoted by the red star. 
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Weak Anion Exchange: DEAE Resin and Tris Buffer 
In addition to strong anion exchange media, the weak anion exchanger DEAE was 
tried. Bio-Rad’s MacroPrep® DEAE is a weak anion exchanger that is a methacrylate 
polymer with a DEAE (diethylaminoethyl) cellulose group attached.82,101 Weak and 
strong ion exchangers have different selectivities,84-85 so it seemed worthwhile to try a 
weak anion exchanger as well. 
The same buffer as for strong AEX was used (17 mM Tris, pH 7.6). Crude lysate 
was run through the DEAE cartridge and eluted using various concentrations of NaCl 
(Figure 6.15). BAF180 eluted at 0.5 M NaCl, along with many contaminants, though a 
faint amount can be seen in the 0.3 M fraction.  
 
Figure 6.15: DEAE anion exchange. Using 17 mM Tris buffers at pH 7.6, crude lysate was run through the 
media and eluted at varying concentrations of NaCl. The BAF180 band (denoted by the red star) was seen 
in the 0.5 M NaCl fraction, along with several contaminant proteins. 
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Anion Exchange: Prepacked Cartridges vs. Self-Packed Columns 
Initially, prepacked cartridges were used. Manipulation of NaCl concentrations 
were unable to separate the “contaminant proteins” from BAF180. After possible 
variations in buffers were explored, a longer column was tried. In chromatography, 
resolution often increases with column length, so there was a possibility that increasing 
the column length of Bio-Rad High Q® resin would separate out the two contaminant 
proteins (approximately 70 and 80 kDa, see Figure 6.3). Approximately 10 mL resin 
slurry was packed into a 0.7 x 20 cm Econo® glass column. Unfortunately, elongating 
the column did not separate the three bands (results not shown). The new finding that the 
“contaminants” are fragments of BAF180 explain these results. 
Hydroxyapatite (Mixed-Mode) Chromatography 
Hydroxyapatite chromatography is not often utilized for protein purification, even 
though it was first published in the 1950s.84,102 Hydroxyapatite (Ca10(PO4)6(OH)2) is a 
mixed-mode (also called multimodal) media (or resin), meaning that its interactions with 
the proteins appear to be a combination of electrostatic and metal affinity 
interactions.84,102-109 
Bio-Rad’s Bio-Scale™ Mini CHT™ ceramic hydroxyapatite type I pre-packed 
cartridges were chosen for analysis. CHT is a ceramic hydroxyapatite that is much more 
stable than the traditional forms102-109 and CHT can reportedly separate mixtures that 
other methods cannot.103-107 Type I is recommended for acidic proteins (the pI of BAF180 
is 6.29).103-107 
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CHT™ Type I Bio-Scale™ mini cartridge was prepared as directed in manual.110 
NaH2PO4 buffers at pH 7.2 were used with increasing concentration to elute the proteins. 
The loading buffer had 10 mM NaH2PO4, which was increased step-wise to 400 mM (10 
mM, 50 mM, 100 mM, 200 mM, 300 mM, 400 mM). Acceptable purity results were not 
obtained with this method. Results demonstrate that BAF180 is eluting in 200 mM 
NaH2PO4 along with many other cellular proteins (Figure 6.16). 
 
Figure 6.16: CHT Type I chromatography. BAF180 elutes at 200 mM NaH2PO4 along with many other 
cellular proteins. All concentrations are referring to NaH2PO4 concentration. 
 
Hydrophobic Interaction Chromatography 
Hydrophobic interaction chromatography (HIC) takes advantage of the structure 
of a protein molecule and its interactions with water. Decreasing salt gradients are used to 
elute a bound protein off a column.111-115 
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Bio-Rad’s Macro-Prep® t-butyl resin was chosen because it has strong 
interactions with proteins that are weakly hydrophobic.116-118 Because BAF180 is soluble 
in aqueous solutions, it was reasoned that the degree of hydrophobicity of the protein 
cannot be too high, otherwise it would not be soluble in water. Macro-Prep® t-butyl resin 
consists of a methacrylate bead with t-butyl and carboxyl groups attached.116-118 
Following manufacturer’s instructions, the t-butyl resin was packed into a 1.5 mm x 10 
cm Econo® glass column, with the bed height approximately three quarters of the 
column height. The elution fraction from anion exchange chromatography (17 mm Tris, 
0.4 M NaCl, pH 7.6) was equilibrated to 1 M NaCl by addition of a 2 M buffer (17 mM 
Tris, 2 M NaCl, pH 7.6) and loaded onto the prepared HIC column. Flow-through was 
collected and subsequent washes were carried out with a decreasing salt gradient (1 M to 
0 M NaCl). The samples were then concentrated and run on an SDS-PAGE gel. Results 
were inconclusive (not shown).  
Size Exclusion Chromatography 
Size exclusion chromatography (SEC), also called gel filtration chromatography, 
is a fairly simple method. Using porous resin, proteins are separated by molecular weight. 
Large proteins cannot enter the pores and are thus eluted first. Smaller proteins are able to 
travel through the pores (the degree to which they can enter the pores depends on their 
size), and are thus slower to elute.119-123 
Sephadex G-50 
Sephadex G-50 has an approximate fractionation range of 1-30 kDa, meaning it 
can separate proteins with molecular weights of 1-30 kDa;120-122 it was chosen because it 
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was readily available. The Sephadex G-50 column was prepared by swelling the resin 
particles in 50 mM Tris-Cl, pH 7.4 on a hotplate for approximately 1 hour. The slurry 
was then poured into a 2 x 23 cm glass column; the resultant bed height was 
approximately 10 cm. Crude lysate was added and 8 – 2 mL fractions were collected 
(Figure 6.17). Separation did not occur. 
          
Figure 6.17: Size-exclusion chromatography of crude BAF180 lysate. 8 – 2 mL fractions were collected 
and concentrated. No separation was seen, though dilution was occurring. Note that the lysate used was 
from low-producing cells and so the BAF180 band (~190 kDa) was very faint. BAF180 eluted in fractions 
5-8. The band for BAF180 is found in the red box. 
 
SEC was also tried with partially purified samples. Anion exchange (AEX) was 
able to remove all but 2 contaminant proteins (now known to be degradation products) 
from BAF180. This eluent fraction (0.4 M NaCl) was concentrated and run through the 
column. 11 – 2 mL fractions were collected and concentrated. Though the bands are faint, 
BAF180 still eluted with contaminant proteins (Figure 6.18). 
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Figure 6.18: Size-exclusion chromatography of partially purified BAF180. AEX fraction B4 (0.4 M NaCl) 
was concentrated and then run through a Sephadex G-50 column. BAF180 still eluted with the other 
contaminants (fraction 4), though partial separation did occur. BAF180 is denoted by the red star. 
 
Longer SEC Column Packed with Sephadex G-50 
A longer SEC column (0.7 cm x 20 cm) was packed to a bed height 
approximately 17 cm (Sephadex G-50) and the 0.4 M AEX fraction was run through. In 
chromatography, resolution is dependent on column length.121 30 – 2 mL fractions were 
collected. Though the gels were not great, faint bands at ~70 and ~80 kDa (the size of the 
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contaminants) can be seen eluting in the same fractions (Figure 6.19). This led to the 
supposition that this longer column would not be able to separate BAF180 either. 
 
Figure 6.19: Size-exclusion chromatography of partially purified BAF180 on a longer column. Though the 
bands are very faint, the two contaminant proteins can be seen eluting together in fractions 2-4.  
 
SEC with Sephacryl 400-HR 
Another SEC media was tried. Sephacryl 400-HR has a fractionation range of 20-
8,000 kDa. Pre-swelled resin was packed into a 15 x 750 mm column, with a bed height 
approximately 500 mm. Concentrated AEX 0.4 M NaCl fraction was loaded onto the 
column. The first 23 mL were collected, followed by 34 fractions of 1 mL each. The 
results were inconclusive, as no bands were seen (results not shown). 
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Ultrafiltration and Dialysis 
Attempts were also made to purify by size directly from a crude sample. Both 
ultrafiltration and dialysis utilize membranes with distinct molecular weight cut offs 
(MWCO), allowing proteins of smaller molecular weight to flow out of the membrane, 
while proteins of higher molecular weight are retained.  
Ultrafiltration devices are able to dialyze and concentrate samples during 
centrifugation. Proteins smaller than the MWCO are able to flow-through the membrane, 
as does buffer. For subsequent spins (centrifugation), additional buffer is added. Two 
types of ultrafiltration devices were tried, both with a 100 kDa MWCO, but with a 
different membrane composition. Merck Millipore’s Amicon® Ultra used a regenerated 
cellulose membrane124 and Corning’s® Spin-X® used a PES (polyethylsulfone) 
membrane.125 
The Amicon® Ultra ultrafiltration devices were tried on early samples; this was 
during growth and lysis optimization, so the protein content is not the same as after 
optimization. However, after four centrifugation cycles, the sample appears to be 
concentrating and the purity is slightly improved (Figure 6.20). Unfortunately, these 
results could not be replicated.  
A PES membrane has lower protein binding than other membranes.126-127 The 
Corning® Spin-X® ultrafiltration devices have a PES membrane. Unfortunately, they did 
not serve as an efficient means of purifying BAF180 from endogenous cellular proteins 
(Figure 6.21). No significant difference in protein content was observed. MWCO can be 
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relative, so the retention of proteins around 100 kDa is not unexpected; however, proteins 
50 kDa and below should have been removed. The reason that proteins below 50 kDa 
were not removed is not understood. 
        
Figure 6.20: Ultrafiltration with Amicon® Ultra device. These early samples had not yet been optimized, so 
the protein content is different than it is currently. However, after four centrifugation cycles, the sample is 
slightly more concentrated and slightly purer. 
         
Figure 6.21: Ultrafiltration with Corning Spin-X device. The difference in the crude and Spin-X samples is 
negligible. 
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Additionally, dialysis membranes with 100 kDa (Figure 6.22A) and 50 kDa 
(Figure 6.22B) MWCO were tried. Oddly, the protein composition of the BAF180 
sample prior to dialysis was nearly the same as after dialysis; it just appeared slightly less 
concentrated, though this could have been due to variations in SDS-PAGE loading. It is 
unclear why larger pore dialysis membranes were unable to remove the smaller proteins.  
        
Figure 6.22: Dialysis with high MWCO membranes. (A) Overnight dialysis with 100 kDa MWCO 
membrane did not appear to improve the purity of crude BAF180 sample. It appears that the dialyzed 
sample is slightly less concentrated. (B) Sample purity was not improved with use of a 50 kDa membrane. 
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Chapter 7 : Conclusion and Future Work 
For the first time, BAF180 has been successfully expressed in a heterologous 
host. Though attempts to express BAF180 in E. coli were unsuccessful, expression in the 
yeast Pichia pastoris was successful. Using the GAP promoter, BAF180 was cloned and 
expressed in wild-type X33 cells. Growth and lysis conditions were optimized and high-
producing strains were discovered. BAF180 was successfully purified from crude lysate 
using anion exchange chromatography. It was initially believed that, during anion 
exchange chromatography, two contaminant proteins were eluting with BAF180 (as seen 
in SDS-PAGE gel), so more purification methods were tried. However, western blot 
results indicate that the other bands are actually fragments of BAF180. Using an antibody 
that recognized an epitope on the C-terminus, multiple protein bands were recognized, 
indicating that the so-called “contaminant” proteins are actually fragments of BAF180. 
These results suggest that significant amounts of BAF180 are being degraded by 
proteases during cell lysis. A higher concentration of protease inhibitor cocktail will be 
tried in an effort to increase the yield of full-length BAF180. 
In the future, the recombinant BAF180 should be studied using thermodynamic 
and kinetic methods such as isothermal titration calorimetry and fluorescence anisotropy. 
All possible binding partners should be explored via use of a peptide array featuring post-
translationally modified histone peptides. The results will indicate whether neighboring 
PTMs impact the binding of BAF180 to acetylation sites. Neighboring PTMs have been 
known to impact the binding of many proteins, sometimes increasing the affinity and 
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sometimes decreasing. Kinetic studies (such as ITC) could be performed using the 
peptides that had the strongest interactions. 
It would also be interesting to determine the structural content of full-length 
BAF180 by circular dichroism (% α-helices, % β-sheet, and % random coil); 8 of the 
individual domains (not HMG-box) have been cloned and crystallized, but it would be 
interesting to see if any of the structural characteristics change due to neighboring amino 
acids. Other proposed experiments include determining the role of the HMG-box in 
BAF180, confirming proteolytic degradation, determination of gene copy number, and 
increasing the yield of full-length BAF180 by using a protease-deficient strain, testing 
other promoters, or extracellular expression. These experiments are briefly discussed in 
appendix A. 
Expression of the individual domains of BAF180 and in vivo experiments have 
provided some insight into the roles of BAF180. However, a significant gap in our 
knowledge remains between singular domain interactions and cellular impacts of 
BAF180: the molecular-level interactions of the complete BAF180 protein are unknown. 
The success of finally expressing and purifying full-length BAF180 in a heterologous 
host will provide us with the opportunity to study the fine nuances of the protein in vitro. 
The intricate interactions with individual cellular components can now be quantified and 
fully explored. With this information, small-molecule drugs that target the BAF180 
protein can be developed. 
  
213 
 
 
214 
 
Appendix A: Other Proposed Experiments 
Exploring the Role of the HMG-box Domain 
Referring back to the introductory chapter, the role of BAF180 in heart 
development was mentioned. While phenomenological consequences of BAF180 knock-
out are known, the exact interactions that cause these events are unknown. The HMG-box 
domain of BAF180 may be involved in proper embryonic development. BAF180 is 
known to be critical for proper heart development in embryos (see Section 1.4.2.2) and 
proper expression of various other HMG-box-containing proteins have been 
demonstrated to be required for normal embryonic development.1 It would be interesting 
to determine if the role of BAF180 in heart development is reliant on its HMG-box. 
BAF180 knockout mice, generated as per Wang et al., could be used to create mice with 
different constructs (instead of wild-type BAF180) in the embryo and wild-type BAF180 
in the placenta.2  The different constructs would contain different types of domains3 (i.e. 
bromodomains, BAH domains, HMG-box domain) and a partial-sequence of BAF180 
(all bromodomains, both BAH domains, but no HMG-box). Each embryo would be 
studied to determine if each of them are able to survive past embryonic day E12.5-E15.5, 
when BAF180 KO mice died.2 Gene expression of each of the embryos could also be 
analyzed to see if the same genes that were up-regulated upon BAF180 KO are also up-
regulated in the mutants.2 The role of BAF180 in maintaining genomic stability and 
proper DNA damage repair may also stem from its HMG-box. This theory could be 
tested by generating constructs, like those described above, and transfecting them into 
BAF180 KO cancer cells. The results of the construct containing just the bromodomains 
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and the BAH domains (i.e. lacking the HMG-box) could be used to infer if cancer-
associated mutations of BAF180, which often lack the HMG-box, result in genomic 
instability and aneuploidy. 
Proteolytic Degradation 
Western blot experiments were successfully carried out using the Tris-acetate gel 
system. When probed with an anti-PBRM1 antibody that recognized an epitope on the C-
terminus of BAF180, multiple bands were seen. The most intense band appears at 
approximately 190 kDa, the expected molecular weight of BAF180. The other bands 
were a lower molecular weight than this. It is believed that degradation of the protein is 
causing these small bands. Further western blot experiments should be performed with an 
antibody recognizing an epitope on the N-terminus and an antibody recognizing an 
epitope near the middle of BAF180 to confirm this hypothesis. Four antibodies are 
available from ThermoFisher which recognize epitopes in these regions (Table A.1). The 
antibody currently used recognizes an epitope somewhere between amino acids 1329-
1689 (full-length BAF180 is 1689 amino acids long). Experiments using these other 
antibodies will provide additional evidence that BAF180 is being degraded. 
Table A.1: PBRM1 antibodies available from ThermoFisher. 
 
 
 
Antibody Catalog Number Epitope Region
PA5-41591 AA31-80
PA5-27268 AA105-374
730027 AA501-637
730076 AA773-917
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Determination of Copy Number via qPCR 
As mentioned in chapter 4, a recombinant gene is integrated into the Pichia 
genome via homologous recombination. Because of this, multiple copies of the gene can 
sometimes be inserted (~1% chance). qPCR should be performed to determine the exact 
copy number of BAF180 in the high-producing cells. It would also be interesting to test 
the low-producing cells as well, since multiple gene copies can sometimes result in 
decreased expression levels.4-6 
Increasing Yield by Expression in Protease-Deficient Strains 
The possible expression of BAF180 in a protease-deficient Pichia pastoris strain 
could also be explored. The protease-deficient strains are not recommended for initial 
expression attempts as they have some potentially serious problems, such as poor growth 
and low transformation efficiency.5-8 However, because so much of the recombinant 
BAF180 is being degraded, these strains might be worth a try. It should be noted that 
these strains improve the yield only 10% of the time for secreted proteins. No reports 
using these to increase intracellular expression levels are available (see Section 4.2). 
Increasing Yield by Extracellular Expression 
A secretion signal could be added to the N-terminus of BAF180 which would 
allow for the secretion of the protein into the growth media. Generally it is recommended 
that expression of a protein in a heterologous host be done in the same manner as in its 
native host (i.e. if a protein is produced intracellularly in its native host, it should be 
intracellularly expressed in the heterologous host.  
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Increasing Yield with the AOX1 Promoter 
Expression of BAF180 with the inducible AOX1 promoter could also be tried. The 
GAP (used here) and AOX1 promoters are generally thought of as most efficient. Some 
proteins are expressed at higher quantities when using the GAP promoter than with the 
AOX1 promoter, and visa-versa.5-6,9-16 
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Appendix B: Protocols 
Preparation of samples for SDS-PAGE on Tris-glycine gels 
Protein samples were separated via SDS-PAGE and samples were prepared as follows:  
1. Combine in a tube:  20 μL protein sample 
5.4 μL 4x SDS-PAGE Loading Buffer 
1.4 μL betamercaptoethanol 
2. Incubate at 95 °C for 10 minutes 
3. Centrifuge 13k g for 1 minute 
4. Incubate on ice for 5 minutes 
Preparation of Samples for SDS-PAGE on Tris-acetate gels 
Protein samples for SDS-PAGE with Tris-acetate gels were prepared differently than for 
Tris-glycine gels. The sample preparation was based on guidelines in the NuPAGE 
manual.1  
1. Combine in a tube: 10 µg protein sample 
6.25 μL NuPAGE LDS Sample Buffer 
2.5 μL NuPAGE Reducing Agent 
H2O to 25 μL 
2. Incubate samples for 10 minutes at 70 °C 
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Creation of E. coli Freezer Stock 
1. Plate cells on LB with the correct antibiotic and grow overnight at 37 °C. 
2. Inoculate a 15 mL LB culture (with correct antibiotic) with one colony. Grow 
overnight at 37 °C and 250 rpm. 
3. Transfer the cultures to 30 mL oakridge tubes and centrifuge at 3000 rpm for 10 
minutes at 4 °C. 
4. Decant out most of the media, leaving only a little left in the tube (~1-2 mL). Re-
suspend cells gently. 
5. Add 1 mL of re-suspended cells to cryogenic freezer tubes. Add 1 mL cold 50% 
glycerol in water. Invert 2-3 times to mix. Store at -80 °C. 
Preparation of CaCl2 Chemically Competent DH5α E. coli Cells 
This procedure is not original but the origin is unknown. 
1. Streak LB plates with DH5α cells. Don’t use an antibiotic as DH5α does not have any 
resistance. Grow overnight at 37 °C. 
2.  Inoculate 5 mL of LB with 1 DH5α colony. Grow overnight at 37 °C and 250 rpm. 
3. Transfer 5 mL culture to a fresh 100 mL culture. Incubate ~2 hours. 
4. Remove cells from incubator and place on ice for 10 minutes. Keep the cells cold 
during the rest of the procedure. 
5. Centrifuge for 3 minutes at 6000 rpm and 4 °C. Decant media.  
6. Gently re-suspend cells in 10 mL cold 0.1 M CaCl2. Incubate on ice for 20 minutes.  
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7. Centrifuge cells again. Decant supernatant and gently re-suspend cells in 5 mL cold 
0.1 M CalCl2/15% glycerol. Aliquot 100 µL into microcentrifuge tubes and store at -
80 °C. 
Transformation with Chemically Competent E. coli cells 
The procedure outlined in the pET30 manual was modified slightly for transformation 
of chemical competent E. coli cells.2 
1. Remove prepared chemical competent cells (aliquots of 20 µL) from the -80 °C 
freezer. Thaw tubes on ice 2-5 minutes. 
2. Add 2 µL ligation reaction directly to cells. Pipet to mix. Incubate the tubes 
(cells/DNA) on ice for 5 minutes. 
3. Heat the tubes at 42 °C for 30 seconds. Remove immediately and place on ice for 2 
minutes. 
4. Add 80 µL of LB and plate on LB plates with correct antibiotic 
Preparation of Electrocompetent E. coli Cells  
Electrocompetent E. coli cells were prepared following the protocol outlined in the 
“Micropulser Electroporation manual” from Bio-Rad, Inc.3 
1. Begin a DH5α/Rosetta(DE3) culture in 5 mL LB. Incubate overnight at 37 °C and 
250 rpm. 
2. Transfer all 5 mL of the DH5α culture into 500 mL fresh LB. Incubate at 37 °C and 
250 rpm until cells reach an OD600 = 0.5-0.7. 
3. Chill cells on ice for approximately 20 minutes. 
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4. Transfer cells to a cold 500 mL centrifuge bottle and centrifuge at 4000 g for 15 
minutes at 4 °C. 
5. Decant the media. Resuspend the cell pellet in 500 mL ice-cold 10 % glycerol. 
Centrifuge at 4000 g for 15 minutes at 4 °C. 
6. Decant the media. Resuspend the cell pellet in 250 mL ice-cold 10 % glycerol. 
Centrifuge at 4000 g for 15 minutes at 4 °C. 
7. Decant the media. Resuspend the cell pellet in 20 mL ice-cold 10 % glycerol. 
Centrifuge at 4000 g for 15 minutes at 4 °C. 
8. Decant the media. Resuspend the cell pellet in 500 mL ice-cold 10 % glycerol. 
Centrifuge at 4000 g for 15 minutes at 4 °C. 
9. Resuspend cell pellet with 10 % glycerol to a final volume of approximately 2 mL. 
The cell density should be 1-3 x 1010 cells/mL. 
10. Prepare 40 µL aliquots and store at -80 °C. 
Native Lysis of E. coli Cells 
The native lysis procedure was as follows: cells were re-suspended in native lysis 
buffer (100 mM NaH2PO4, 10 mM Tris, 300 mM NaCl, pH 8.0) at 5mL/gram cell and 
100 mg/mL lysozyme was added (final concentration: 3 mg/mL). The cell suspension 
was incubated on ice for 30-45 minutes before being sonicated at 25% amplitude for 80 
seconds (10 sec on/10 sec off). The lysed cells were centrifuged for 10 minutes at 10,000 
g and the supernatant recovered. The cell pellet/debris was re-suspended in 5 mL native 
lysis buffer. 
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Denaturing Lysis of E. coli Cells 
For the denaturing lysis protocol, the cells were re-suspended in denaturing lysis 
buffer (100 mM NaH2PO4, 10 mM Tris, 300 mM NaCl, 8 M urea, pH 8.0) at 5 mL/gram 
cell and incubated on ice for ~1 hour. The suspension was centrifuged at 10,000 g for 10 
minutes and the supernatant recovered. To the cell pellet/debris, 5 mL of denaturing lysis 
buffer was added and the cells re-suspended. 
Electroporation/Transformation of pGAPZA into E. coli DH5α 
Cells 
The parent vector pGAPZA and the plasmid construct pGAPZA-BAF180 were 
transformed into E. coli DH5α cells for propagation. The procedure was slightly modified 
from the protocol outlined in the “MicroPulser Electroporation manual” from Bio-Rad, 
Inc.3 Note that low-salt LB is used instead of regular LB. 
1. Thaw electrocompetent E. coli cells on ice. Wrap an electroporation cuvette in 
aluminum foil and place on ice. Place a microcentrifuge tube on ice as well. 
2. Add DNA to 40 µL of electrocompetent cells.  Mix and incubate on ice for 1 minute. 
• Note: For transformation of pGAPZA, 1 µL of 10 ng/µL was used 
• Note: For transformation of pGAPZA-BAF180, all 20 µL of the ligation 
reaction was used 
3. Transfer DNA-cell mixture to 0.2 µm electroporation cuvette. Place cuvette in 
micropulser slide. 
4. With micropulser set to “Ec2’, pulse the electroporation cuvette.  
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5. Immediately add 1 mL of low-salt LB to the cuvette. Pipet up and down with a PAGE 
gel loading tip. 
6. Transfer the cell suspension to a 15 mL tube and incubate for 1 hour at 37 °C and 225 
rpm. 
7. Pour the cell suspension onto pre-warmed low-salt LB plates with 25 µg/mL zeocin 
and incubate overnight at 37 °C. (Note: Zeocin is inactive at high salt concentrations, 
hence the use of low-salt LB). 
Linearization of pGAPZA-Pb1 Construct Using AvrII 
1. Combine 1 µL of AvrII (5 units) per 1 µg DNA (WHICH?). In total, digested 12 µg 
of pGAPZA-Pb1 construct. Performed 3 – 4 µg digested because the DNA recovery 
limit with the Zymo kit in 5 µg. 
  
2. Incubated at 37 °C for 16 hours, then purified the DNA digest using the Zymo DNA 
Clean and Concentrator kit. Recovered 7380 ng DNA. 
3. Used the vacuum centrifuge (Savant Refrigerator Condensation Trap and Savant 
Speed Vac Concentrator) to concentrate the recovered DNA. 
4. Decided to do another AvrII digest, this time incubated at 37 °C for 2 hours. The 
mixture was the same as for the 16 hour digest.  
5. Combined both purified digests to final volume of ~8 µL.  
DNA X µL (4000ng)
CutSmart 5 µL
AvrII 4 µL
H2O to 50 µL
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Preparation of Electrocompetent Pichia pastoris X33 Cells 
Electrocompetent X33 cells (Pichia pastoris) were prepared as per protocol found in 
the pGAPZA manual from Invitrogen.4 
1. Begin 5 mL culture of X33 in YPD; incubate at 30 °C and 225 rpm overnight 
2. Prepare 500 mL of fresh YPD in a 2 L flask. Inoculate this culture with 200 µL 
Alternatively: 
1. Begin 5 mL culture of X33 in YPD; incubate 8 hours and 30 °C and 225 rpm 
2. Prepare 500 mL of fresh YPD in a 2 L flask. Inoculate this culture with all 5 mL. 
Both methods: 
3. Centrifuge the cells for 5 minutes at 1500 g and 4 °C. Decant media and re-suspend 
cells in 500 mL ice-cold sterile distilled deionized water. 
4. Centrifuge the cells for 5 minutes at 1500 g and 4 °C. Decant media and re-suspend 
cells in 250 mL ice-cold sterile distilled deionized water. 
5. Centrifuge the cells for 5 minutes at 1500 g and 4 °C. Decant media and re-suspend 
cells in 20 mL ice-cold sterile 1 M sorbitol. 
6. Centrifuge the cells for 5 minutes at 1500 g and 4 °C. Decant media and re-suspend 
cells in 1 mL ice-cold sterile 1 M sorbitol. Approximate volume of sorbitol cell 
suspension should be 1.5 mL. 
7. Keep the cells on ice and use that day. Do not freeze (transformation efficiency 
greatly decreases with frozen prepped cells). 
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Electroporation/Transformation of Pichia pastoris Cells 
A micropulser apparatus from Bio-Rad, Inc. was for the transformation of pGAPZA 
and pGAPZA-BAF180 into Pichia pastoris cells. The following procedure, adapted from 
the “MicroPulser Electroporation manual” was used.5 
1. Combine 80 µL of electrocompetent X33 cells and 10 µg of linearized pGAPZA-Pb1 
construct in a 1.5 mL microfuge tube. Transfer the mixture to an ice-cold 0.2 cm 
electroporation cuvette using a gel loading tip. 
2. Incubate the cuvette on ice for 5 minutes 
3. Pulse the cells with the Bio-Rad Micropulser under “Pic” setting. The pulse for this 
transformation was 2.00 kV and 5.00 ms. 
4. Immediately add 1 mL ice-cold 1 M sorbitol to the cuvette. Pipet gently with a gel 
loading tip to mix. Transfer the mixture to a cold, sterile 15 mL tube. 
5. Incubate the tube at 30 °C without shaking for 2 hours. 
6. Spread 5 µL, 10 µL, 15 µL, 25 µL, 50 µL, 75 µL, 100 µL, 125 µL, 150 µL, 175 µL 
and 200 µL onto YPDS (__% yeast extract, __% peptone, __% dextrose, __% 
sorbitol) plates with 100 µg/mL zeocin. Grow at 30 °C for 3 days. (Note: Sorbitol was 
added to stabilize the transformants). 
Purification of Zeocin Resistant Transformants and Selection of 
Multicopy Integrants 
Transformants resulting from the successful transformation of pGAPZA-Pb1 into 
X33 cells needed to be purified to ensure that there were no mixed colony transformants. 
The mixed colony transformants have a tendency to lose the foreign DNA. 
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1. After successful transformation, streaked the 6 colonies onto 25 µg/mL zeocin plates. 
Grew ~42 hours. 
2. Remove colonies from 25 µg/mL plates and streak on 100 µg/mL plates. Grow for 3 
days.  
3. Create freezer stocks of the clones that grew on 100 µg/mL. Start 5 mL YPD 
overnight cultures and prep for storage at -80 °C. 
Isolation of High-Producer Strains 
The high-producer strains were only identified after lysis using SDS-PAGE 
visualization. Since the colonies had already been lysed, creation of new colonies was 
necessary to form a stock of high-producer cells. 
1. Take 200 µL of the soluble lysate and add to 3 mL YPD. Grow at 30 °C for 20-24 
hours. 
2. Pour culture onto YPD + zeocin plates. 4 plates were made, each with a different 
amount of starter culture added: 150 µL, 200 µL, 250 µL, and 500 µL. Cells grow 
better on zeocin plates agar when there is lower cell density.4 
3. Grow for 3 days at 30 °C. 
4. Make freezer stock using the protocol described in this chapter 
Plating for Single Colonies 
1. Streak Pichia pastoris clone on YPD agar + 100 µg/mL zeocin. Grow 3 days at 30 
°C. 
2. Pick up one colony from this plate using a toothpick. 
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3. In a 1.5 mL epi tube, add 200 µL YPD. Gently swirl the toothpick in the media to 
dislodge the colony. The purpose of this step is to dilute the number of cells that get 
plated in the next step. 
4. Using a new toothpick, streak on YPD agar + 100 µg/mL zeocin. Grow 3 days at 30 
°C. 
Creation of Freezer Stock from Pichia pastoris Cells 
After successfully plating for single colonies (see notes), freezer stocks needed to 
be made. Single colonies from the same plate were grow up in a series of 5, 7, and 10 mL 
cultures. They were grown overnight at 30 °C and 225 rpm. The three different volumes 
were grown to ensure that at least one of the cultures would be in exponential mode. 
Colonies from 5 separate plates (therefore 5 separate parent strains) were grown in this 
manner. The following day, 800 µL of culture (do not spin down) and 200 µL of 100 % 
glycerol, sterilized were combined in a 2 mL cryogenic vial and flash frozen in liquid 
nitrogen and immediately transferred to storage at -80 °C.  
Isolation of genomic DNA from Pichia pastoris 
Lysis of Yeast Cells 
Reagent needed: Lyticase 
1. The desired P. pastoris strain was streaked onto YPD plates and grown for 2-3 days at 
30 °C. 
2. 25 U of lyticase solution was added to a PCR tube and one colony, approximately 2 
mm, was suspended in the solution. 
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3. The samples were incubated in the PCR machine for 30 minutes at 30 °C. 
4. The sample was frozen at -80 °C for 15 minutes, then thawed at room temperature, 
and vortexed on medium speed to release the intracellular contents. 
5. This freeze, thaw, and vortex step was repeated a second time. 
Phenol-Chloroform Extraction 
Reagents needed:  Phenol:Chloroform:Isoamyl alcohol (P:C:I, 25:24:1) 
     Chloroform:Isoamyl alcohol (C:I, 24:1) 
     TE Buffer: 50 mM Tris-HCl, 0.5 mM EDTA, pH 7.5 
1. The lysed cell suspension was diluted in 250 µL TE buffer and 250 µL P:C:I was 
added. 
2. The solution was vortexed gently then centrifuged at 17,000 g for 2 minutes at 4 °C. 
3. The top layer (aqueous phase, DNA containing) was carefully transferred to a clean 
tube without disturbing the interface. The volume was approximately 250 µL. 
4. To the original tube, 250 µL TE buffer was added. 
5. Steps 2 and 3 were repeated and the water phases were combined. 
6. To the tube with the aqueous phases, 250 µL C:I was added. This removed the phenol 
layer from the remaining aqueous solution. 
7. The solution was vortexed gently and centrifuged at 17,000 g for 2 minutes at 4 °C. 
8. Any remaining aqueous solution was removed. 
Ethanol Precipitation 
Reagents needed:  3 M sodium acetate, pH 5.2 
100 % Ethanol, ice cold 
231 
 
70 % Ethanol 
Sterile ddiH2O 
1. In a 1.5 mL microcentrifuge tube, 400 µL of the aqueous solution from above (DNA-
containing solution) was combined with 40 µL 3M sodium acetate, pH 5.2 (final 
concentration: 0.3 M) and 880 µL 100% ice-cold ethanol. This solution was vortexed. 
2. The solution from step 1 above was incubated at -80 °C for 45 minutes and then 
centrifuged at 40,000 g for 15 minutes at 4 °C. 
3. The DNA pellet was very small, indistinguishable to the naked eye. The supernatant 
that contained salts and organic contaminants was removed, leaving a little (~10-30 
µL) remaining. 
4. The DNA pellet was resuspended in 1 mL 70 % ethanol and then centrifuged at 
40,000 g for 15 minutes at 4 °C. 
5. The supernatant was carefully removed, again leaving a small amount in the tube. In 
this step, a faint opaqueness was noticed on the bottom of the tube. 
6. The DNA pellet was dried at 40 °C for approximately 30 minutes. There was still 
some supernatant left. 
7. Sterile ddiH2O, enough to bring the volume to approximately 50 µL, was added and 
the DNA pellet was resuspended. 
8. The DNA concentration and purity was determined using the Nanodrop 1000 
spectrophotometer (ThermoFisher). 
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Optimization of Growth Time 
1. Grow up 4 separate 5 (or 7, or 10) mL YPD cultures at 30 °C and 225 rpm overnight. 
The 4 cultures were all started from the same parent strain (i.e. single colony on same 
plate). 
2. Transfer a 2 mL aliquot of the 5 (or 7, or 10) mL culture to fresh 50 mL YPD (in 125 
mL flask). Grow at 20.5 °C and 225 rpm over four days. There will be a total of 4 
cultures.  
3. Combine the remaining culture (from each of the 4 separate) into one tube and spin 
down at 12,000 g for 15 min at 4 °C. 
4. Every 24 hours, remove one of the cultures and spin it down. Decant the supernatant 
into a separate tube and freeze both at -20 °C. There will be a time point sample for 0 
hours, 24, 48, 72 and 96 hours.  
5. Once all the sample are acquired, lyse the yeast cells with the following procedure: 
Lysis buffer:  
• Tris-HCl 50 mM, pH 7.4 
• PMSF 10 mM 
Add 2 mL lysis buffer/gram cell pellet. 
Aliquots of 1 mL of re-suspended cell pellet were added to 0.5 mm zirconia/silica 
disruption beads (0.5 mL) and lysed with vortex for 30 sec by vigorous mixing followed 
by 30 sec incubation on ice. This mix/freeze cycle was repeated a total of 6 times. 
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Samples were collected by centrifugation at 12,000 g for 15 min at 4 °C and the 
supernatant was removed for further analysis on an SDS-PAGE gel. 
Lysis of Pichia pastoris Cells – Procedure 
Breaking (Lysis) buffer:  50 mM NaH2PO4, pH 7.4 
1 mM EDTA 
5% glycerol 
1 mM PMSF (add immediately prior to use) 
Cells were re-suspended in breaking buffer at 2 mL breaking buffer/gram cell. 
This suspension (wash to remove any residual media) was then centrifuged 3,000 g for 5 
minutes at 4 °C. The supernatant was decanted and breaking buffer was added to re-
suspend cells (2 mL breaking buffer/gram cell). In a 1.5 mL tube, 1 mL cell suspension 
was combined with 250 µL (measured by displacement) zirconia/silica disruption beads 
(0.5 mm). The samples were vortexed on maximum speed for 30 seconds and then rested 
on ice for 30 sec. This vortex/rest cycle was repeated a total of 12 times. The lysis 
mixture was centrifuged at 12,000 g for 15 minutes at 4 °C. The lysate (soluble fraction) 
was transferred to a new 1.5 mL tube. To the tube with cells/beads, 1 mL 6 M urea was 
added to extract any insoluble proteins. A 200 µL pipet tip was used to loosen the cell 
debris from the wall of the tube and then the tube was vortexed to re-suspend completely. 
Both the lysate and the urea/cells/beads tubes were centrifuged at 12,000 g for 15 minutes 
at 4 °C. The lysate was transferred to a third tube and the urea extraction was transferred 
to a different tube. Both tubes were centrifuged at 20,000 g for 15 minutes at 4 °C to 
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clear them. The cleared lysate and urea extraction were transferred to different tubes for 
storage. 
Aliquots of 1 mL of re-suspended cell pellet were added to 0.5 mm zirconia/silica 
disruption beads (0.5 mL) and lysed with vortex at max speed for 30 sec followed by 30 
sec incubation on ice. This mix/freeze cycle was repeated a total of 6 times. Samples 
were collected by centrifugation at 12,000 g for 15 min at 4 °C. 
Dot Blot 
These experiments were performed with 0.45 µm nitrocellulose membrane and Pierce 
Fast Western Kit, ECL substrate. 
1. Spot 2 µL of protein sample onto 0.45 µm nitrocellulose membrane. Allow to dry 
completely. Hydrate the membrane in 1x wash buffer for 5 minutes. 
2. Prepare primary antibody solution by combining 10 mL of antibody diluent with 10 
µL of anti-BAF180. Incubate membrane in solution for 1 hour at room temperature 
with gentle shaking. 
3. Remove membrane from antibody solution and wash for 5 minutes with 1x wash 
buffer. 
4. Prepare secondary antibody solution by combining 10 mL of antibody diluent with 1 
mL Optimized HRP Reagent. Incubate membrane in solution for 10 minutes. 
5. Remove membrane from antibody solution and perform 3 consecutive washes, 5 
minutes each, with 1x wash buffer 
235 
 
6. Prepare ECL detection reagent by combining 5 mL ECL detection reagent 1 and 5 
mL ECL detection reagent 2. Incubate membrane briefly (5 minutes max). 
7. Take images using a CDD camera 
Western Blot Transfer 
1. Transfer SDS gel from gel box to 2x NuPAGE transfer buffer with 0.2% SDS. 
Equilibrate for 10 minutes 
2. Cut a notch on corner of membrane to indicate direction 
3. Active the PVDF membrane by submerging it in 100% methanol for 30 seconds. 
Briefly wash the membrane in water to decrease the alcohol concentration, then place 
in 1x NuPAGE transfer buffer with 0.1% SDS 
4. Place blotting paper and sponges in 1x NuPAGE transfer buffer with 0.1% SDS 
5. Assemble the cassette (see ) 6-7 
 
Figure B.1: Assembly of a western blotting “sandwich”. 
6. Place cassette in tank with the grey side facing the anode (black).7-8 
7. Run at 70 V for 1 hour 
Grey Side of Cassette
Sponge
Sponge
Blotting paper (3 pieces)
Gel
Membrane
Blotting paper (3 pieces)
Black Side of Cassette
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Appendix C: PCR Programs and Primers  
Testing for Presence of Individual Domains 
Table C.1: PCR conditions for BAF180 KpnI domain test. Testing Bromodomain 1 (D1) → D3; D3 → D5, 
D3 → D6. 
 
 
Table C.2: PCR conditions for BAF180 domain test 1. Testing start codon to end of bromodomain domain 
3 (D3), D1 → D3, D3 → D6, and D6 → stop codon. 
 
 
Table C.3: PCR conditions for BAF180 domain test 2. Testing from start codon to end of D2, D1 → D2, 
D2 → D3, D3 → D4, D4 → D5, D5 → D6. 
 
Program 
Name Domains
For Use with 
Primers
Product 
Size
Temp 
(°C) Time
BAF180 KpnI
domain test
D1 -> D3 92, 97 1323 Initial Denaturation: 95 30 sec
D3 -> D5 96, 101 1138 # Cycles: 30
D3 -> D6 96, 103 Denat: 95 30 sec
Anneal: 59 30 sec
Elong: 68 1 min 20 sec
Final Elongation 68 5 min
Hold 4
Program 
Name Domains
For Use with 
Primers
Product 
Size
Temp 
(°C) Time
BAF180 
Domain Test 1
Start -> D3 322, 97 1452 Initial Denaturation: 95 30 sec
D1 -> D3 92, 97 1323 # Cycles: 30
D3 -> D6 251, 103 1500 Denat: 95 30 sec
D6 -> Stop 102, 47 2583 Anneal: 48 20 sec
Elong: 68 90 sec
Final Elongation 68 5 min
Hold 4
Program 
Name Domains
For Use with 
Primers
Product 
Size
Temp 
(°C) Time
BAF180 
Domain Test 2
Start -> D2 322, 295 852 Initial Denaturation: 95 30 sec
D1 -> D2 92, 95 723 # Cycles: 30
D2 -> D3 94, 97 909 Denat: 95 20 sec
D3 -> D4 138, 99 693 Anneal: 49 15 sec
D4 -> D5 98, 101 732 Elong: 68 45 sec
D5 -> D6 253, 254 747 Final Elongation 68 5 min
Hold 4
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Table C.4: PCR conditions for BAF180 domain test 3. Testing for presence of D1 → D3 and D3 → D6. 
 
 
 
 
PCR Program for Modification of BAF180 Gene Sequence 
(insertion of Kozak consensus sequence, deletion of stop codon, 
insertion of enterokinase site, 3' KpnI site) 
Table C.5: PCR conditions for modification of BAF180 gene sequence: insertion of Kozak consensus 
sequence, deletion of stop codon, insertion of enterokinase site, and modification of 3' restriction enzyme 
site to KpnI. 
 
 
 
 
Program 
Name Domains
For Use with 
Primers
Product 
Size
Temp 
(°C) Time
BAF180 
Domain Test 3
D1->D3 92, 97 1323 Initial Denaturation: 95 30 sec
D3->D6 96, 103 1500 # Cycles: 30
Denat: 95 20 sec
Anneal: 50-60 15 sec
Elong: 68 1 min 40 sec
Final Elongation 68 5 min
Hold 4
Program 
Name
For Use with 
Primers Product Size
Temp 
(°C) Time
SH 328/329
328/329 4985
Initial 
Denaturation: 98 30 sec
# Cycles: 30
Denat: 98 10 sec
Anneal: 76.3 30 sec
Elong: 72 2 min
Final Elongation 72 2 min
Hold 4
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Table C.6: BAF180 primer sequences. 
Archive 
Number 
Sequence Name 
092 GGTGGTCATATGCCAAGCAGGAAAAGGAGG
A 
BAF180 Bromo1 - 
forward 
093 GCTGCTGGTACCATTGTCTTGCCCATCTTC BAF180 Bromo1 - 
reverse 
094 GGTGGTCATATGGATGGGCAAGACAATCAG
G 
BAF180 Bromo2 - 
forward 
095 GCTGCCGGTACCTGAGCCATATTGAAGTGC
CAT 
BAF180 Bromo2 - 
reverse 
096 GGTGGTCATATGGCACTTCAATATGGCTCA BAF180 Bromo3 - 
forward 
097 GCTGCTGGTACCGGTGGCTGAAGAGATCAT
GC 
BAF180 Bromo3 - 
reverse 
098 GGTGGTCATATGAGCATGATCTCTTCAGCCA
C 
BAF180 Bromo4 - 
forward 
099 TCCTCCGGTACCGAGTTTGGGAGAAGCCAT
GTC 
BAF180 Bromo4 - 
reverse 
100 GGTGGTCATATGGCTTCTCCCAAACTCAA BAF180 Bromo5 - 
forward 
101 GCTGCTGGTACCCTCTTGAATCAGCAAAGTC
ACATT 
BAF180 Bromo5 - 
reverse 
102 GGTGGTTCTAGAATGCCAAATGTGACTTTGC
TGATTC 
BAF180 Bromo6 - 
forward 
103 GCTGCTGGTACCTGTGGTATAGCTGAGTGCC
G 
BAF180 Bromo6 - 
reverse 
136 GGTGGTATTAATATGCCAAGCAGGAAAAGG
AGGA 
BAF180-bd1 fwd (Ase 1) 
137 GGTGGTATTAATATGGATGGGCAAGACAAT
CAGG 
BAF180-bd2 fwd (Ase 1) 
138 GGTGGTATTAATATGGCACTTCAATATGGCT
CA 
BAF180-bd3 fwd (Ase 1) 
139 GGTGGTATTAATATGAGCATGATCTCTTCAG
CCAC 
BAF180-bd4 fwd (Ase 1) 
140 GGTGGTATTAATATGGCTTCTCCCAAACTCA
A 
BAF180-bd5 fwd (Ase 1) 
141 GGTGGTATTAATATGCCAAATGTGACTTTGC
TGATTC 
BAF180-bd6 fwd (Ase 1) 
142 GGTGGTAAGCTTCCAAATGTGACTTTGCTGA
TTC 
BAF180-bd6 fwd (hind3) 
143 CGTGCTGCGGCCGCAGTTGTGGTATAGCTG
AGTGCCG 
BAF180-bd6 rev (Not1) 
146 GGTGGTATTAAT ATGTCCATGGGTTCCA   BAF180 fwd (Ase1) 
147 GCTGCTGGTACCAACATTTTCTAGGTTGTAT
GC       
BAF180 rev (Kpn1) 
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249 GGTGGTGCTCTTCCAACCCAAGCAGGAAAA
GGAGGA 
BAF180 Bromo1 - 
forward 
250 GGTGGTGCTCTTCCAACGATGGGCAAGACA
ATCAGG 
BAF180 Bromo2 - 
forward 
251 GGTGGTGCTCTTCCAACGCACTTCAATATGG
CTCA 
BAF180 Bromo3 - 
forward 
252 GGTGGTGCTCTTCCAACAGCATGATCTCTTC
AGCCAC 
BAF180 Bromo4 - 
forward 
253 GGTGGTGCTCTTCCAACGCTTCTCCCAAACT
CAA 
BAF180 Bromo5 - 
forward 
254 GGTGGTCTGCAGTTATGTGGTATAGCTGAGT
GCCG 
BAF180 Bromo6 - 
reverse 
255 GGTGGTGGTCATATGCCCAAGCAGGAAAAG
GAGGA 
BAF180 Bromo1 - 
forward 
256 GGTGGTGGTCATATGCGATGGGCAAGACAA
TCAGG 
BAF180 Bromo2 - 
forward 
257 GGTGGTGGTCATATGCGCACTTCAATATGGC
TCA 
BAF180 Bromo3 - 
forward 
258 GGTGGTGGTCATATGCAGCATGATCTCTTCA
GCCAC 
BAF180 Bromo4 - 
forward 
259 GGTGGTGGTCATATGCGCTTCTCCCAAACTC
AA 
BAF180 Bromo5 - 
forward 
308 GGCGAAGCTT TTCCATGGGTTCC BAF180 fwd_outer 
(whole protein) 
309 CGCGCCGGATCC GTGATTAAAC BAF180 rev_outer 
(whole protein) 
322 CGGGTACC ATGGGTTCCAAGAGAAGA BAF180, full length, 
forward 
323 CCGGCGAATTC CTGATCCACAACTCTTTATG BAF180, full length, 
reverse 
324 GGCGCC GTCCCTATTTCAATCAATTGAA 5' GAP 
328 gcgctggtacgtagGAATTCGAACTCAAAatgggttccaa
gagaagaag 
Modifications of BAF180 
gene sequence, fwd 
329 GCGCTAATGATGTGAGGTACCCTTGTCGTCG
TCGTCAACATTTTCTAGGTTGTA 
Modifications of BAF180 
gene sequence, rev 
336 GCG CGT TGC ATA ATG ATG TGG AGA AAG BAH1 forward 
337 GCG CCT GGG CAT AAC TTA AAG TAT TCC 
TT 
BAH1 reverse 
338 GCG CGA GCA GCT CCA TTA CAA T BAH2 forward 
339 GGC CCT CCT TCT GAG GAA CAA TTG BAH2 reverse 
340 GCG CAG TGC AAA GAA GGA AGG HMG forward 
341 GCG CCC TTG GTT CAT CAC ACC HMG reverse 
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Copyright Permissions 
 
Regarding Figure 1.5: 
 
  
 
Creative Commons Attribution License (CC BY) 
This article is available under the terms of the Creative Commons Attribution License (CC 
BY).  
You may distribute and copy the article, create extracts, abstracts, and other revised 
versions, adaptations or derivative works of or from an article (such as a translation), to 
include in a collective work (such as an anthology), to text or data mine the article, 
including for commercial purposes without permission from Elsevier. The original work 
must always be appropriately credited.  
 
Permission is not required for this type of reuse. 
 
  Copyright © 2017 Copyright Clearance Center, Inc. All Rights Reserved.  Comments? We would like to hear from you. E-mail us at customercare@copyright.com 
 
 
 
 
Regarding Figure 1.13:  
The sketch of the outline of the human body is in the public domain. All notations are 
original. [http://diagrampic.com/printable-human-body-outline/] 
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Regarding Crystal Structures:  
All crystal structures were found on Protein Data Bank (PDB).1-2 As such, they are in the 
public domain. Images were manipulated using Protein Workshop.3 
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